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Abstract
Malignant transformation evolves as the outcome of 2 connected processes
operating within a population of competing cells: on the one hand, the continuous
accumulation of random mutations by individual cells at a rate dictated by the
degree of genetic instability and, on the other hand, the simultaneous natural
selection acting on the resultant phenotypes. Successive rounds of environmental
pressures lead to the emergence of cells that acquired diverse advantageous
hallmarks such as growth factor-independent proliferation, mostly driven by
constitutively activated signaling cascades to which neoplastic cells develop
an addiction that can be therapeutically exploited. For instance, the JAK-STAT
pathway is frequently hyperactivated in T-ALL and the use of JAK inhibitors in
lymphoid malignancies is currently under pre-clinical investigations. In the present
thesis, we took advantage of the TS1 cell line recapitulating in vitro JAK-STAT
pathway-driven T-cell transformation in order to un...
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SUMMARY 
 
Malignant transformation evolves as the outcome of 2 connected processes 
operating within a population of competing cells:  on the one hand, the continuous 
accumulation of random mutations by individual cells at a rate dictated by the 
degree of genetic instability and, on the other hand, the simultaneous natural 
selection acting on the resultant phenotypes. Successive rounds of environmental 
pressures lead to the emergence of cells that acquired diverse advantageous 
hallmarks such as growth factor-independent proliferation, mostly driven by 
constitutively activated signaling cascades to which neoplastic cells develop an 
addiction that can be therapeutically exploited. For instance, the JAK-STAT 
pathway is frequently hyperactivated in T-ALL and the use of JAK inhibitors in 
lymphoid malignancies is currently under pre-clinical investigations. In the present 
thesis, we took advantage of the TS1 cell line recapitulating in vitro JAK-STAT 
pathway-driven T-cell transformation in order to unravel the underlying genetic 
events and evaluate the efficacy of JAK inhibitors.  
 
In our first study, we found that growth factor-independent TS1 clones acquired an 
activating point mutation in JAK1 and/or JAK3, which function as partners in the 
signal transduction downstream of γc-sharing cytokine receptors. Furthermore, TS1 
cells transformed by an activated mutant of JAK1 became resistant to JAK 
inhibitors by acquiring a secondary mutation in JAK3 and vice versa. We 
demonstrated that the presence of two inhibitor-sensitive JAK1 and JAK3 mutants 
cooperatively activate STAT3 and STAT5 factors thereby increasing the resistance 
to JAK inhibitors.  
 
In our second study, we focused on the molecular mechanism underlying the high 
rate of spontaneous mutagenesis in TS1 cells. We demonstrated that loss of MLH1 
expression, a key component of the mismatch repair system, promotes the 
occurrence of oncogenic point mutations in JAK kinases driving transformation and 
acquired resistance to inhibitors. We confirmed the clinical relevance of our 
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findings by showing that chronic myeloid leukemia cells from patients that relapsed 
upon ABL-targeted therapy have a lower expression of MLH1 messenger RNA 
than leukemic cells from patients at diagnosis. Moreover we identified a particular 
mutational signature present in our TS1 cell model and corresponding to the one 
described in primitive CD32+ cells from chronic myeloid leukaemia patients that 
might attest MLH1-deficiency. Taken together, our findings suggest that MLH1 
status should be considered in order to predict response to targeted therapies. 
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ABBREVIATIONS 
 
6-TG 6-Thioguanine 
AMKL Acute Megakaryoblastic Leukemia 
AML Acute Myeloid Leukemia 
B-ALL B-cell Acute Lymphoblastic Leukemia 
BAT Best Available Therapy 
BER Base Excision Repair 
bMMRD bi-allelic Mismatch Repair Deficiency 
BTK Bruton Tyrosine Kinase 
CLL Chronic Lymphocytic Leukemia 
CML Chronic Myeloid Leukemia 
CNL Chronic Neutrophilic Leukemia 
DS-ALL Down Syndrome-associated ALL 
EGFR Epidermal Growth Factor Receptor 
EMT Epithelial to Mesenchymal Transition 
EPO Erythropoietin 
ET Essential Thrombocythemia 
ETP-ALL Early T-cell Precursor ALL 
FDA Food and Drug Administration 
FERM band 4.1, Ezrin, Radixin, Moesin 
FLT3 Fms-Like receptor Tyrosine kinase 3 
G-CSF Granulocyte Colony-Stimulating Factor 
GF Growth Factor 
GIST Gastro-Intestinal Stromal Tumors 
GM-CSF Granulocyte/Monocyte Colony-Stimulating Factor 
HL Hodgkin Lymphoma 
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HPRT  Hypoxanthine-guanine Phosphoribosyl Transferase 
HSC Hematopoietic Stem Cell 
IDL Insertion-Deletion Loop 
IFN Interferon 
IL Interleukin 
JAK Janus Kinase 
JH JAK Homology region 
JMML Juvenile Myelomonocytic Leukemia 
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LGL Large Granular Lymphocyte Leukemia 
MAPK Mitogen-Activated Protein Kinase 
MDS Myelodysplasic Syndrome 
MLH1 MutL Homolog-1 
MMR Mismatch Repair 
MPN Myeloproliferative Neoplasm 
MSC Mesenchymal Stromal Cells 
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MTOR Mammalian Target of Rapamycin 
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PDGFR Platelet-Derived Growth Factor Receptor 
PI3K Phosphatidylinositol-3'-Kinase 
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SOCS Supressor Of Cytokine Signaling 
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INTRODUCTION 
 
1. JAK kinase targeting in hematological malignancies: A sinuous pathway 
from identification of genetic alterations towards clinical indications 
 
1.1 Introduction 
 
Mature blood cells have a limited lifespan and are continuously renewed through a 
multi-step process called hematopoiesis, initiated in the bone marrow by the 
proliferation and differentiation of a small population of pluripotent hematopoietic 
stem cells (HSCs) (Figure 1). Undergoing asymmetric divisions, HSCs have the 
ability to replenish their pool by self-renewal and to differentiate into lineage-
committed progenitors with increasingly restricted potential that will ultimately give 
rise to all specialized blood cells1. A network of hematopoietic cytokines tightly 
dictates fate (proliferation, differentiation or apoptosis) of the various progenitors 
allowing the maintenance of steady state blood cells level in the periphery or the 
amplification of specific cell types in response to a particular stimulus to meet 
physiological needs. Abnormalities in the hematopoietic program disrupt 
homeostasis and drive the accumulation of intermediate progenitors and/or mature 
cells in the bone marrow, blood and/or peripheral lymphoid organs resulting in a 
variety of malignancies2.  
 
Overview of the JAK-STAT pathway 
Hematopoietic cytokines bind at the surface of target cells to their cognate 
receptors composed of at least two single membrane-spanning chains. Except 
several tyrosine kinase receptors like c-Kit, Fms-like tyrosine kinase 3 (FLT3) or 
the receptor of macrophage colony-stimulating factor (M-CSF), the intracellular part 
of hematopoietic receptor chains lacks intrinsic enzymatic activity. However, these 
receptor chains constitutively and specifically associate with a member of the 
Janus kinase family (JAK1, JAK2, JAK3 or TYK2) in order to form functional 
 Introduction  
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complexes able to transduce ligand-induced signals. Following cytokine 
engagement, receptor chains reorientate or oligomerize leading to juxtaposition, 
and hence transactivation of the 2 associated JAKs. Once activated, JAKs 
phosphorylate tyrosine residues on themselves and in the cytoplasmic part of the 
receptor creating docking sites for downstream Src homology-2 (SH2) domain-
containing adaptors and effectors proteins. Depending on the amino acids 
surrounding the phosphotyrosine, any one or more of the 7 signal transducer and 
activator of transcription factors (STAT-1, -2, -3, -4, -5a, -5b and -6) can be 
recruited and phosphorylated at the receptor, homo- or heterodimerize and 
translocate into the nucleus to regulate transcription of target genes3.  
 
Figure 1. Hematopoiesis. Hematopoiesis originates from a hematopoietic stem cell, which 
can undergo either self-renewal or hierarchical differentiation into lineage-committed 
progenitors with decreasing potential that ultimately will give rise to all mature blood cells. 
Cytokines and their receptor-associated JAK necessary for the progenitors to pass through 
the different maturation steps are indicated. (HSC) Hematopoietic stem cell, (CMP) Common 
myeloid progenitors, (CLP) Common lymphoid progenitors, (GM) Granulocyte macrophage 
progenitors, (BCP) B cell progenitor, (TNK) T and Natural killer cells progenitors, (EP) 
Erythroid progenitors, (Mk) Megakaryocyte, (GP) Granulocyte progenitors, (MP) 
Macrophage progenitors, (TPO) Thrombopoietin, (SCF) Stem Cell Factor, (IL) Interleukin, 
(GM-CSF) Granulocyte/Monocyte Colony-Stimulating Factor, (G-CSF) Granulocyte-CSF, (M-
CSF) Monocyte-CSF, (TSLP) Thymic Stromal-Derived Lymphopoietin. 
 Introduction  
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The JAK-STAT pathway constitutes a signal transduction system where a large 
spectrum of extracellular cytokines and nearly as many cognate transmembrane 
receptors converge towards an intracellular code employing 4 JAK kinases and 7 
STAT factors4. Signal specificity downstream of cytokine receptors is achieved by 
the nature of the STAT dimers formed at the receptor, the kinetics and intensity of 
STAT activation as well as the triggering of additional signaling pathways such as 
the mitogen-activated protein kinases (MAPK) and the phosphatidylinositol-3ʼ-
kinase (PI3K). Transient JAK-STAT pathway activation is achieved by several 
mechanisms of negative regulation that operate at each step of signal transduction 
such as ubiquitin-mediated receptor internalization, dephosphorylation of tyrosines 
in the JAK activation loop by constitutive phosphatases and induction of 
Suppressor of Cytokine Signaling (SOCS) proteins5.  
In 2005, several groups reported a unique acquired somatic activating mutation of 
JAK2 (V617F) in 95% of Polycythemia Vera patients (PV) and in about half of 
Essential Thombocythemia (ET) and Primary Myelofibrosis (PMF) patients6-9. The 
discovery of JAK2 V617F gave an impetus for the screening of JAK mutations in 
other hematological neoplasms. Thanks to improvement of sequencing techniques 
and the conduction of massive sequencing projects, the catalogue of genetic 
alterations in hematological malignancies is constantly updated as still more and 
more new mutational targets are discovered. This review will depict an overview of 
the different molecular mechanisms underlying constitutive activation of the JAK-
STAT pathway and their respective frequencies among hematological neoplasms. 
The use of JAK inhibitors in the clinic and in ongoing trials, resistance phenomena, 
as well as future challenges will be discussed. This chapter will begin by 
documenting insights into the structural organization of JAK kinases, their mode of 
activation as well as the role of the different family members in hematopoiesis. 
 
 Introduction  
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Janus kinases 
JAK1, JAK2 and TYK2 tyrosine kinases are ubiquitously expressed and non-
covalently bound to a distinct, mostly non-overlapping repertory of receptor chains. 
By contrast, JAK3 expression is restricted to the hematopoietic lineage and it 
associates exclusively with the common gamma-chain (γc). Based on their primary 
sequences, JAK kinases were initially divided into 7 highly conserved JAK 
Homology regions (JH1-7, starting from the C-terminal end) but were thereafter 
organized in 4 functional domains10.  
The N-terminal moiety of JAK kinases constitutes the receptor-binding module with 
a FERM (band 4.1, Ezrin, Radixin, Moesin) domain (JH4-7) and an atypical SH2 
domain (JH3)11. It has been experimentally established that both domains do not 
exist as individual functional entities but structurally cooperate for non-covalent 
anchoring to two membrane-proximal regions of defined receptors12,13. This was 
corroborated by a recent crystal structure study showing that the N-terminal part of 
TYK2 forms a contiguous, Y-shaped receptor-binding module that interacts with the 
interferon alpha receptor 1 (IFNAR1) via a composite interface formed by the 
FERM and SH2 domains14. The selectivity of the JAK member engaged by a 
particular receptor chain does not exclusively depend on intrinsic sequences within 
its cytoplasmic domain but also on the stoichiometry of the receptor. For example, 
forced homodimers of chimeric receptors encompassing the intracellular part of IL-
2Rβ fused to the extracellular part of EPO-R activated JAK2 despite the fact that 
the naturally activated kinase was JAK115. Of note, JAK-receptor association is 
needed to ensure proper trafficking and localization of the complex to the plasma 
membrane16-18.  
The C-terminal moiety of JAKs contains the catalytic kinase domain (JH1), whose 
active conformation is stabilized upon phosphorylation of tandem tyrosine residues 
in its activation loop. Inappropriate kinase activity of JH1 in the absence of stimulus 
is prevented by a directly adjacent pseudo-kinase domain (JH2)19. The precise 
molecular mechanism by which JH2 regulates JAK activity remains incompletely 
understood but insights have been provided by several recent works20. The 
 Introduction  
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pseudokinase domain has long been considered as catalytically inactive because it 
lacks critical conserved residues needed for phosphate coordination and transfer 
such as the nearly invariant aspartic acid in the catalytic site and the third glycine 
of the GxGxφG motif in the ATP-binding loop. However, JAK2 JH2 crystal structure 
revealed that the pseudo-kinase domain adopts a classical bilobal kinase-fold and 
binds ATP in a noncanonical mode21. The precise function of the nucleotide binding 
of JH2 is still debated. JH2 has been demonstrated to phosphorylate two negative 
regulatory sites of JAK2, namely Ser523 in the SH2-JH2 linker and Tyr570 in JH2 
itself22. Whether this weak kinase activity is relevant for autoinhibition is still a 
matter of controversy since those residues are not conserved among other family 
members and disruption of JH2 nucleotide binding does not lead to constitutive 
JAK2 activation. Rather, it has been proposed that JH2 constitutively binds ATP 
without hydrolysis, making ATP an essential structural stabilizer of JH223. 
Study of recombinant JH1 and JH1-JH2 constructs from JAK2 showed that the 
presence of JH2 drastically decreases JH1 kinase activity by increasing the Km for 
ATP possibly via an interdomain interaction that changes JH1 conformation24. 
Owing to the recently solved crystal structure of JH1-JH2 from TYK2, this 
intramolecular inhibitory interface has been localized near the JH1 catalytic site 
and is predominantly mediated by the N-lobes of each domain25. The JH1-JH2 
crystal structure of TYK2 supports a mode of inhibition in cis with the pseudokinase 
domain inhibiting the directly adjacent kinase domain within the same protein. 
Nevertheless, it is unclear whether this intramolecular JH1-JH2 interplay is 
operative in a physiological receptor context. Because cytokine receptor complexes 
crucially comprise two or more subunits each associated with a JAK monomer, one 
cannot exclude an in trans mechanism of inhibition where the pseudokinase 
domain of one JAK molecule locks the kinase domain of the opposing JAK. 
Recently, Brooks et al. used fluorescence resonance energy transfer (FRET) to 
monitor the movements of JAK2 JH1 and JH2 domains during stimulation of the 
homodimeric growth hormone (GH) receptor. Activation resulted in an increase in 
distance between the two JH2 while bringing the two JH1 in closer vicinity, 
 Introduction  
 
 14 
consistent with the in trans inhibition model26. Supporting evidences for both in cis 
and in trans inhibition models could be conciliated by the hypothesis that distinct 
mechanisms operate between different JAK family members or that the type of 
associated receptors governs the mode of regulation27.  
 
Role of JAK kinases in hematopoiesis 
As outlined in figure 1, JAK2 plays a role in function and maintenance of HSCs28 by 
participating directly to signal transduction of thrombopoitein (TPO)29 and by 
contributing to signaling downstream of the stem cell factor (SCF)30. JAK2 is also 
crucial at various stages of myelopoiesis through binding to receptors of 
erythropoietin (EPO), TPO, granulocyte-colony stimulating factor (G-CSF), 
granulocyte/macrophage-colony stimulating factor (GM-CSF), interleukin (IL)-3 and 
IL-5. The EPO receptor exists as a preformed homodimer31, while those for TPO 
and G-CSF are believed to homodimerize upon ligand binding. Receptors for GM-
CSF, IL-3 and IL-5 consist of heterodimers of a cytokine-specific α chain and the 
common β chain that assemble as ligand-induced tetramers. In all cases, signal 
transduction will result from transactivation of a pair of juxtaposed JAK2 molecules. 
By contrast, JAK1 cooperates with JAK3 for lymphopoiesis by binding to 
heterodimeric receptors of the common γc family, IL-2R, IL-4R, IL-7R and IL-15R 
with JAK1 anchored to the specific chain and JAK3 to the common γc. Both 
kinases play obligatory and non-redundant functions as cells lacking either JAK1 or 
JAK3 are unable to respond to γc cytokines32,33. However, the catalytic activity of 
each partner is not of equal importance since kinase-dead form of JAK3 but not 
JAK1 still allows signal transduction via these receptors34. Therefore, in the context 
of γc-containing receptors, JAK1 functions as the primary signaling effector 
whereas JAK3 serves as scaffold and partner of JAK1. JAK2 in concert with JAK1 
could possibly be implicated in late development of immature B-lymphocytes 
through signaling downstream of the thymic stromal-derived lymphopoietin 
(TSLP)35. In respect to their implication in the maturation and amplification of the 
different myeloid and lymphoid lineages (Figure 2), genetic alterations leading to 
 Introduction  
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oncogenic activation of particular hematopoietic cytokine receptor complexes give 
rise to neoplasms of corresponding cell types.  
               
 
 
Figure 2.  Hematopoietic cytokine-receptor complexes. Hetero- or homo-oligomerized 
receptor chains specifically engage a member of the JAK kinases in order to form signaling-
competent hematopoietic receptor complexes. Myelopoiesis is driven by cytokines whose 
receptors signal through the transactivation of a pair of juxtaposed JAK2 molecules. 
Lymphopoiesis is mostly driven by interleukins that bind to the shared γc-receptor family, 
which signals through the cooperative action of JAK1 and JAK3. JAK2 and JAK1 participate 
to the signaling of TSLP, a cytokine involved in late development of B-lymphocytes. JAK1, 
JAK2 and TYK2 can work as partners whereas JAK3 works exclusively in concert with 
JAK1. JAK2 is the only family member that can function with itself as opposing JAK. (EPO) 
Erythropoietin, (TPO) Thrombopoietin, (G-CSF) Granulocyte-colony stimulating factor, (IL) 
Interleukin, (GM-CSF) Granulocyte/monocyte-CSF, (TSLP) Thymic stromal-derived 
lymphopoietin. 
 
1.2 Activating alterations of JAK kinases 
 
Hematological malignancies have been associated with activating alterations in the 
four members of the JAK family at different frequencies, the majority of them being 
point mutations. Contrasting with the dominance of the JAK2 V617F mutation in 
myeloproliferative neoplasms (MPN), the mutations described later in other 
hematological malignancies in JAK1, JAK2, JAK3 and more recently in TYK2 are 
much more heterogeneous both regarding the mutated residues and the frequency 
 Introduction  
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of mutation in a given disease. The JAK2 locus can also be implicated in 
translocations resulting in the overexpression of wild-type JAK2 or the generation 
of constitutively active fusion proteins. Figure 3 gives a general outlook of the 
different myeloid and lymphoid neoplasms for which the overall frequency of 
analyzed cases with genetic alterations affecting any component of the cytokine 
receptor-JAK-STAT axis reached at least 10%. 
 Introduction  
 
 17 
 
 
 Introduction  
 
 18 
Figure 3.  Frequencies of genetic alterations affecting the receptor-JAK-STAT axis 
among hematological malignancies. Diagrams give an overview of the maximal overall 
frequency of cases with genetic alterations of the receptor-JAK-STAT axis in (A) myeloid 
lineage, (B) lymphoid progenitors and (C) lymphoid mature cells disorders. The overall 
frequency of JAK-STAT pathway mutations (i.e. the sum of the individual mutation 
frequencies for each component) is indicated in red while the absolute contributions of each 
are detailed using a specific colour code (yellow for JAK1, violet for JAK2, green for JAK3, 
turquoise for TYK2, blue for cytokine receptors, black for STAT3, beige for STAT5b and 
brown for STAT6). Schematic protein representations are used to localize the identified point 
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mutations with the affected functional domains indicated in red. (MPN) Myeloproliferative 
neoplasms, (PV) Polycythemia vera, (ET) Essential thrombocythemia, (MF) Myelofibrosis, 
(CNL) Chronic neutrophylic leukemia, (CML) chronic myeloid leukemia, (JMML) juvenile 
myelomonocytic leukemia, (AMKL) Acute megakaryoblastic leukemia, (ALL) Acute 
lymphoblastic leukemia, (DS) Down-syndrome, (T-PLL) T-prolymphocytic leukemia, (ATLL) 
adult T-cell lymphoma, (NKTCL) NK/T-cell lymphoma, (NK- and T-LGL) NK- and T-large 
granular lymphocytic leukemia,  (PMBL) Primary mediastinal B-cell lymphoma, (HL) Hodgkin 
lymphoma, (FL) Follicular lymphoma. 
 
Frequencies of alterations in JAK kinase genes among hematological malignancies 
In accordance with its role in lymphopoiesis, activating mutations of JAK1 were 
described in lymphoid neoplasms with the highest frequency in T-cell acute 
lymphoblastic leukemia (ALL) (6.5-27%)36-38 and lower frequencies in B-ALL 
(1.5%)39 and T-cell prolymphocytic leukemia (T-PLL) (8-12.5%)40-42. JAK1 mutants 
were also reported in very rare cases of acute myeloid leukemia (AML)43. 
As already mentioned, the JAK2 V617F mutation is highly prevalent in classical 
MPNs so that its screening has become a standard diagnostic procedure in the 
clinic. The same JAK2 V617F mutation was described later in a small proportion of 
patients with atypical MPNs44, and in some cases of myelodysplastic syndromes 
(MDS), particularly in patients suffering from refractory anemia with ringed 
sideroblasts and thrombocythemia45. In addition, mutations in the exon 12 of JAK2 
were described in JAK2 V617F-negative PV patients who typically harbored 
isolated erythrocytosis46.  
JAK2 mutations were also found in lymphoid malignancies such as high-risk B-ALL 
(8.5%)39 and B-ALL associated with Downʼs syndrome (18-28%)47-53. Noticeably, 
the vast majority of lymphoid lineage JAK2 mutations affects the R683 residue in 
JH2. Interestingly, JAK2 R683 variants are frequently associated with the 
overexpression of CRLF2, suggesting that this cytokine receptor chain is involved 
in the functional signaling platform of these mutants54.  CRLF2 is a JAK2-binding 
chain that forms together with IL-7Rα and JAK1 the functional receptor complex for 
thymic stromal-derived lymphopoietin (TSLP). The rationale for the specific 
association of JAK2V617F with MPN and JAK2R683 with ALL is speculative. The 
JAK2V617F mutant might be more efficient in transactivating another JAK2 in 
homodimeric cytokine receptor complexes such as EPO-R or TPO-R, whereas 
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conversely the JAK2R683 variants might preferentially activate a JAK1 molecule in 
the heterodimeric TSLP receptor complex. Alternatively, the two mutants might 
differ in their affinity for a particular receptor chain, substrate specificity or intensity 
of signal transduction. Finally, hypermutability of the V617 and R683 hot spots 
might be influenced by cell type-dependent factors such as secondary DNA 
structures, the chromatin context of adjacent regions or specific replicative 
polymerases. 
Rare chromosomal rearrangements juxtaposing the kinase domain-coding portion 
of the JAK2 gene to genomic regions coding for the oligomerization domain of 
either TEL, BCR, PCM1, Pax5 or ETV6 were described essentially in ALL and 
several cases of atypical chronic myeloid leukemia (CML)51,55-59. The resultant 
fusion proteins oligomerize, facilitating transphosphorylation of the JAK2 activation 
loops, and constitutively trigger several downstream signal transduction pathways, 
such as STAT555, PI3K60 or the MAP kinases61 independently of the presence of 
anchoring receptors. Interestingly, although artificial chimeric TEL-JAK1, TEL-JAK3 
and TEL-TYK2 proteins are able to sustain cytokine-independent growth of Ba/F3 
cells62, there is no patient-derived chromosomal translocation that fuses the kinase 
domain of JAK1, JAK3 or TYK2 to a dimerizer described so far. This is probably 
related to an intrinsic genetic instability of the JAK2 locus, which can otherwise 
also be subject to amplifications in 30-50% of Hodgkin lymphomas (HL) and 
primary mediastinal B-cell lymphomas (PMBCL)63-65.  
Gain-of-function mutations in JAK3 are scattered throughout the different functional 
domains and are found in diverse malignancies from both myeloid and lymphoid 
origins. JAK3 mutations were initially described in acute megakaryoblastic 
leukemia samples (AMKL) (15%)66 and were subsequentially identified in juvenile 
myelomonocytic leukemias (JMML) (12%)67. Concerning the lymphoid lineage-
malignancies, JAK3 mutations were reported in a significant proportion of T-ALL68, 
especially in an aggressive subtype called early T-cell precursor-ALL (ETP-ALL)38, 
as well as in diverse mature T-cell neoplasms 40,42,69-71.  
More recently, TYK2 mutants were discovered in T-ALL (21%) and seem to 
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promote cell survival via activation of STAT1 downstream of IL-10R and 
upregulation of the anti-apoptotic BCL2 protein72.  
 
Characterization of JAK mutants 
Functional characterization of the different JAK variants revealed that they display 
common features as well as mutant-specific particularities. As demonstrated for 
JAK1, JAK2 and JAK3, mutants require a functional FERM domain and the 
presence of anchoring homo- or heterodimeric cytokine receptors to promote 
signaling and cell transformation73-75. One notable exception is the JAK1 L910P 
mutant that exhibits residual activity upon inactivating mutation in its FERM-
domain75. JAK1 mutants can trigger STAT activation via IL2-Rβ or IL-9Rα 
homodimers without need for JAK3 and γc74. By contrast, JAK3 mutants (with the 
exception of JAK3 L857Q) are strictly dependent on JAK1 kinase activity76. Intrinsic 
specificity among distinct mutants of the same JAK is illustrated by qualitative and 
quantitative differences in STAT activation, FERM-domain requirement, 
susceptibility to JAK inhibitors and, concerning the JAK1 mutants, sensitivity to 
type-I interferons75-78. 
The overwhelming majority of activating JAK mutations occur in the pseudokinase 
domain (JH2). The mechanism through which such mutations increase the activity 
of the kinase domain was almost exclusively studied for JAK2 V617F. 
Superimposing the crystal structures of the pseudokinase domains of JAK2 V617F 
and the analogous JAK1 V658F mutants with their wild-type counterparts 
highlighted a stiffening and extension of the αC helix mediated by the action of a 
phenylalanine triad21,79. The aromatic ring of the phenylalanine at position 617 in 
JAK2 and 658 in JAK1 fills in the site normally occupied by that of a highly 
conserved phenylalanine residue in the SH2-JH2 linker (F537 in JAK2 and F575 in 
JAK1) thereby inducing the rotation of a third phenylalanine located in the αC helix 
(F595 in JAK2 and F636 in JAK1). Replacement of either partner of this F-F-F triad 
by non-aromatic residues diminishes constitutive kinase activity79,80. Interestingly, 
JAK2 V617F is transferable to JAK1 and TYK2 but not JAK3 evoking a different 
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autoinhibition mechanism of JAK3 compared to the three others81. 
Besides JAK2 V617F, most of the cancer-associated mutations in the 
pseudokinase domain of JAK1, JAK2 and JAK3 are clustered in the N-lobe and the 
SH2-JH2 linker fragment. Mapping of the analogous affected residues on the 
crystal structure of TYK2 revealed that they localize in or near the JH1-JH2 
interface and probably relieve the inhibitory influence25. On the other side of the 
interface, all known kinase N-lobe mutations participate directly to the JH1-JH2 
interaction.  
1.3 Activating alterations in cytokine receptors  
 
The first mechanism of constitutive receptor activation involves point mutations or 
small insertions/deletions of residues located in and around the transmembrane 
domain (TMD) that result in unliganded chains reorientation or dimerization. 
Several examples are listed hereunder. TPO-R possesses an intracytoplasmic 
juxtamembrane amphipathic motif necessary for preventing its activation in the 
absence of ligand82. Mutations in this motif (W515K/L/A) were described in 5% of 
JAK2 V617F-negative MF and ET patients83,84 and were shown to change the 
spatial conformation of the receptor enabling TPO-independent JAK2 
transphosphorylation85. Additionally, mutations in the TMD of TPO-R (S505N and 
S505A) cause familial ET86. Small in-frame insertions/deletions in the TMD of the 
IL-7 receptor α-chain (IL-7Rα) were found in about 10 % of T- and B-ALL87,88. 
These sequence modifications often introduce an unpaired cysteine in the TMD 
and promote formation of intermolecular disulfide bonds between IL-7Rα mutant 
subunits, thereby driving constitutive signaling via JAK1 and independently of IL-7, 
γc or JAK387. Point mutations inserting a cysteine in the extracellular domain of IL-
7Rα (S185C) and CRLF2 (F232C) were identified in few B-ALL cases and could 
act via the same activation mechanism89. Membrane-proximal mutations of CSF3R 
(T615A and T618I), the receptor for G-CSF, are highly prevalent in atypical CML 
and in chronic neutrophilic leukemia (CNL), and induce ligand-independent 
activation of the receptor by a mechanism that remains to be elucidated90,91. More 
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recently, a whole-exome sequencing study provided the first report of 2 
concomitant sequence modifications in γc (a small deletion in the TMD and the 
K315E mutation in the intracellular part) detected in a sample of T-PLL41. The 
significance of this finding is not yet clear as only one patient in a series of 50 
analyzed samples harbored these γc mutations. 
A second mechanism of receptor activation has been described in patients with 
CNL or atypical CML and involves truncations of the cytoplasmic tail of CSF3R, 
leading to escape of negative regulation90. Those truncated proteins are the result 
of frameshift or nonsense mutations and increase the proliferative signal by 
impairing receptor internalization and altering the interaction with negative 
regulators such as SOCS3. Interestingly, proliferation of cells transformed with 
these mutants was relatively insensitive to JAK2 inhibitors, but could be efficiently 
blocked by SRC inhibitors, such as dasatinib, indicating that SRC signaling could 
be preferentially activated by these truncated proteins. CSF3R truncating mutations 
were very recently identified in 2% of pediatric AML92. 
The last reported cytokine receptor alteration is the overexpression of CRLF2 that 
has been already mentioned in this review. CRLF2 is aberrantly expressed in 50 % 
of patients with DS-ALL and in 10 % of non-DS ALL54,89,93,94, essentially owing to 
chromosomal rearrangements juxtaposing the CRLF2 locus to the immunoglobulin 
heavy chain enhancer or P2RY8 promoter. In B-ALL, CRLF2 overexpression in 
frequently associated with JAK2 R683 variants or IL-7Rα mutations, suggesting 
that concomitant genetic events affecting components of the TSLP-receptor 
complex are required for its oncogenic potency. 
Taken together, gain-of-function alterations of cytokine receptors are diverse and 
encompass mutations in TM region that induce ligand-independent receptor 
dimerization/activation, cytoplasmic tail truncations that abolish negative regulation 
and chromosomal translocations that enhance protein expression. At present, such 
genetic modifications are well established for TPO-R, CRLF2, IL-7Rα and CSF3R 
but it is not excluded that whole-exome sequencing studies will further highlight 
alterations in additional cytokine receptor chains as suggested by the recent finding 
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of very rare mutations in γc. 
Calreticulin mutations in JAK2 and TPO-R mutation-negative ET and MF 
In December 2013, the molecular diagnostic gap that remained after the discovery 
of TPO-R mutations in JAK2-negative ET and MF patients has been partially filled 
in. Two independent groups reported that 25% of ET and MF patients conveyed 
small insertions/deletions in an unexpected gene coding for the calreticulin, a lectin 
chaperone involved in the folding quality control machinery of the endoplasmic 
reticulum (ER) and in calcium homeostasis95,96. All identified sequence 
modifications invariably provoked a +1 base shift to the same alternative open 
reading frame resulting in the generation of a novel C-terminus with impaired 
calcium-binding and loss of the ER-retention motif, although CALR WT and mutant 
forms did not show any difference in the pattern of subcellular localization95. 
Expression of the most frequent CALR mutant caused transformation to cytokine-
independent cells with phosphorylation of STAT5 by means of a still unknown 
mechanism but the homogeneity within the frameshifted variants evokes a strong 
selective pressure towards newly acquired functionalities rather than loss-of-
function alterations96. JAK2, TPO-R and CALR mutations were mutually exclusive 
genetic events in MPN with the remaining 10% triple negative being associated to 
the worse prognosis. 
 
1.4 Activating mutations in STAT factors 
 
For the moment, STAT3 and STAT5b mutations were only demonstrated in T- and 
NK-cell leukemias, while mutations of STAT6 have been associated with B-cell 
lymphomas. However, given their crucial function at all hematopoietic stages, it can 
be expected that further sequencing studies will emphasize the role of STAT family 
genes mutations in the pathogenesis of additional hematological malignancies from 
different origins. 
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STAT3 mutations 
The occurrence of STAT3 mutations stressed the common molecular pathogenesis 
of chronic lymphoproliferative disorders of NK cell and T-cell large granular 
lymphocyte leukemia  (NK- and T-LGL) as similar percentages (27-30%) of 
patients from both disease entities convey these somatic mutations97,98. Altogether, 
8 different substitutions clustered in the exon 21 coding for the SH2 domain were 
identified and all affected residues mapped at the interface of STAT dimers. In vitro 
studies showed that Y640F and D661V mutants are constitutively phosphorylated 
and localize in the nucleus. Patients with STAT3 mutations presented more often 
with disease-related autoimmune phenomena like rheumatoid arthritis and 
autoimmune hemolytic anemia than did patients without these mutations97,98. An 
overproduction of immune cytokines or a better resistance to apoptosis in STAT3-
mutated LGL cell population, including auto-reactive T cells, might explain this 
clinical association. 
 
STAT5b mutations 
Two different proven gain-of-function STAT5b mutations (Y665F and N642H) were 
found in 2% of STAT3 mutation-negative T-LGL patients with the N642H 
substitution being associated with an aggressive fatal disease course99. The same 
and new mutations were later encountered in 36% of T-PLL representing the 
highest frequency among all other mutated JAK-STAT components (JAK1, JAK3, 
IL-7Rα and γc) in the analyzed cohort41. STAT5b mutations are uncommon in T-
ALL but their occurrence underlines the significance of the IL7R-JAK-STAT5 
pathway in the pathogenesis of T-ALL100. Interestingly, while STAT5b mutant blasts 
were resistant to JAK inhibitors, the cells were highly sensitive to inhibitors of 
STAT5b target such as anti-apoptotic BCL-2 proteins100. 
 
STAT6 mutations 
Identification of heterozygous point mutations in the DNA binding domain of STAT6 
in 36% of PMBCL represented the first observation of recurrent STAT mutations in 
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human cancers101. Very recently, additional activating STAT6 substitutions were 
described in 11% of follicular lymphomas (FL) and were demonstrated to prolong 
residency of STAT6 in the nucleus resulting in a exaggerated transcriptional 
response to IL-4 highly present in the tumor microenvironment102.  
1.5 Loss of negative regulators  
 
The activation of the JAK-STAT pathway is limited in time and amplitude by several 
regulatory mechanisms. For instance, constitutive phosphatases serve as 
quenchers of phosphotyrosines mediating activation and recruitment of 
downstream effectors. Additionally, inducible regulators of the suppressor of 
cytokine signaling (SOCS) family mediate ubiquitin-tagging for proteasomal 
degradation of the receptor complex, suppression of JAK catalytic activity or 
competition with STAT factors for docking sites on receptor. Loss-of-function 
alterations or epigenetic silencing affecting genes involved in the repression 
process are expected to result in more intense and sustained cytokine receptor 
signaling. Some illustrating examples will be documented in this section.  
PTPN2 is a protein tyrosine phosphatase (PTP) able to dephosphorylate tyrosine 
residues located in the activation loop of JAK1 and JAK3103. Mono- or bi-allelic 
inactivation of PTPN2 through deletion of the entire gene locus was found in 6% of 
T-ALL cases104, sometimes in co-occurrence with JAK1 activating mutations104. 
Downregulation of PTPN2 sensitizes to JAK1- but not JAK2-mediated 
transformation and reduces the sensitivity to JAK inhibitors of transformed cells105.  
Similarly, loss-of-function mutations of CD45, another JAK-regulating phosphatase 
encoded by the PTPRC gene, were detected in rare cases of T-ALL106. 
Remarkably, all CD45 mutations occurred in combination with activating mutations 
in IL-7Rα, JAK1, or LCK. Deletions or methylation of the PTPRK locus coding for a 
phosphatase that directly binds to and dephosphorylates STAT3, were recently 
reported in 55% of nasal NKTCL107. 
LNK is an adaptor protein that inhibits JAK2 activation downstream of TPO-R and 
EPO-R108. Mutations or deletions in the pleckstrin-homolgy (PH) domain of LNK 
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are reported in rare cases of MPN109,110. They occur either as an isolated event in 
chronic phase diseases109 or concomitantly with JAK2 V617F mutation in patients 
that progress to AML110.  
The Casitas B-lineage lymphoma (Cbl) E3 ubiquitin ligase serves as negative 
regulator of proliferative signals by targeting a variety of tyrosine kinases and 
associated signaling components among which FLT3, c-kit, M-CSFR, JAK2, 
STAT5111. Homozygous loss-of-function mutations of Cbl lead to prolonged 
cytokine receptor complex activation and have been described in a small 
pourcentage of primary AML112, as well as in classical and atypic MPN in which 
they have been associated with progression to secondary AML113. 
SOCS1 mutations were described in HL and PMBCL and were associated with 
nuclear phospho-STAT5 accumulation114. Reduced expression of SOCS1 and 
SOCS3, related to the hypermethylation of their promoter, has been described in 
different lymphoid hematological malignancies115 among which MPN, in 
association116 or not117 with the JAK2V617F mutation. 
Taken together, these observations underline the role played by deficiency of JAK-
STAT negative regulation processes in the pathogenesis of diverse hematological 
neoplasms. Of note, such alterations can occur in concomitance with activating 
receptor or JAK mutations meaning that they are not mutually exclusive genetic 
events104,106. Hence, it is postulated that loss of suppression does not directly drive 
tumorigenesis, but rather contributes to the hyperactivation of the JAK-STAT 
pathway. Also, as tyrosine phosphatases are not JAK-restricted but possess 
multiple targets, their lack could exert a broader oncogenic impact on the 
intracellular signaling, beyond the JAK-STAT pathway. Finally, some of these 
alterations, such as PTPN2 deletions, reduce the sensitivity of transformed cells to 
JAK inhibitors indicating that their screening in patients could be relevant for the 
prediction of treatment response.  
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1.6 JAK inhibition in hematological malignancies 
 
The oncogene addiction concept postulates that, despite the large amount of 
genetic lesions conveyed by a single cancer cell, some tumors rely on one single 
dominant oncogene for growth and survival, so that inhibition of this specific 
Achillesʼ heel is sufficient to halt the neoplastic phenotype118. At the clinical level, 
translation of the oncogene addiction model into the rational and effective design of 
targeted therapeutics against individual oncoproteins is best exemplified by the 
success story of Imatinib, an ATP-competitive tyrosine kinase inhibitor (TKI) of 
BCR-ABL that induced a dramatic shift in life expectation of CML patients119. The 
finding of aberrant JAK-STAT activation in a great majority of MPN and a 
significant portion of other hematological malignancies raised the hope for an 
Imatinib-like TKI therapy. The heterogeneity in the nature of the underlying genetic 
mechanisms can be overcome by exploiting the signaling bottleneck provided by 
the limited number of JAK kinases (Figure 4). However, it should be noted that 
activating mutations in STAT factors are relatively insensitive to JAK inhibitors. 
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Figure 4. Mechanisms of constitutive JAK-STAT pathway activation in hematological 
malignancies. The molecular mechanisms underlying activation of the JAK-STAT pathway 
are depicted and can affect all the components of the cascade. They can result from small 
nucleotide sequence modifications or larger changes at the chromosomal level.  
 
Ruxolitinib in myeloid malignancies 
The discovery of the MPN JAK2 V617F mutation in 2005 has been rapidly 
transduced into the clinic. Not more than 6 years later, Ruxolitinib, a dual JAK1/2-
specific ATP-competitive inhibitor, was US Food and Drug Administration (FDA)-
approved for the treatment of intermediate- and high-risk MF, a disease for which 
allo-stem cell transplantation was the only curative option. In clinical trials, 
Ruxolitinib treatment yielded efficacy in controlling splenomegaly and alleviating 
MF-associated symptoms compared to placebo (COMFORT-I)120 or best available 
therapy (BAT) (COMFORT-II)121. Surprisingly, MF patients benefit from Ruxolitinib 
therapy regardless of their JAK2 mutational status. Consistent with this unexpected 
observation, gene expression profiling data showed that MPN samples are 
characterized by a shared transcriptional signature of activated JAK2-STAT5 
signaling, irrespective of disease phenotype or somatic genotype122. Subsequent 
identification of mutations in TPO-R and Calreticulin, which result in activation of 
the JAK2-STAT5 pathway as discussed above, provided an explanation for this 
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observation. The central role played by aberrant JAK-STAT pathway activation in 
MPN gave a rationale for the unrestricted efficacy of Ruxolitinib and raised the 
hope that mutation-positive and -negative PV, ET and MF patients could efficiently 
respond to JAK inhibitors.  
However, Ruxolitinib exerted only limited salutary effect in terms of reversion of 
bone marrow fibrosis and reduction of allele burden, suggesting that the 
concentration required to kill neoplastic cells is impossible to reach in patients 
without inducing serious adverse events due to total inhibition of physiological 
cytokine signaling. Indeed, because of its lack of specificity towards JAK2 mutated 
forms, Ruxolitinib impedes physiological hematopoisesis leading to unwanted 
adverse events, the most frequently encountered being anemia and 
thrombocytopenia (incidence >20%)123. 
Alternatively, the MPN cells might not be JAK2 oncogene-addicted but the benefit 
observed on constitutional symptoms might be related to the alleviation of the 
proinflammatory tumor microenvironment rather than selective suppression of the 
disease clone120. The fact that Ruxolitinib also inhibits JAK1, an important player in 
innate and specific immune responses, might contribute to this anti-inflammatory 
activity. However, the drawback of this JAK1 inhibition is reduced control of silent 
infections and increased incidence of opportunistic diseases occasionally observed 
upon long-term administration124-127.  
Notwithstanding those side effects, the substantial bettering in life quality of MF 
patients encouraged the conduction of additional clinical trials, with the purpose to 
either enlarge Ruxolitinib indications or test other JAK2 inhibitors. Recently, a 
phase III clinical study aiming at evaluating the efficacy of Ruxolitinib as second-
line treatment in PV patients intolerant to hydroxyurea came to the conclusion that 
JAK2 inhibition was superior to standard therapy in controlling hematocrit, reducing 
spleen size and improving PV-associated symptoms128. Ongoing phase III clinical 
trials in MF patients assess the efficacy and safety of less myelosuppressive novel 
JAK2 inhibitors such as Momelotinib (CYT387) versus Ruxolitinib (NCT01969838) 
and Pacritinib (SB1518) versus BAT (NCT01773187). Besides classical MPN, a 
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phase II trial currently estimates the potential of Ruxolitinib in CNL and atypical 
CML, where genetic activating alterations of CSF3R are encountered in a 
significant proportion of cases as described above and are associated with a poor 
outcome (NCT02092324). Ruxolitinib has already proved efficacy in a CSF3RT618I 
bone marrow transplant mouse model129 and one case of CSF3RT618I-positive 
atypical CML patient has been reported to experience significant clinical response 
to Ruxolitinib130. Further encouragement emanates from reports of two patients 
with PCM1-JAK2-positive chronic eosinophilic leukemia who achieved complete 
hematologic and cytogenic responses on Ruxolitinib131,132, although, in two other 
described cases, rapid remission was only of limited duration and relapse occurred 
within 24 months133. 
 
Ruxolitinib in lymphoid malignancies 
In pre-clinical experiments, Ruxolitinib treatment yielded a significant decrease of 
circulating blast counts in murine xenograft models of Ph-like B-ALL134 and ETP-
ALL135, two recently described high-risk subtypes of ALL with aberrant activation of 
the JAK-STAT pathway for which novel therapies are needed. In the ETP-ALL 
model, the efficacy of treatment was independent of the presence of JAK-STAT 
mutations raising the possibility that the therapeutic potential of Ruxolitinib extends 
beyond the cases with JAK-STAT mutations135. As suggested for MPN, a JAK 
activation footprint may be more significant than the presence of a mutation for 
predicting response to therapy. This notion broadens greatly the numbers of 
patients that could potentially benefit from JAK inhibitors and will probably motivate 
the set up of future clinical trials in lymphoid malignancies. A recent clinical report 
described a unique case of refractory PMBCL with an activating JAK3 mutation 
(A573V) that experienced partial disease remission upon treatment with Tofacitinib, 
a JAK1/3-specific inhibitor, in combination with immuno-chemotherapy136. 
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1.7 JAK inhibitor resistance in hematological malignancies 
 
Albeit Ruxolitinib has proved effective in patients with MF, a fraction of them 
experienced treatment failure137. Besides discontinuation due to drug-related 
toxicity (such as early-onset cytopenias), Ruxolitinib treatment failure in MF 
manifests as primary refractoriness or secondary resistance. Primary refractoriness 
can be defined as the absence of onset of any or minimal clinical response (<35% 
reduction of spleen volume compared to baseline), whereas secondary resistance 
is indicated by the loss of previously confirmed clinical response (such as splenic 
relapse) or progression to leukemia123. In a cohort of 39 Ruxolitinib-treated MF 
patients, resistance was observed in 41% of cases, mostly as a late event (after 
median exposure of 1 year) and rarely as primary refractoriness (<10%). The same 
study identified a significant correlation between resistance and the absence of 
mutations in JAK2, MPL, TET2, and SRSF2 at diagnosis138. 
Based on clinical experiences with other TKI-therapies, it could be expected that 
resistant patients would have acquired mutations at the drug-binding site of the 
target kinase, as illustrated by the emergence BCR-ABL mutations in CML 
patients119. Yet, a dozen of different point mutations conferring resistance to 
Ruxolitinib were discovered using in vitro random mutagenesis screens of JAK2 
and in vitro selection of spontaneous resistant cell lines78,139-141. However, up to 
now, no mutations in JAK2 could be detected in patients treated with Ruxolitinib, 
indicating that such mechanism is rarely involved in clinical resistance138. The 
tolerable dose of Ruxolitinib provides only a partial inhibition of the kinase, which 
might exert a therapeutic pressure insufficient for the selection of resistant mutants. 
Rather, the chronic exposure to suboptimal inhibitor concentrations might favor 
less drastic escape mechanisms. A reversible stage of so-called “inhibitor 
persistence” has been observed in Ruxolitinib-treated patients and in JAK2V617F-
transformed cell lines cultured with gradually increasing doses of Ruxolitinib in 
vitro142. Cells were allowed to persist despite JAK2 inhibition thanks to restoration 
of the JAK–STAT signaling via overexpression of JAK2, which facilitates its 
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heterodimeric transactivation with JAK1 or TYK2. Interestingly, inhibitors of HSP90, 
a chaperone known to stabilize JAK2, synergize with JAK2 inhibitors and 
overcome TKI persistence as well as genetic resistance140,142,143. A phase II study 
is currently evaluating the potency of a HSP90 inhibitor in MF and refractory PV/ET 
patients (NCT01668173). 
1.8 Perspectives for the use of JAK inhibitors in hematological malignancies 
 
At present, clinical data revealed that the targeted therapy concept prompted by 
the success story of Imatinib would be more complex to apply with JAK inhibitors. 
The incapacity of Ruxolitinib to achieve allele burden reduction is potentially due to 
the absence of strong JAK2 oncogene addiction of MPN cells as discussed before. 
Nevertheless, broader investigations are encouraged by the substantial benefit of 
JAK2 inhibition irrespective of mutational status in MPN patients, preclinical 
evidences for Ruxolitinib indication in additional malignancies (CNL, ETP-ALL, Ph-
like ALL) and significant clinical response to JAK inhibitors in rare case reports 
(CSF3RT618I-positive or PCM1-JAK2-positive MPNs and a JAK3A573V-positive 
PMBCL).  
A second hurdle resides within the lack of selectivity of the currently used 
inhibitors, which implies that the tolerable doses range within a narrow therapeutic 
window because of the collateral inhibition of other JAK members. Specific 
inhibitors for one of the four close-related JAK kinases could partially tackle this 
drawback but is challenging due to high similarity in the active site within the family. 
Ruxolitinib (and other JAK inhibitors under clinical evaluation) falls within the so-
called type I family, which means that it precisely targets the well-conserved ATP-
binding pocket of JAK1 and JAK2 in both active and inactive conformations144,145. 
By contrast, inhibitors that have a type II binding mode (such as Imatinib) 
specifically engage and stabilize inactive kinases by exploiting an additional less 
conserved allosteric site directly adjacent to the ATP binding pocket, providing 
another handle for tuning selectivity144. Type II inhibition of JAK2 with NVP-
CHZ868 demonstrated a potent disease-modifying activity with significant reduction 
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of allele burden in different in vivo MPN models146. Alternatively, a covalent 
inhibitor exploiting a non-conserved cysteine residue in the active site of JAK3 has 
been shown to display strong target specificity147. Very recently, a new class of 
inhibitors were identified to bind to and lock the pseudokinase domain of TYK2 in a 
conformation that stabilizes the autoinhibitory interaction with the adjacent kinase 
domain, preventing its receptor-mediated activation148. Those JH2 stabilizers 
occupy a site analogous to the ATP-binding site of catalytic kinase domains by 
forming hydrogen bonds with non-conserved residues, presenting a novel 
approach in the design of highly selective inhibitors148. 
Paradoxically, increasing the specificity by developing type II, covalent or JH2 
inhibitors could in turn result in a lower overall clinical benefit due the loss of 
collateral inhibition of cancer-related inflammation processes. In addition, one can 
speculate that more potent inhibitors would raise the selective pressure to a 
threshold that allows the emergence of tumor subclones harboring drug-resistant 
mutations, as observed with Imatinib therapy, stressing the need for alternative 
strategies. 
MPN disorders stem from the constitutive activation of JAK2 at the apex of 
downstream signal propagation mediated by interconnected cascades of effectors 
(STAT3/5, PI3K/Akt/mTOR, MAPK) that synergistically act on cell proliferation149. 
The PI3K/Akt/mTOR pathway activation is required for JAK2 V617F-induced 
transformation of cells as well as JAK2 V617F-induced tumorigenesis in mice150 
and CD34+ cells derived from MPN patients showed increased levels of phospho-
mTOR151. Therefore, simultaneous intervention at both arms of the JAK-STAT and 
PI3K signaling cascades became a rational intervention option. Two independent 
groups demonstrated that combining Ruxolitinib with a PI3K inhibitor synergistically 
inhibited proliferation of in vitro MPN cell models and reduced spleen weight in 
MPN preclinical models152,153. A similar synergistic action was also observed 
between mTOR and JAK2 inhibitors154. A translational phase I clinical study is 
currently evaluating the safety and maximal tolerated doses for the combination of 
Ruxolitinib and BKM120, a PI3K inhibitor, in MF patients (NCT01730248). In 
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addition to further clinical benefit, simultaneous blockade of the oncogenic 
signaling at multiple levels by combined therapy approaches (such as Ruxolinitib 
with PI3K inhibitors or HSP90 inhibitors) might avoid the emergence of resistance 
by distributing the selective pressure between distinct targets.  
1.9  Conclusion 
 
A promising future is awaiting JAK inhibitors in the therapeutic arsenal of 
hematological malignancies provided that appropriate indications are identified. 
Contrasting with the direct connection between Imatinib and BCR-ABL+ leukemias, 
the path to determining relevant applications for JAK inhibitors is more sinuous. 
First, the genetic alterations converging towards constitutive JAK activation are 
diverse and sometimes unexpected, such as the recently discovered calreticulin 
mutations. Furthermore, certain subtypes of ALL display an activated JAK 
transcriptional signature in the absence of known genetic abnormalities and 
respond to JAK inhibitors treatment in preclinical models, which makes the 
identification of suitable clinical indications even more complex. Second, once 
targetable candidate diseases are selected, their JAK oncogene-addiction remains 
to be clinically validated. Finally, the optimal therapeutic window is narrowed by the 
collateral inhibition of non-mutated JAKs, which represents a subtle balance 
between, on the one hand, adverse side effects due to impairments of 
physiological processes such as hematopoiesis or immunity and, on the other 
hand, beneficial contributions of alleviating cancer-related pro-inflammatory 
microenvironment. Therefore, it is very likely that JAK inhibitors combined to other 
targeted therapies will be more efficient in synergistically modifying the natural 
history of the disease, overcoming inhibitor persistence and preventing the 
emergence of resistant subclones. 
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2. Acquired resistance mechanisms against Tyrosine Kinase Inhibitors in 
cancer therapies 
 
Oncogene addiction and targeted anti-cancer therapies 
Development and survival of certain tumors rely on the activation of a specific 
pathway driven by a genetically altered or overexpressed oncoprotein, mostly 
receptor and non-receptor kinases, pinpointing a therapeutically exploitable 
"Achilles' heel"155. Indeed,	  the neoplasic phenotype of malignant cells is particularly 
susceptible to blockade of this single oncogene by small molecule inhibitors or 
monoclonal antibodies evoking a state of addiction, while inactivating the wild-type 
counterpart in normal tissue is relatively well tolerated, presenting a tumor-specific 
therapeutic window118. The molecular mechanism underlying oncogene addiction 
remains elusive but could involve a cellular reprogramming resulting in a strict 
dependence or a differential decay rate between the short-lived pro-survival and 
the long-lived pro-apoptotic signals emanating from the oncoprotein provoking a 
oncogenic shock following its acute inhibition156. 
Although switching-off the signaling cascade upon which cancer cells have 
become dependent can yield a temporary relief and even complete remission, its 
efficacy is invariably limited in time by acquired drug resistance phenomena 
highlighting the plasticity of tumors157. Insights into the various strategies 
implemented by tumor cells to circumvent inhibitory action of targeted therapies 
unveil recurrent themes, including alterations of the drug target, restoration of the 
oncogenic pathway and activation of compensatory signals via kinase switching or 
salutary growth factors production by the microenvironment. In addition, 
overexpression of ATP-binding cassette (ABC) transporters promoting drug efflux 
or inactivation of p53 mediating pro-apoptotic signaling have emerged as key 
factors contributing to multidrug resistance. It has been proposed that reduction of 
the intracellular small molecule inhibitor concentration or the failure to induce cell 
death might allow the progression of stronger adaptive mechanisms such as 
secondary mutations that are responsible for the replenishment of the tumor158,159. 
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In this chapter, each type of evasion stratagem will be broached with particular 
emphasis on the molecular mechanisms of resistance to Tyrosine Kinase Inhibitors 
(TKI) with Imatinib as pioneering example.  
 
Secondary point mutations in the drug target 
Tyrosine kinases are highly amenable for the development of ATP-competitive 
small molecule drugs, however, owing to the conserved nature of the ATP-binding 
pocket, rationally designed TKI usually hit multiple targets at clinically used 
concentrations160. For instance, Imatinib, although being dedicated to inhibit ABL1, 
also binds with high affinity to c-Kit and platelet-derived growth factor receptor 
alpha (PDGFRα), which implies that it can treat tumors driven by the activation of 
anyone of those kinases, such as BCR-ABL positive CML and ALL 161, 
gastrointestinal stromal tumors (GIST)162,163 and FIP1L1-PDGFRα-induced 
myeloproliferative diseases164 respectively. However, Imatinib-treated patients 
frequently relapse predominantly due to the acquisition of point mutations in the 
kinase domain of the respective target. A great majority of them involve 
substitutions of the conserved threonine gatekeeper residue regulating access of 
TKIs to the ATP-binding cleft for a bulky amino acid165, pointing to impaired drug 
binding by steric hindrance as the main cause of resistance (T315I in BCR-ABL, 
T670I in cKit and T674I in PDGRα)166-169. In addition to Imatinib, gatekeeper 
mutations appear as a common molecular mechanism of resistance against a 
variety of TKIs. Non-small cell lung cancer (NSCLC) patients frequently acquire the 
equivalent T790M mutation in Epidermal Growth Factor Receptor (EGFR) upon 
treatment with EGFR inhibitors170,171. In vitro screens for resistant mutations 
identified the F691I substitution at the gatekeeper position in FLT3172,173 and 
analysis of engineered gatekeeper mutations in 4 other kinases (ABL1, PDGFRβ, 
SRC and FGFR1) demonstrate loss of sensitivity to selective inhibitors174. 
Besides the T315I mutation, at least 90 distinct point substitutions scattered 
throughout the kinase domain of ABL1 have been reported in Imatinib-resistant 
CML patients. One set of mutations, such as F359V, affects residues at contact 
points between the ABL kinase domain and the inhibitor, whereas a second 
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category, including the highly prevalent Y235F and E255K mutations, is postulated 
to destabilize an auto-inhibited conformation175 to which Imatinib preferentially 
binds, shifting the equilibrium toward the active state that preclude drug 
binding176,177. This suggests that at least some BCR-ABL Imatinib-resistant 
mutations might act as intrinsic gain-of-function alterations of the fusion protein, 
independently of their effect on drug sensitivity. Indeed, several groups reported 
that the Y235F and E255K mutants displayed enhanced kinase activity178,179 and 
transformation potency compared with native BCR-ABL180. Interestingly, this also 
applies for the gatekeeper mutations in several kinases among which EGFR as 
they were shown to stimulate kinase activity and promote malignant cell 
transformation181-183. This supports the hypothesis that acquired resistance results 
from the therapy-induced selection of pre-existing tumor subclones carrying drug-
resistant mutations that were allowed to maintain in the population through 
increased cell fitness. Accordingly, sensitive allele-specific polymerase chain 
reaction–based analysis of therapy-naive CML184-186 and NSLC187,188 samples 
revealed the same mutation as the one detected at relapse, consistent with the 
selective model.  
More potent second- (Dasatinib, Nilotinib and Bosutinib) and third-generation 
(Ponatinib) TKIs have been approved for treatment of CML and overcome nearly 
all Imatinib-insensitive mutants with the exception of the recalcitrant T315I that is 
only inhibited by Ponatinib189. However, those inhibitors still exert a therapeutic 
pressure that leads to the emergence of cells harboring novel (less numerous) 
resistant mutations mapping at contact points of the drug. Sequential switch from a 
TKI to another in relapsed CML patients may rescue clinical response as profiles of 
insensitive mutants are mostly specific to each drug, but carries the risk of 
selection for compound BCR-ABL mutations (i.e. 2 or more amino acid changes in 
a same molecule) with enhanced oncogenic potency190,191. This is of particular 
concern since clinically reported compound mutations pairing 2 key positions (most 
of the time including T315I) endows cells with a high resistance to TKIs, including 
Ponatinib192. Another drawback of sequential TKI use is illustrated by the I315M 
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substitution that evolved through a single nucleotide change from a baseline T315I 
mutation and confers a pan-TKI resistance192. 
Additional clinical illustrations of acquired kinase domain mutations upon TKI 
therapy are encountered in other kinase-driven malignancies such as FLT3 
mutation-positive AML and BRUTON tyrosine kinase (BTK)-driven chronic 
lymphocytic leukemia (CLL). In contrast to the wide array of BCR-ABL resistance 
mutations, relatively few FLT3 and only one BTK resistant mutations have been 
identified193. Similarly to BCR-ABL, activating kinase domain mutations of FLT3 
confer resistance by directly interfering with drug binding or inducing a switch into 
an active conformation194. Ibrutinib is a covalent inhibitor of BTK and replacement 
of the cysteine at the binding site (C481S) results in a protein that is only reversibly 
inhibited in relapsed CLL patients195,196. 
 
Amplification of the target 
Another adaptation implemented by CML cells in order to reinstate BCR-ABL 
signaling despite inhibition involves intrachromosomal amplification of the genomic 
region encompassing BCR-ABL166,197,198 or transcript overexpression199 thereby 
altering the drug-target ratio. Similarly, increased copy number of EGFR and FLT3 
genes has been observed in in vitro selected resistant cell lines200,201 and in 
patients202. Finally, in JAK2-driven malignant cell lines, a state of so-called inhibitor 
persistence has been associated with increased JAK2 levels resulting from 
messenger RNA overexpression and protein stabilization142.  
 
Hiding of the target 
Paradoxically to the previous paragraph, cells can evade targeted therapies by 
suppressing oncogene expression. Epidermal growth factor receptor 2 (HER2) is 
frequently upregulated serving as oncogenic driver in invasive breast cancers and 
can be targeted by a monoclonal antibody (Trastuzumab). Interaction of 
Trastuzumab with its antigen can be prevented by truncations of the extracellular 
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part of HER2 or epitope masking by higlhy glycosylated membrane-bound 
proteins203.  
 
Activating mutations in downstream effectors of the target 
Some resistant cells restore oncogenic signaling by acquiring activating alterations 
in effectors downstream of the inhibited kinase resulting in a total independence on 
the primary oncogene. For instance, BTK inhibitor (Ibrutunib)-resistant CLL 
patients acquire gain-of-function mutations in Phospholipase C-γ2 (PLCγ2), which 
is directly activated by BTK in normal B-cell receptor signaling195. Computational 
evolutionary models predict that Ibrutinib-resistant mutants exist before initiation of 
therapy and have a small fitness advantage in the absence of treatment204, as 
observed with BCR-ABL. 
The PI3K/AKT/mTOR and RAS/RAF/MEK/MAPK cascades mediate intracellular 
response downstream of several tyrosine kinase receptors such as EGFR.  
Activating mutations in PI3KCα or BRAF are occasionally found in EGFR inhibitor-
resistant NSCLC patients202,205 and an activating mutation in MEK1 has been 
identified in one RAF inhibitor-resistant melanoma patient206. 
 
Activation of compensatory pathways  
Inhibitor-treated cancer cells can compensate for the lack of oncogene signaling by 
switching their dependence towards functionally redundant kinases through the 
exploitation of pathway crosstalk and relief of negative feedback loops207. 
Numerous illustrations of alternative pathway activation in TKI-resistant cell lines 
and patients have been described in the literature. BCR-ABL addicted cells 
counteract inhibition by upregulating the activation of FYN, FAK208 or PI3K209 
kinases. Likewise, resistance to EGFR inhibitors can be mediated by amplification 
of MET that drives the activation of the alternative kinase ERB3 in NSCLC 210,211 or 
by the relief of transcriptional PDGFRβ repression in glioblastomas212. BRAF-
mutated melanoma cells are cross-resistant to BRAF selective inhibitors owing to a 
flexible switch among the three different RAF isoforms that rescues MAPK 
signaling213. The JAK-STAT, PI3K/AKT/mTOR and RAS/RAF/MEK/MAPK kinases 
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pathways are functionally interconnected effector cascades downstream of many 
interleukin receptors. Therefore, blockade of one signaling arm leads to the 
compensatory hyperactivation of one of the two others214-216. 
 
Epithelial to mesenchymal transition 
Epithelial to mesenchymal transition (EMT) is a critical dedifferentiation process by 
which cells lose adhesion and polarity, while gaining invasive and metastatic 
properties217. Furthermore, EMT contributes to TKI resistance and has been 
observed in inhibitor-insensitive hepatoma, lung and breast cancer cells218,202,219. 
The overexpression and constitutive activation of the receptor tyrosine kinase AXL 
(from the Greek word 'anexelekto', or 'uncontrolled') has been shown to orchestrate 
EMT leading to acquired TKI resistance and its pharmalogical inhibition restored 
sensitivity of cells to inhibitors220,221. The classification of tumors into epithelial or 
mesenchymal by assessing the expression AXL and downstream gene signature 
profile can serve as a predictive marker of response to targeted therapies222,223. 
 
Prosurvival signals from the microenvironment  
Recent lines of evidence suggest that the tumor microenvironment promotes TKI 
resistance either by direct cell to cell contacts or via secretion of soluble growth 
factors224. For instance, co-culture with mesenchymal stromal cells (MSC) 
protected CML stem and progenitor cells  from TKI-induced apoptosis through 
cellular adhesion225. Additional secreted factors might play a role since CML were 
shown to be less sensitive to BCR-ABL inhibitor in the presence of SCF226. Another 
study demonstrated that TKIs upregulated the expression of chemo-attractants, 
adhesion molecules, and prosurvival growth factors in MSCs. TKI-primed MSCs 
produced IL-7 that provided salutary survival signal to BCR-ABL+ ALL cells227. 
 
Perspectives for the use of TKIs in anti-cancer therapies 
Altogether, these observations stress the unlikelihood for TKIs to represent a 
stand-alone successful long-term anti-cancer therapy considering the diversity of 
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resistance mechanisms resulting from intrinsic tumor plasticity and 
microenvironment interactions157. Nevertheless, rational drug combinations appear 
as promising therapeutic alternative options since the avenues for the development 
of drug resistance might be more limited228 (Figure 5).  
The most prevalent adaptation to ATP-competitive TKIs involves the acquisition of 
target mutations that modify the drug binding site or the overall conformation of the 
kinase domain and confer a fitness advantage in the absence of inhibitor. The 
emergence of such pre-existing subclones can be overcome by combining 
alternative inhibitors that differ in binding sites and thus have distinct spectra of 
insensitive mutants229,230. For instance, combination of BCR-ABL ATP-competitors 
with allosteric inhibitors suppressed the appearance of resistance mutations in vitro 
and displayed efficacy against the recalcitrant T315I mutant in a murine bone-
marrow transplantation model231.  
Alternatively, some tumor cells restore oncogenic signaling through activating 
alterations in other components within the same cascade as illustrated with BRAF 
inhibitor-treated melanomas232. A phase III clinical trial demonstrated that 
cotreatment with inhibitors of BRAF and its downstream effector MEK, as 
compared with BRAF inhibitor alone, improved the rate of progression-free survival 
in previously untreated melanoma patients (NCT01584648)233. However, hitting a 
single signaling cascade at multiple points provides the tumor with a relatively 
simple escape route by activation of alternative compensatory pathways. This 
adaptation can be easily tackled by the use of multikinase inhibitors or co-
administration of drugs targeting independent kinases such as EGFR and MET 
inhibitors in NSCLC, which proved efficient in overcoming EGFR-TKI resistance in 
pre-clinical models234. Additionally, prevention of EMT by AXL inhibitors and 
abolishment of stromal protective mechanisms with antagonists of growth factors 
receptors or adhesion molecules might substantially improve sustained clinical 
response to TKIs. 
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Figure 5. Main mechanisms of resistance against TKIs in tumor cells. Some tumor cells 
are addicted to the pro-survival signals emanating from a mutated or overexpressed tyrosine 
kinase, which renders them sensitive to the targeted blockade of this single oncogene. 
However, upon TKI treatment as monotherapy, resistant cells frequently emerged. The 
escape strategies implemented by resistant cells are diverse and can be overcome by 
specific rational drug combinations.  
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3. Mismatch repair and mutator phenotype of cancer cells 
 
Mutations and cancers 
Mutations are permanent and transmissible modifications of the genetic material 
arising from exposure to exogenous and endogenous mutagens, uncorrected 
replicative errors, inaccurate DNA repair and mistakes in chromosomal segregation 
during cell division. Commonly recognized forms of mutations encompass 
variations in the nucleotide sequence as well as abnormalities in the structure and 
number of chromosomes. Hereditable changes in the pattern of cytosine 
methylation and other DNA modifications without alteration of the primary DNA 
sequence are defined as “epimutations”235.  
In most cases, such modifications in the genetic information do not improve nor 
harm cellular functions but they occasionally manifest as an acquired aberrant 
phenotype such as anarchical proliferation or any one of the well-established 
hallmarks of cancer cells236. Malignant transformation stems from the sequential 
acquisition of diverse phenotypic abnormalities by accumulation in a single cell 
genome of multiple key mutations in tumor suppressors and proto-oncogenes.  
Fortunately, the occurrence of such mutations is hampered by the extraordinary 
accuracy and efficacy with which cells normally replicate their genome and resolve 
DNA lesions (Figure 6). Indeed, human cells are equipped with 5 major DNA repair 
pathways, which correct specific types of mutations and DNA damages with a 
relative overlap and redundancy237. Three systems are specialized in the repair of 
single strand lesions  (base excision repair, nucleotide excision repair and 
mismatch repair) while two others protect cells from chromosomal rearrangements 
by dealing with double strand breaks (non-homologous end joining and 
homologous recombination). In addition, DNA damage-sensors can trigger cell-
cycle arrest or apoptosis above a critical threshold of unrepaired injuries. 
Altogether, the whole set of DNA repair effectors and damage sensors are termed 
"genome caretaker proteins". Finally, as ultimate safeguard, the limited number of 
mitoses undergone by somatic cells before entering a state of full differentiation or 
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senescence, represents a key mechanism for preventing the accumulation of 
mutations. The major contribution of this last point is buttressed by the strong 
positive correlation between the lifetime risk for a specific cancer type and the 
cumulative number of divisions undertaken by the self-renewing stem cells 
maintaining homeostasis of that particular tissue238. 
 
 
Figure 6. Cells possess several safeguards that prevent persistent mutations. The 
genome integrity is continuously challenged by extrinsic and intrinsic DNA damaging factors. 
Against this constant attack, cells dispose over escape routes leading to either DNA repair, 
mitosis arrest or cell death. In addition, the restricted number of divisions undergone by a 
single cell before differentiation or senescence limits the accumulation of mutations. Despite 
these safeguards, a small portion of DNA lesions persist and are converted into mutations 
that increase the risk for cancer development. (ROS) Reactive oxygen species. 
 
Mutation rate in normal cells 
Despite the armamentarium of cellular defense lines, a small fraction of damages 
evade and are converted into fixed mutations that are passed on to daughter cells 
when their occurrence is somatic or to all cells of the offspring when arising in the 
germ cells (egg or sperm). Germline mutations are the ultimate source of genetic 
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diversity within a population serving as a fuel for evolution of species. Historically, 
the rate of de novo mutations per generation has been estimated by indirect 
approaches such as analyzing the genome sequences at defined loci in close 
relatives or looking at phylogenetic distance between humans and chimpanzees239. 
The advent of next-generation sequencing (NGS) techniques provided a more 
direct and comprehensive method for comparing the entire genomes of parents-
offspring trios. 3 independent pedigree studies came up with a consistent 
estimation of the single nucleotide variation (SNV) rate of 1.2 x10-8 per base pair 
per generation, meaning that each zygote conveys about 75 de novo point 
mutations among the 6.4x109 bases that constitute the human diploid genome240-
242. However, those studies used DNA extracted from blood and the contribution of 
somatic mutations occurring early in development remained unclear243. 
The rate of de novo mutations per somatic cell division is more challenging to 
calculate and we still lack an accurate and unbiased estimation. Historically, due to 
technical limitations, the somatic mutation rate was rudimentarily measured in in 
vitro cultured cells based on the mutation frequency at sentinel loci, i.e. genes of 
which a wide range of single inactivating mutations are viable and manifest as a 
readily detectable phenotype. For instance, the X chromosome-linked 
hypoxanthine-guanine phosphoribosyltransferase (HPRT) locus has been widely 
used because its invalidation confers an easily appreciable resistance to 6-
thioguanine (6-TG). Practically, HPRT mutant frequencies were determined initially 
and at several time points while maintaining cells in a logarithmic growth. Mutation 
rate at the HPRT locus was obtained as the slope of the regression line plotting the 
6-TG resistant frequency as a function of population doubling244. The HPRT 
sentinel method suffers from multiple shortcomings in estimating the global 
mutation rate of somatic cells within an individual. First, only inactivating genetic 
alterations are detected while neutral and activating mutations are not. Second, it 
seems likely that growing cells in vitro induces a plethora of genetic instabilities 
and estimation based on cell lines might not reflect the actual in vivo mutation rate. 
In addition, as it has become obvious that mutation frequency across the genome 
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is strongly influenced by replication timing, transcription levels and chromatin 
organization, measuring mutation rate on a small genomic portion provides a highly 
biased estimation 245,246.  
The small scale issue associated with the sentinel method could be addressed by 
NGS of genomes from monozygotic twins that represent an attractive model for 
studying somatic mutations apart from germline ones, as any change between co-
twins would arise from somatic events. 33 pairs of monozygotic twins were 
genotyped at 506,786 common single nucleotide polymorphism (SNP) sites across 
the genome in search for variations generated early in development that would 
result in heterozygous point mutations present in only one twin and absent in its co-
twin247. Based on this study, the somatic point mutation rate was estimated as 
6x10-8 per nucleotide per cell division meaning that somatic cells acquire 380 de 
novo mutations each time they replicate their genome.  
 
Mutational load of cancer cells 
Recent whole-genome sequencing of matched tumor-normal samples from a wide 
variety of cancer types revealed that the mutational load differs over several orders 
of magnitude. A single malignant cell genome conveys an averaged number of 
somatic lesions ranging from 1,000 in childhood brain tumors and acute leukemias, 
up to 100,000 in melanoma and lung cancers248. The ultimate purpose of these 
global sequencing projects was to create a comprehensive catalogue of 
significantly mutated cancer-associated genes that would represent potential 
targets for therapy246. Unexpectedly, the list of genes frequently mutated appeared 
to be disappointingly restrained (125 among 20,000 protein coding genes)249 even 
within samples from the same tumor type highlighting the substantial inter-tumor 
heterogeneity and the stochastic nature of cancer evolution250. 
How cancer cells manage to acquire such a mutational complexity throughout 
tumor progression despite the relatively low mutation rate is under continuous 
debate. There exist two proposed scenarios for the accumulation of mutations in 
cancer cells, the power of natural selection and the mutator hypothesis. The first 
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model suggests that the mutational load results from the increased number of 
mitoses in highly proliferative cancer cells without an elevation of the intrinsic 
mutation rate. Alternatively, the second hypothesis postulates that acquisition of 
the large number of mutations present in cancer cells within a reasonable time 
requires an increase of the spontaneous mutation rate.  
 
Natural selection for driver mutations  
It is well established that cancer develops as the outcome of 2 connected 
processes occurring among cell populations within tissues of a multicellular 
organism, the continuous acquisition of random mutations by individual cells and 
the simultaneous natural selection acting on the resultant phenotypes251. 
Analogous to Darwinian evolution, the natural selection weeds out cells that have 
acquired deleterious mutations and fosters cells carrying alterations, defined as 
“driver mutations”, that endow them with a proliferative or survival advantage over 
their neighbors. Most of the time, these competitions lead to the clonal expansion 
of cells with limited growth potential and manifest as benign proliferations. 
Occasionally, after repetitive rounds of selection, a single cell sequentially 
accumulates a sufficient set of advantageous genetic abnormalities, each of which 
exerts a small but positive effect on net cell growth that allows it to further progress 
into a malignant lesion. Epimutations can be subject to the same natural selection 
process, provided that they generate phenotypic changes for selective pressure to 
act on251. A classical tumor contains 2 to 8 of such rate-limiting mutations 
outnumbered by a overwhelming majority of passenger mutations, i.e. neutral 
alterations that do no influence cell fitness but expand because they coincidentally 
arose along with driver mutations249.  
Based on the most recent estimation of the spontaneous somatic mutation rate 
(6x10-8/bp/division) and the rationalistic assumption of maximum 100 mitoses since 
cancer initiation, tumor genomes might bear about 40,000 somatic mutations. 
Accordingly, the scenario where tumor development is only driven by the strength 
of natural selection for cells that stochastically acquired driver mutations at a 
 Introduction  
 
 49 
normal rate is compatible with the greatest part of cancer cases. However, a 
subset of genomes from endometrial, stomach, colorectal, lung and skin cancers 
(representing 3.6% of all analyzed cancers) displayed more than 100,000 somatic 
mutations, a phenotype referred to as "hypermutation"252. In hypermutated lung 
cancers and melanomas, mutational burden could be explained by an established 
chronic exposure to particular mutagens, tobacco smoke and ultra-violet light 
respectively. In the remaining hypermutated cases, an increase of the intrinsic 
mutation rate must be required in order to reach such a heavy mutational load.  
 
Mutator phenotype and increased likelihood of acquiring driver mutations 
As mutations occur more or less randomly across the genome, some of them affect 
genes encoding caretaker proteins resulting in a reduced genome stability or 
"mutator phenotype". Mutator cells have an elevated intrinsic mutation rate that 
increases the likelihood to acquire advantageous alterations required to overcome 
each selective bottleneck in cancer evolution253. Consequently, across multiple 
rounds of natural selections for driver mutants, there is a simultaneous progressive 
enrichment of inactivating mutations in caretaker genes that will further generate 
heterogeneity and fuel tumorigenesis254. This concept is supported by studies in 
E.coli demonstrating that, within a population, the proportion of bacteria expressing 
a mutator phenotype is greatly increased after growth on restricted medium and 
can be further enhanced by sequentially submitting the surviving colonies to 
additional selective pressures255. Both environmental selective pressure and 
genetic instability are likely to contribute to cancer progression and may be tightly 
linked and interdependent as illustrated on figure 7.  
The involvement of a mutator phenotype in human cancers emanated from the 
discovery of the etiological factors causing cancer-predisposing hereditary 
syndromes with marked genetic instability. Indeed, inherited cancer syndromes 
frequently involve loss-of-function mutations in genes involved in DNA repair. This 
was first highlighted in Xeroderma Pigmentosum, where patients develop multiple 
skin cancers during childhood due to an inherited defect in one component of the 
 Introduction  
 
 50 
nucleotide excision repair (NER) pathway specialized in the resolution of helix-
distorting DNA lesions such as photo-induced pyrimidine dimers256. Later on, 
impairments of the mismatch repair (MMR) system, which removes biosynthetic 
errors arising in the newly replicated strand during genome duplication, were found 
to underlie hereditary non-polyposis colon cancer (HNPCC) syndrome257. 
 
 
 
Figure 7. Cancer progression is driven by natural selection and mutator phenotype. 
In normal tissue, cells accumulate mutations as a result of DNA lesions that escaped from 
the multiple repair processes. Natural selection fosters the expansion of cells that have 
acquired advantageous phenotypes conferred by driver mutations. With each selective 
bottleneck related to tumor growth (for example: reduced nutrition, hypoxia, cell-cell contact 
inhibition, anti-tumoral immunity), malignant cells with increasing numbers of driver 
mutations will outgrow. Cells that acquired by chance a loss-of-function mutation in 
caretaker genes will accumulate more mutations and have a higher likelihood to overcome 
selective pressure. Increased genetic instability, referred to as mutator phenotype, will 
further generate additional mutations resulting in genetically distinct cell variants within the 
tumor population. 
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Postreplicative mismatches 
DNA replication fidelity is guaranteed by two components highly conserved among 
species that both contribute to mutation avoidance. In mammalians, the first 
safeguard resides within the intrinsic accuracy of nuclear DNA polymerases-ε and -
δ (encoded by the genes POLE and POLD1) mediating synthesis of leading and 
lagging strands respectively. Replicative polymerases possess a high selectivity for 
Watson-Crick base pairing and err only once every 104 nucleotides, in the 
presence of a balanced dNTP pool. Moreover, replicative polymerases possess a 
3ʼ-5'-exonuclease activity that preferentially excises non-complementary 
nucleotides prior to the incorporation of the next base, lowering the error rate by 1 
order of magnitude (10-5). Besides the 2 major replicases pol-ε and -δ that perform 
the bulk of the work, 6 additional exonuclease-deficient DNA polymerases (pol-ζ, -
η, -ι, -κ, -ν, -θ) contribute to genome duplication by incorporating nucleotides 
opposite to DNA lesions that otherwise impede progression of pol-ε and -δ, hence 
the term "translesion polymerases"258.  
Mismatches generated during DNA chain elongation that persist once the 
replication fork has passed must be corrected before the next cell division in order 
to avoid mutation in 50% of progeny. They are handled through a second-line 
defense provided by the MMR machinery, further improving the overall fidelity of 
genome duplication by 2-3 orders of magnitude.  
 
Overview of the mismatch repair system 
MMR is a multicomponent system that requires the coordinated action of at least 
10 proteins in order to achieve efficient mismatch recognition, strand 
discrimination, excision of the error-containing nascent DNA tract and replacement 
by the correct sequence  (Figure 8)259,260. MMR process is initiated by dimers of the 
bacterial MutS homologs (MSH) that cover double stranded DNA and scan it in a 
search for helix distortions caused by non-complementary base pairs. There exist 3 
mammalian MSH proteins that associate as 2 different heterodimers, either MSH2-
MSH6 (MutSα) or MSH2-MSH3 (MutSβ) recognizing respectively small 
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mismatched or misinserted bases (1-2 nucleotides) and larger insertion-deletion 
loops (IDL). Upon DNA heteroduplex engagement, the MutS dimer undergoes a 
ADP-ATP exchange-driven conformational change into a sliding clamp and recruits 
a second heterodimer composed of MutL homologs (MLH). 4 mammalian 
homologs for MutL protein have been identified (MLH-1, -3 and post-meiotic 
segregation (PMS)-1,-2) that assemble as 3 distinct heterodimers, each of which 
comprising a  MLH1 subunit. The MLH1-PMS2 complex (referred to as MutLα) is 
the main regulator of downstream steps of repair. The 2 other MLH heterodimers, 
MutLβ (MLH1-PMS1) and MutLγ (MLH1-MLH3), participate to a lesser extent to 
MMR and partially compensate for the lack of MutLα in vitro, but fulfill other 
functions like chromosome segregation and meiotic recombinations261.  
At this step of MMR process, the mismatch recognition factors face the issue of 
strand discrimination. Because the correct genetic information resides within the 
template strand, excision must be directed to the error-containing nascent strand. 
Distinction between both is mediated via discontinuities in the newly synthesized 
strand providing loading sites for exonuclease-1 (EXO1) and requires the 
interaction of MSH-MLH dimers with proteins from the replication machinery, 
Replication factor C (RFC) and Proliferating cell nuclear antigen (PCNA) 
associated respectively with the 5'- and 3'-termini of the nascent DNA strand. The 
MutS-MutL complex can diffuse along DNA in both directions and will unavoidably 
encounter a strand end. Concerning the lagging strand, gaps between 2 Okazaki 
fragments endow EXO1 with ample initiation sites for hydrolyzing phosphodiester 
backbone with a 5'-3' polarity. By contrast, incisions in the continuous leading 
strand are generated by the latent endonuclease activity of MutLα, which is 
potentiated upon association with PCNA and RFC262,263. Once its endonuclease 
function is stimulated, MutLα introduces random single strand breaks including 
nicks 5' distal to the mismatch that will serve as starting point for the 5'-3' 
directional excision of the erroneous DNA tract. Replication protein A (RPA) 
protects single stranded DNA generated during excision and facilitates resynthesis 
by pol-δ followed by nick ligation mediated by DNA ligase-I264. 
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Figure 8. Resolution of polymerase errors by the proofreading activity and the 
mismatch repair system. Mismatches that escape proofreading activity of replicative 
polymerases are recognized by one of the 2 MutS dimers (MutSα/β). Once bound to a 
mismatch, MutS recruits a second heterodimer (MutLα/β/γ). Together they form a sliding 
clamp that diffuses along DNA in search for strand discrimination signal provided by DNA 
termini associated with replication factor C (RFC) and proliferating cell nuclear antigen 
(PCNA). Strand discontinuities serve as loading sites for the 5'-3' exonuclease1 (EXO1) that 
excises the error-containing DNA tract generating single stranded-DNA protected by 
replication protein A (RPA). The missing piece is resynthetized by polymerase-δ and both 
ends are ligated by DNA-ligase1. 
 
Modulation of MMR 
Since MMR is an immediate post-replicative correction mechanism, its activity is 
unsurprisingly coordinated in time and space along with the cell cycle. MMR genes 
reach their highest expression level during the DNA synthesis S phase265. In 
addition, the epigenetic histone marker H3K36me3, abundant during G1 and S 
phases, directly interacts with MSH6 thereby ensuring that MutSα is enriched on 
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chromatin before mispairs are introduced during duplication266. MMR process 
seems to be more effective in early replicating regions compared to late replicating 
heterochromatin which generates somatic mutation rate variations across the 
human genome267. Differences in accessibility of the repair machinery to DNA and 
the time available for correction before the next round of replication might 
contribute to this phenomenon. As genes fulfilling essential cellular functions map 
into early-replicating regions, it is conceivable that enhanced MMR in euchromatin 
is a beneficial trait protecting against cell survival-incompatible DNA lesions that 
has been selected for during evolution267. 
Efficacy of MMR can be influenced by additional intrinsic and extrinsic factors, 
some of them are related to tumorigenesis. As such, imbalanced dNTP pool 
decreases the fidelity of replicative polymerases268. MicroRNA (miR)-155 and miR-
21 down-regulate the expression of MLH1, MSH2 and MSH6	   269-271. MLH1 is 
transcriptionally repressed under hypoxic stress272,273. EGFR signaling mediates 
the phosphorylation of PCNA thereby inhibiting its interaction with MMR proteins274. 
Finally, acquired MMR deficiency involving epigenetic silencing of MLH1 occurs 
naturally in the ageing process of hematopoietic stem and progenitor cells, which 
might partially explain why hematological malignancies arise at a higher rate in 
older individuals275. 
 
MMR deficiency in familial cancers  
As already mentioned, mutations in genes encoding proteins involved in the MMR 
system are highly prevalent (65%) among families with HNPCC also known as 
Lynch syndrome, which is characterized by a dominantly inherited predisposition to 
a spectrum of cancers, primarily of colorectal and endometrial origins257. HNPCC 
individuals classically inherit a heterozygous loss-of-function alteration in genes 
encoding one the 7 mismatch recognition proteins that endows them with a high 
susceptibility to tumor development following somatic inactivation of the remaining 
allele by loss of heterozygosity. Mutations are highly prevalent in MSH2 and MLH1 
(50% of cases), less frequent in MSH6 (10%) and PMS2 (5%) while being very rare 
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in MSH3, MLH3 and PMS1, reflecting the key role of the 2 obligatory components 
of MutS and MutL heterodimers and the functional redundancy between other MSH 
and MLH factors276. The majority of the genetic MLH1 and MSH2 alterations are 
frameshift and nonsense mutations resulting in truncated proteins unable to 
interact with partners277. MLH1 can also be affected by missense substitutions of 
key residues. MLH1 and MSH2 mutations carriers have a cumulative risk for 
colorectal cancer at the age of 70 of approximately 40%278. 
A minority of families meeting the HNPCC clinical criteria but without alteration in 
the primary coding sequences of MMR proteins were shown to convey soma-wide 
mono-allelic methylation of the MLH1 or MSH2 locus, as an alternative cause of 
Lynch syndrome. Concerning the MLH1 gene, the molecular alterations underlying 
such epimutations are diverse (SNV in promoter, deletions of the first exons or 
larger rearrangements of the MLH1 flanking region)279-281. By contrast, MSH2 
epimutation are mainly caused by recurrent deletions in the 3' region of the 
upstream adjacent gene (EPCAM) encompassing its poly-adenylation signal. This 
results in a transcriptional read-through from EPCAM into the MSH2 locus and 
inactivation of the MSH2 promoter by methylation in tissue where EPCAM is 
expressed282. 
Germline mutations in the EXO1 gene identified in otherwise mutation-negative 
HNPCC patients were shown to encode mutants with reduced nuclease activity283 
or impaired interaction with MSH2284. However, their implication in HNPCC is still 
debated as some EXO1 variants occur naturally in healthy population285. 
Some individuals with dominantly inherited susceptibility to colorectal adenomas 
and carcinomas, resembling HNPCC, but in which mutations of known 
predisposing genes have been excluded, were found to carry an heterozygous 
germline missense mutation in POLD1 or POLE genes encoding the catalytic 
subunits of polymerases ε and δ. Mutations map to the exonuclease domain and 
are predicted to impair the proofreading function of polymerases assuring the first 
safeguard against post-replicative mismatches286. 
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Bi-allelic MMR-deficiency syndrome 
Rare individuals that inherit 2 mutations in both alleles of one MMR gene (MLH1, 
MSH2, PMS2, MSH6) present with childhood brain tumors and hematological 
malignancies (predominantly T-cell leukemias and lymphomas) in addition to early-
onset of colon cancer, a syndrome referred to as bi-allelic MMR-deficiency (b-
MMRD)287. A recent whole-genome sequencing study showed that a subset of 
brain tumors from bMMRD patients displayed an ultra-hypermutated phenotype (> 
250 point mutations per Mb), largely surpassing the mutational load of a reference 
dataset of 7,000 pediatric and adult cancer genomes288. Interestingly, non-
neoplasic cells from these patients have a similar number of variants compared to 
control individuals suggesting that cancer developed further to a second genetic 
hit. This latter turned out to be an early acquired somatic loss-of-proofreading 
mutation in POLE or POLD1, which results in a total ablation of post-replicative 
errors repair. As a consequence, malignant cells rapidly accumulate a large excess 
of de novo mutations each time they replicate, reaching but not exceeding the 
upper limit of 20,000 exonic mutations. This number represents the critical 
threshold for tolerable mutational load above which damage of additional genes 
becomes incompatible with cancer cell survival because essential cellular functions 
would be impaired288. 
MMR deficiency in sporadic cancers  
Besides familial cancers, MMR defects occur in a significant proportion (12-20%) of 
sporadic counterparts of the HNPCC-spectrum tumors, namely cancers of the 
gastro-intestinal, gynecologic and urologic tracts, principally due to bi-allelic MLH1 
methylation and more rarely to mutations in MMR genes289-291. Recently, 
comprehensive molecular characterization of colorectal and endometrial cancers 
classified tumors based on mutation frequencies into hypermutated (>12 
mutations/megabase) and ultra-hyper mutated (>50 mutations/megabase)292,293. 
Hypermutated tumors harbored the MLH1 methylation profile usually observed in 
sporadic HNPCC-spectrum tumors while ultra-hypermethylated tumors conveyed 
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mutations in the exonuclease domain of POLE combined or not with genetic 
abnormalities of other MMR factors, similarly to bMMRD. 
The increased risk for childhood leukemias and lymphomas associated with 
bMMRD syndrome suggests that alterations in MMR genes could underlie sporadic 
hematological malignancies. Furthermore, knocking-out MSH2 or MLH1 in mice 
causes an increased incidence of early-onset lymphomas (predominantly of the 
thymus)294,295. Historically, first evidences for involvement of compromised MMR in 
human sporadic blood cancers have been provided by means of leukemia and 
lymphoma cell lines in which inability to repair mismatches in vitro correlated with 
loss of expression or mutations in MMR genes296,297. Those observations are now 
confirmed in patients. MLH1 expresssion is epigenetically silenced in 24% and 
63%  
of AML and NKCL patient samples298,299. Cells from adult T-cell leukemia (ATL) 
patients display reduced or loss of expression of at least two MMR proteins300. 
Interestingly, some sporadic tumors display features of MMR deficiency but no 
detectable genetic or epigenetic alterations in known predisposition genes, 
indicating that there exist other ways for a malignant cell to downregulate the repair 
fidelity of mismatches. Recently, two MMR-deficient cancer cell lines were shown 
to convey inactivating mutations in the SETD2 gene coding for the histone 
modifying enzyme that catalyses the trimethylation at the lysine 36 of histone 3 
generating the epigenetic marker H3K36me3 needed for the recruitment of MutSα 
to chromatin266. Conversely, cells that artificially overexpress KDM4C, the enzyme 
that demethylates H3K36me3, are defective in MMR function301. At present, such 
genetic alterations affecting the epigenetic machinery were only observed in vitro 
but represent serious alternative candidates to explain MMR deficiency of cancer 
cells devoid of "classical" lesions. Finally, the expression of miR-155 is inversely 
correlated with MLH1 and MSH2 protein amounts in colorectal cancer tissues and 
a number of colon tumors with unknown cause of MMR inactivation overexpress 
MiR-155270. Table 1 gives a general outlook of the catalogue of the cancer-related 
genetic alterations affecting the MMR system. 
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Table 1. Genetic alterations affecting the MMR system in human malignancies and 
cell lines  
 
Mutational pattern of MMR-deficient tumors 
While most cancers typically harbor gross chromosomal rearrangements and 
aneuploidy, MMR-deficient tumors tend to be diploid and exhibit a normal rate of 
chromosomal alterations302. Genetic instability in cancer with compromised MMR 
almost invariably manifests as length variations in genomic regions composed of 
repeated short nucleotide tracks called microsatellites, a phenotype referred to as 
microsatellite instability (MSI). Owing to their repetitive nature, microsatellites are 
particularly susceptible hotspots for slippage errors occurring by mispairing 
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between template and newly synthesized strands resulting in small IDL that are not 
properly corrected in the absence of MMR and give rise to differences in the 
number of repeats.  
In addition to serve as a widely used diagnostic marker indicating that the tumor 
has developed as a consequence of MMR deficiency, MSI actively drives 
tumorigenesis by promoting frameshift mutations in microsatellites within the 
coding sequence of known tumor-suppressors. Accordingly, in MSI+ colorectal 
cancers, the TGFβ receptor II (TGFBR2) and the pro-apoptotic protein BAX are 
recurrently inactivated by slippage-induced insertions/deletions within 
polynucleotide tracts present in their open reading frames303,304. Interestingly, 
MSH3 and MSH6 genes also contain mononucleotide repeats that are frequently 
subject to inactivating frameshift mutations, further increasing the genetic instability 
of MSI+ cells305. The drawback of this increased mutability is that it boosts at the 
same time immunogenicity by generating tumor-specific antigens in sufficient 
amount to elicit T-cell responses306. Nevertheless, MSI+ tumors manage to evade 
anti-tumoral immunity by acquiring frameshift mutations in genes encoding key 
actors of antigen presentation, predominantly truncations of the light chain of the 
HLA-I complex (B2M) but also proteins of the antigen processing machinery such 
as the transporters TAP1 and TAP2307-310. 
Besides frameshift mutations in microsatellites, deficits in MMR function also 
enhance the rate of spontaneous and carcinogen-induced single base substitutions 
in MMR-deficient mice and cell lines, which could be corrected by complementation 
for the missing MMR gene311-313. Analysis of exome-sequencing data of MSI+ colon 
tumors generated a list of missense mutation hotspots in 33 genes and led to the 
identification of novel oncogenes314.  
Figure 9 proposes a graphic schematization for the evolution of the mutational load 
as a function of time in hereditary syndromes and sporadic cancers related to 
MMR-deficiency. Key inherited and acquired genetic alterations are indicated, 
some of them having a slope-modifying effect because they increase intrinsic 
mutation rate leading to hypermutated and ultra-hypermutated tumors. 
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Figure 9. Evolution of the mutational load in MMR-deficient tumors. In biallelic MMR 
deficiency syndrome (bMMRD), individuals inherit bi-allelic mutations in one MMR gene. 
Upon early acquisition of mutation in one gene encoding replicative polymerases (POLE or 
POLD1), cells accumulate random mutations in a rapid burst reaching a plateau at the cell 
survival compatible threshold (20,000 exonic mutations).  As a result, bMMRD patients 
present with very early cancer onset during childhood, mostly brain tumors and 
hematological malignancies. By contrast, in hereditary non-polyposis colon cancer 
(HNPCC), individuals inherit a germline heterozygous (epi)mutation in one MMR gene and 
cells accumulate mutations only after somatic inactivation of the remaining WT allele that 
occurs later in life. Alternatively, MMR-deficient tumors can develop after somatic bi-allelic 
methylation of MLH1 in individuals without mutation in MMR genes at birth. In both cases, 
cells accumulate point substitutions but preferentially frameshift mutations in genes 
containing microsatellites including tumor suppressors and MMR genes (MSH3 and MSH6) 
resulting in an even further increased mutation rate leading to hypermutated cancers 
(mutational load between 10 and 50 mutations/megabase). Inactivating mutations of 
POLE/POLD1 can also occur leading to ultra-hypermutated tumors (50-200 
mutations/megabase). 
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In conclusion, the mutator phenotype characteristic of MMR deficiency endows 
tumors with a specific spectrum of genetic abnormalities irrespective of hereditary 
and sporadic origin, namely frameshift deletions/insertions in tumor suppressor 
genes and missense mutations in oncogenes315. Interestingly, the ensuing 
mutational landscape is distinct from MMR-proficient counterparts 316, indicating 
that MSI+ and MSI- tumors progress through different carcinogenic genetic events 
and might therefore represent variant clinicopathological entities. For instance, 
MSI+ colorectal cancers have fewer APC, KRAS and TP53 mutations while 
displaying higher numbers of BRAF and TGF-β pathway-related alterations in 
comparison with MSI- tumors. 
 
Non-canonical functions of MMR proteins 
Additionally to correction of postreplicative errors during the S phase of mitosis, 
MMR proteins also take part in the cellular response to specific DNA damages and 
in the processing of modified bases317. Although base excision repair (BER) and 
nucleotide excision repair (NER) are the two main pathways believed to 
orchestrate the removal of modified nucleotides, MutSα has been shown to interact 
with oxidized, alkylated or crosslinked bases318,319. 2 models have been proposed 
to describe the mechanism by which MMR proteins activate signaling cascade 
leading to prolonged G2 arrest and eventual cell death 320. In the first model, MMR 
proteins bind DNA lesions and initiate futile repetitive cycles of repair that will be 
aborted after several unsuccessful attempts leaving a gap opposite to the damaged 
base321. These single-stranded breaks persist until the next round of replication 
when cell cycle checkpoint proteins recognize them as aberrant DNA structures 
and provoke mitosis arrest or cell killing. The alternative scenario is in favor of an 
active role of MMR factors by directly recruiting the Ataxia telangiectasia-mutated 
(ATM) or ATM- and Rad3-related (ATR) protein kinases which in turn activate 
downstream substrates that will relay cell-cycle arrest and apoptosis signaling via 
different pathways depending on the type and level of DNA damages. 
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In conclusion, MMR deficiency contributes to tumor development by exerting a dual 
deleterious effect: on the one hand, increased mutation rate due to persistence of 
replicative errors as well as modified bases and, on the other hand, defective 
apoptosis in response to DNA damage. Accordingly, studies of mice carrying 
mutations that selectively inactivate the mismatch repair activity of MSH2 but 
preserve its damage-response function indicate that the increased mutation rate in 
MMR-deficient cells is sufficient to drive tumorigenesis but defective apoptosis can 
further accelerate it322.  
 
Clinical implications of MMR deficiency in tumors 
One major clinical implication of MMR pathway playing a role in DNA damage 
signaling resides in the fact that many of the anti-cancer chemotherapeutics are 
DNA-damaging agents. Consequently, cancerous cells lacking a functional MMR 
pathway tolerate the presence of injured DNA resulting in primary refractoriness to 
a wide range of clinically used genotoxic molecules such as 6-thioguanine, 
alkylating agents and cisplatin derivatives 323-328. Moreover, initially MMR-proficient 
ovarian cancer cells can acquire a MMR-deficient phenotype by MLH1 promoter 
silencing upon exposure to chemotherapeutic drugs in vitro329,330. In line with this, 
hypomethylating agents like 5ʼ-AZA-2ʼdeoxyCytidine have been shown to 
resensitize cisplatin-resistant MLH1-silenced ovarian and colon cancer cells in vitro 
and in vivo331,332. All these experimental data are supported by consistent clinical 
observations. Loss of MMR function was significantly more prevalent in AML 
patients with chemotherapy-relapsed diseases compared with newly diagnosed 
patients333. Furthermore, MMR defects are widespread among secondary cancers 
that arise after successful chemotherapy for a primary malignancy334,335. 
Besides primary tolerance to classical DNA damaging anti-cancer treatment, MMR 
deficiency in tumors is postulated to also affect the efficacy of targeted therapies. 
Indeed, as describe earlier, the absence of efficient MMR system confers an 
increased mutation rate or mutator phenotype. The mutator hypothesis predicts 
that tumors are constituted of a highly heterogeneous population of genetically 
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distinct cell variants within which malignant cells harboring drug resistant mutations 
are likely to pre-exist336. Consequently, it has been assumed that MMR deficient 
tumors are prone to develop secondary resistance to any oncogene-targeted 
therapy although this statement based on theoretical assumptions still lack 
experimental and clinical evidences. 
 
General conclusion 
Defective MMR plays a critical role in the initiation, progression and therapeutic 
response of cancers from diverse origins (colorectal, endometrial, brain and 
hematological) (Figure 10). At early tumorigenesis, defective apoptosis in response 
to endogenous DNA damage-induced stress endows MMR-deficient cells with a 
slight proliferative advantage and contributes to their expansion within the 
malignant population. In more advanced stages, adaptation to selective 
environmental pressures related to tumor growth as well as immunity evasion are 
favored by the elevated random mutagenesis readily detectable as MSI. MMR-
deficient cancer cells are armored against anti-cancer treatments. On the one 
hand, as they tolerate DNA damages, genotoxic chemotherapeutics will face 
primary refractoriness. On the other hand, progressive enrichment of MMR-
deficient cells with increasing genetic instability results in a growing number of 
genetically distinct tumor subclones, which theoretically raises the probability of 
pre-existing variants harboring drug-resistant mutations that will lead to rapid 
relapse after oncogene-targeted therapy.  
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Figure 10. MMR-deficiency plays an active role in tumorigenesis. At the onset of 
cancer, DNA damages induced by endogneous genotoxic stress fail to elicit apoptosis in 
MMR-deficient, which results in their slight expansion. As the tumor progresses, malignant 
cells are exposed to environmental constraints that can be partially counteracted by MMR-
deficiency, leading to a progressive enrichment in MMR-deficient cells within the tumor 
population. MMR-deficiency also influences the response to anti-cancer therapies. 
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OBJECTIVES 
 
Previous discoveries reported by my host laboratory demonstrated that IL-9 
exerted no proliferative activity on freshly isolated lymphocytes but could act as a 
growth factor for in vitro derived T lymphocyte cell lines and promoted their 
malignant transformation associated with constitutive activation of the JAK-STAT 
pathway337. TS1 is one of such IL-9-dependent cell lines derived from a murine 
CD4+ T helper clone, which initially required antigen presentation by feeder cells 
for in vitro growth. However, upon long term culture, cells gradually lost their need 
for antigen stimulation and acquired compensatory IL-9 responsiveness allowing 
the derivation of stable IL-9-dependent cell lines338. The multistep deregulation 
process undergone by T cells during adaptation to IL-9 was accompanied by a de-
differentiation state with the progressive disappearance of T-cell markers 
reminiscent of pre-transformed cells339. Indeed, the IL-9-responsive TS1 cell line 
spontaneously gave rise to growth factor-independent clones with in vivo 
tumorigenic potency340 showing constitutive phosphorylation of JAK1, JAK3, 
STAT3 and STAT5 comparable to those elicited by IL-9 stimulation in parental 
cells341. When I started my PhD project, the causative mechanism remained to be 
elucidated. 
In a first study, we sought to unravel the genetic alterations underlying constitutive 
JAK-STAT signaling in our collection of growth factor-independent TS1 clones and 
aimed at evaluating the efficacy of short-term and long-term treatment with JAK 
inhibitors. This work highlighted the particular genotypic plasticity of TS1 cells 
endowing them with a remarkable faculty of adaptation to environmental selective 
pressures (cytokine withdrawal and JAK inhibitors) by successively acquiring 
activating point mutations in JAK1 and JAK3. As mentioned in the introduction, the 
emergence of tumor cells harboring newly acquired mutations accounts for the 
majority of clinical relapses upon TKI therapies. This led us, in a second study, to 
investigate the molecular mechanism promoting spontaneous mutagenesis in the 
TS1 model with the hope to find clinically relevant observations. 
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1. Cooperating JAK1 and JAK3 mutants increase resistance to JAK 
inhibitors 
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Key Points
• Cells transformed by
activating JAK1 mutations
become resistant to JAK
inhibitor by acquiring
activating mutations in JAK3
and vice versa.
• JAK1 and JAK3 mutants
cooperatively activate STAT
transcription factors.
The acquisition of growth signal self-sufficiency is 1 of the hallmarks of cancer. We pre-
viously reported that the murine interleukin-9–dependent TS1 cell line gives rise to
growth factor–independent cloneswith constitutive activationof the Janus kinase (JAK)-
signal transducer andactivator of transcription (STAT) pathway.Here,weshow that this
transforming event results from activating mutations either in JAK1, JAK3, or in both
kinases. Transient and stable expression of JAK1 and/or JAK3 mutants showed that
eachmutant induces STAT activation and that their coexpression further increases this
activation. The proliferation of growth factor–independent TS1 clones can be efficiently
blocked by JAK inhibitors such as ruxolitinib or CMP6 in short-term assays. However,
resistant clones occur upon long-term culture in the presence of inhibitors. Surprisingly,
resistance to CMP6 was not caused by the acquisition of secondary mutations in the
adenosine triphosphate–binding pocket of the JAK mutant. Indeed, cells that originally
showed a JAK1-activating mutation became resistant to inhibitors by acquiring another
activating mutation in JAK3, whereas cells that originally showed a JAK3-activating mutation became resistant to inhibitors by
acquiringanotheractivatingmutation inJAK1.Theseobservationsunderline thecooperationbetweenJAK1andJAK3mutants inT-cell
transformation and represent a new mechanism of acquisition of resistance against JAK inhibitors. (Blood. 2014;124(26):3924-3931)
Introduction
Hematopoiesis is a tightly regulated process in which cytokines
dictate fate (apoptosis, proliferation, or differentiation) of the various
progenitors through binding to speciﬁc receptors at the surface of
target cells. Most hematopoietic cytokine receptor chains associate
with a member of the Janus kinase (JAK) family to form a competent
cytokine–receptor complex. The JAK family comprises 4 tyrosine
kinases (JAK1, JAK2, JAK3, andTYK2) that bind to aproper repertory
of preassociated homo- or heterodimeric receptor chains. Structurally,
JAK kinases are characterized by the presence of a pseudo-kinase
domain directly adjacent to the kinase domain and are supposed to
prevent inappropriate catalytic activity of the kinase domain in
the absence of stimulus.1 The major substrates of activated JAKs
are the cytoplasmic signal transducer and activator of transcrip-
tion (STAT) molecules.
STAT factors play an active role not only in physiological hema-
topoiesis, but also in tumoral transformation because uncontrolled
STAT activation leads to growth signal self-sufﬁciency.2 In hema-
tologicalmalignancies, a commonmechanism for constitutive STAT
activation is the deregulation of tyrosine kinase activity of the
cytokine–receptor complex by gain-of-function alterations affecting
the JAK itself or its associated receptor chain. A classical illustration
is the activating JAK2V617F mutation identiﬁed in a substantial pro-
portion of patients with chronic myeloproliferative neoplasms
(MPNs).3-6 Among the JAK2V617F-negative MPNs, 5% of essential
thrombocythemia patients harbor a mutation in the thrombopoietin
receptor (commonly MPLW515L or W515K).7 In acute leukemias from
lymphoid or myeloid origin, various JAK1, JAK2, and JAK3mutations
and translocations have been reported.8-18 In childhood acute lympho-
blastic leukemia (ALL), gain-of-functionmutations of the interleukin-7
receptor chain (IL-7Ra) were described in 10% of cases.19,20 JAK
inhibitors therefore represent an appealing therapy for leukemia
patients because a signiﬁcant proportion (20% to 30% in childhood
ALL) seems to acquire growth signal self-sufﬁciency through con-
stitutive activation of the JAK-STAT pathway. Nevertheless, their
efﬁcacy has ﬁrst to be experimentally assessed using preclinical
leukemia models.
TS1 is an IL-9–dependent cell line derived from a murine CD41
T-helper clone. Although normal T cells require antigen presentation
for in vitro growth, repeated biweekly antigen stimulation led to
gradual acquisition of IL-9 responsiveness, loss of the need for
antigen presentation, and emergence of permanent IL-9–dependent
cell lines such as TS1.21 The progressive deregulation undergone
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by T cells during acquisition of IL-9 responsiveness is somewhat
reminiscent of themultistep process leading to cell transformation.22,23
Furthermore, the IL-9–responsive TS1 cell line could spontane-
ously give rise to growth factor (GF)-independent clones that were
tumorigenic in vivo.24 Even though there was no autocrine cytokine
production in the supernatants of these GF-independent clones, they
showed constitutive phosphorylation of JAK1, JAK3, STAT3, and
STAT5 comparable to those induced by IL-9 stimulation in parental
TS1 cells.25
Because of its T-cell origin and its ability to spontaneously reca-
pitulate the transformation process in vitro, the TS1 model provides
us with a unique opportunity to identify T-cell–speciﬁc oncogenic
events potentially implicated in ALL. The aims of our study were
ﬁrst to unravel the geneticmechanisms underlying constitutive JAK-
STAT activation in this model and, second, to test the efﬁcacy of
short- and long-term treatment with JAK inhibitors.
Methods
Cell cultures
TS1 and BW5147 cells were cultured in Iscove-Dulbecco’s medium sup-
plementedwith 10% fetal bovine serum, 50mMb-mercaptoethanol, 0.55mM
L-arginine, 0.24 mM L-asparagine, 1.25 mM L-glutamine, and, for TS1 cells,
murine IL-9 (100 U/mL) was added. CMK cells were cultured in RPMI
medium supplemented with 10% fetal bovine serum.
Stable DNA transfections and selection of clones
Wild-type (WT) JAK3 and human IL-9Ra complementaryDNA (cDNA)were
subcloned into the pMX-IRES-CD4 biscistronic retroviral vector upstream of
the IRES. WT JAK1 and human g chain (gc) cDNA were subcloned into the
pMX-IRES-GFP biscistronic retroviral vector upstream of the IRES. The
JAK3 (R657H, V674A) and JAK1 (Y652H and A634D) mutant cDNA
were generated using QuickChange XL II site-directed mutagenesis kit
(Stratagene). For stable transduction, retroviral supernatants were gener-
ated by transient transfection of the BOSC packaging cell line and used for
infection of 0.53 106 cells as described.26 Populations of cells expressing
markers were isolated by FACS sorting, using a phycoerythrin-coupled
antibody against hCD4 (#555347, BD Pharmingen) diluted 1/30.
For the selection of GF-independent TS1 clones, IL-9–dependent TS1
cells were washed 3 times in phosphate-buffered saline and seeded in 96-well
plates at a concentration of 5000 cells/well in the absence of cytokines. After
1 to 2 weeks, GF-independent clones were picked up from plates in which
less than 20% of wells were positive for proliferation, corresponding to a
probability of clonality superior to 0.9 according to the Poisson distribution.
For the selection of JAK inhibitor–resistant subclones, GF-independent TS1
clones were seeded in 96-well plates at a density of 30 000 cells/well in the
presence of 300 to 600 nM of either pan-JAK inhibitor CMP6 (Calbiochem,
cat#420097) or ruxolitinib (Haoyuan Chemexpress Co., INCB018424). After
2 to 3 weeks, wells containing proliferating cells were counted. Resistant
cells from plates meeting clonality conditions were picked up and ampliﬁed
in the presence of the respective JAK inhibitor.
Luciferase assays
STAT5 transcriptional activity was assessed by measurements of luciferase
expression in HEK293 cells upon transient transfection of appropriate cDNA
and pLHRE-luc vector harboring tandem copies of the STAT5-inducible
lactogenic hormone response element of the rat b-casein gene promoter,
inserted upstream a luciferase gene.27 Another reporter plasmid, Renilla
luciferase (pRLTk, Promega), was cotransfected as an internal transfection
control. Transient transfection of HEK293 cells by LipofectAMINE (Invi-
trogen) was previously described.28 Twenty-four hours after transfection,
luciferase assays were performed using the Dual Luciferase Reporter Assay
kit (Promega).
Western blots
For western blot analysis, 2 3 106 BW5147 or CMK cells were lysed in
200 mL of lysis buffer containing 50 mM tris(hydroxymethyl)aminomethane-
HCl, 1% NP40, 150 mM NaCl, 1 mM EDTA, 15% glycerol, Halt Protease
Inhibitor Cocktail 1/100, phenylmethylsulfonyl ﬂuoride 0.1 mM, and sodium
orthovanadate 0.1mM. A total of 35mL of lysates was loaded on Bolt 4% to
12% Bis-tris precast gels (Novex) and electrophoretically transferred to
nitrocellulose membranes (i-blot Gel Transfer Stacks, Novex). Phosphory-
lation of signaling proteins was investigated with the following phospho-
speciﬁc antibodies from Cell Signaling Technology: anti-pY705 STAT3
(#9131) and anti-pY694 STAT5 (#9351). Blots were reprobed with anti-
JAK1 (#3332), anti-JAK3 (#3775), anti-STAT3 (#9132) (Cell Signaling
Technology), anti-STAT5 (#835, Santa Cruz), or anti-b-actin (#A5441,
Sigma) antibodies as a control.
RNA extraction, cDNA synthesis, PCR, and sequencing
Total RNA was isolated from 106 TS1 cells using TriPure Isolation Reagent
(Roche). Reverse transcription was performed on 1 mg of total RNA using an
oligo-dT primer and M-MULV Reverse transcriptase (RevertAid Reverse
Transcriptase, Thermo Scientiﬁc). TaqDNApolymerase-mediated polymerase
chain reaction (PCR) ampliﬁcation (TaKaRa)was performedandPCRproducts
were sequenced using the DYEnamic Big Dye Terminator Kit (Amersham).
Results
GF-independent TS1 clones acquired point mutations in the
pseudo-kinase and kinase domains of JAK1 and/or JAK3
TS1, a T-lymphocyte cell line, is dependent on IL-9 for proliferation.
Removal of IL-9 from the culture medium results in rapid cell death,
but few cells occasionally succeed to proliferate independently of
GF (at a frequency of approximately 1/20 000). We selected 50
GF-independent TS1 clones. Constitutive STAT5, STAT3, AKT,
JAK1, and JAK3 phosphorylation could be observed in all tested
IL-9–independent clones, but not in IL-9–starved parental TS1 cells25
(supplemental Figure 1, available on the Blood Web site). GF-
independent TS1 clones remained sensitive to JAK inhibitors,
indicating that their proliferation still relies on JAK activity (data
not shown).
Because both JAK1and JAK3were constitutively phosphorylated,
we sequenced the JAK1 and JAK3 cDNA in our collection of 50 GF-
independent TS1 clones and found that all of them had acquired a
missense point mutation affecting a residue of the pseudo-kinase or
kinase domains of either JAK1, JAK3, or both (Table 1). Amajority
of clones harbored a singlemutation in 1 JAK (23with JAK1mutation
vs 22 with JAK3 mutation), but some clones (5 of 50) acquired a
mutation in both kinases of the IL-9 receptor complex. Altogether,
we identiﬁed 16 different mutations (6 in JAK1 and 10 in JAK3)
affecting 14 residues conserved in mouse and human JAK. As
shown in Figure 1, the great majority of mutations map to the inter-
face between pseudo-kinase and kinase domains of JAK1 and
JAK3 that was recently shown to mediate autoinhibitory mecha-
nisms.29 For 7 of the 14 residues mutated in our clones, mutations
have been also described in human cancers (supplemental Table 1).
Although the total number of mutations of JAK1 and JAK3 was
equal (28 JAK1 mutations vs 27 JAK3 mutations), statistics conﬁrm
that they were not randomly distributed among experiments suggest-
ing that the relative expansion of the mutated cells occurred before
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cytokine withdrawal (chi-squared test, P , .05) (supplemental
Table 2).
Activated JAK1 and JAK3 mutants cooperate for downstream
signal transduction
The observation that some GF-independent clones had acquired
mutations both in JAK1 and JAK3 raised the hypothesis that these
mutants might cooperatively contribute to the activation of the sig-
naling pathways necessary for survival and proliferation. To address
this hypothesis,we compared the activation of the JAK-STATpathway
induced by expression of a single JAK mutant vs coexpression of
the JAK1Y652H together with JAK3V674A or JAK3R657H mutants
found in ALL patients. To avoid any bias during selection of
stable transfectants, these mutants were expressed in the murine
lymphoma T cells BW5147, which do not rely on the JAK-STAT
pathway for proliferation.
As shown in Figure 2A, stable expression of JAK1Y652H,
JAK3V674A, or JAK3R657H alone resulted in constitutive phosphory-
lation of STAT5 (Figure 2A, lanes 3, 4, and 6). This phosphorylation
was further increased when JAK1 and JAK3 mutants were coex-
pressed (Figure 2A, lanes 5 and 7). For JAK1, JAK3, and STAT3,
phosphorylation was either exclusively observed in the presence of a
combination of 2mutants or increased in comparisonwith eachmutant
separately. This indicates that, in BW5147 cells, JAK1 and JAK3mu-
tants cooperate in their transphosphorylation and subsequent activa-
tion of downstream signaling molecules STAT3 and STAT5. These
observations were corroborated in the human acute megakaryoblastic
leukemia CMK cell line harboring a heterozygous activatingmutation
in JAK3 (A572V).13 As displayed in Figure 2B, stable expression of
JAK1A634D enhanced the phosphorylation of JAK3 and STAT3 pro-
viding evidence that a JAK1 activated mutant can collaborate with an
endogenous JAK3 mutant.
Furthermore, in HEK293 cells transiently transfected with a
STAT5-responsive luciferase reporter construct, single expression of
JAK1Y652H, JAK3V674A, or JAK3R657H induced STAT5 activation
that was further exacerbated by coexpression of JAK1 and JAK3
mutants (Figure 3). Altogether, these 2 different experimental models
show the cooperation of JAK1 and JAK3 mutants in the activation of
the JAK-STAT pathway in 3 cell lines and support the hypothesis
that JAK1 and JAK3 collaborate toward the transformation of
IL-9–dependent TS1 cells into GF-independent clones.
Secondary mutations in the other JAK of the cytokine receptor
complex confer increased resistance to JAK inhibitors
CMP6 is an adenosine triphosphate (ATP)-competitive tyrosine
kinase inhibitor that effectively inhibits all JAK. In short-term assay,
GF-independent proliferation of TS1 clones could be efﬁciently
blocked by CMP6 with a half maximal inhibitory concentration
(IC50) close to 0.1mM(data not shown). GF-independent TS1 clones
harboring primary mutations in either JAK1 (A3, A4) or JAK3 (A6,
A11, T4, T15)were seeded in 96-well plates in the presence ofCMP6
concentrations inhibiting 100% of cell proliferation within 2 days
(300 to 600 nM). Upon long-term culture, CMP6-resistant clones
arose at a low frequency (1 in 2 million cells). Using this exper-
imental setup, 20 CMP6-selected subclones were obtained from 2
independent TS1 cloneswith the JAK1Y652Hmutation, and 56CMP6-
selected subclones were obtained from 4 independent clones with 3
different JAK3 mutations (L586S, V674A, and T848A). Contrary to
Table 1. List of the JAK1 and JAK3 mutations identified in
GF-independent TS1 clones
JAK1 JAK3
Number of TS1 clones
(n 5 50)
V645A* — 1
Y652H* — 16
Y652D* — 1
K847E — 4
F958V — 1
— A572V* 1
— L586S 6
— R657H* 2
— F666L 1
— V674A* 10
— Y824C* 1
— T848A 1
S646P* L586V 1
Y652H* R657H* 1
Y652H* Y904C 1
Y652H* Y939C 1
F958V Y824C* 1
The 16 different mutations occurring either separately or associated. For each
combination, the absolute frequency is indicated for 50 characterized TS1 clones. All
14 affected amino acids are conserved in mouse and human JAK (amino acid
numbers correspond to human sequence).
*Described in human cancers.
Figure 1. Localization of the 16 identified missense point mutations in JAK1
and JAK3. The figure represents the predicted 3-dimensional structure of kinase
and pseudo-kinase domains of JAK1 and JAK3 based on the recent TYK2 crystal
structure.29 Molecular images were obtained with the PyMOL molecular visualization
system. The pseudo-kinase domain is shown in light blue for JAK1 and green for
JAK3. The adjacent kinase domain is shown in violet for JAK1 and pink for JAK3.
The aC helix is shown in beige and activation loop in red. Mutated residues are
indicated with orange balls.
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our expectations, none of these subclones had acquired any secondary
mutations in the originally mutated JAK. By contrast, 16 of the 20
subclones (80%) with a primary JAK1 mutation had acquired a
mutation in JAK3, whereas 32 of the 56 subclones (57%) with a
primary JAK3 mutation had acquired a mutation in JAK1 (Table 2).
Most of the secondary mutations affect the homologous residues
F958 in JAK1 and Y904 in JAK3 located in the ATP-binding pocket
of the kinase domain.Wepreviously showed thatmutations targeting
the F958 residue of JAK1 not only confer constitutive kinase activity
but also resistance to ATP-competitive JAK inhibitors.30 However,
other secondarymutationswere located in the pseudo-kinase domain
of JAK1 (Y652H and F804L) or in the kinase domain of JAK3outside
the ATP-binding pocket (R840C) and are not expected to directly
confer resistance to JAK inhibitor. For instance, the JAK1Y652H
mutation was previously shown to transform BaF3 cells but did
not change their sensitivity to JAK inhibitors.30 As illustrated in
Figure 3A-B, the proliferation of TS1 clones harboring the primary
JAK1Y652H mutation (clones A3 and A4) was blocked by CMP6with
an IC50#0.1mM in the same range as clones with the JAK3
V674A or
JAK3T848Amutations (clones A11 and T15, respectively). However,
the CMP6-selected subclones A11R21 and T15R3, which both
had acquired the JAK1Y652H as a secondary mutation, showed a 4 to
7 times higher IC50 of 0.4 to 0.7mM. This observation indicated that
increased resistance to a kinase inhibitor such as CMP6 can be con-
ferred by cooperativity between 2 active mutants of JAK1 and
JAK3, which are both intrinsically CMP6-sensitive.
To test this hypothesis in anothermodel, we took again advantage
of the human CMK cell line carrying the JAK3A572V mutation.
Proliferation of CMK cells can be efﬁciently blocked by the JAK1/
2 inhibitor ruxolitinib. However, CMK cells transduced with the
JAK1A634D mutant exhibited a 2-fold shift in IC50 compared with
cells transducedwith JAK1WTor nontransduced (nontransduced:
88 nM; JAK1WT: 75 nM; JAK1A634D: 163 nM) (data not shown).
These experiments show that acquiring a secondary activating
mutation in another JAK allows for increased resistance to JAK
inhibitors that block both JAKs. However, a striking observation
from the CMP6-selected subclones described in Table 2, is that
such secondary mutations did not occur in the other allele of the
originally mutated JAK. This contrasts with JAK2V617F-MPNs
patients, where homozygosity is often observed because of homolo-
gous recombination. JAK2 associates with homodimeric receptors
such as the erythropoietin-receptor, whereas JAK1 and JAK3 are
involved in signaling by heterodimeric cytokine receptor complexes
using the commongc. In this respect, our data suggest that signalingby
heterodimeric receptor complexes is further boosted by acquiring
another heterozygous activating mutation in the JAK partner rather
than by having both alleles of a single JAK mutated.
To address this question, we reconstituted homozygous and
heterozygous JAK conﬁgurations in HEK293 cells by transiently
Figure 2. JAK1 and JAK3 mutants cooperatively activate the JAK-STAT
pathway. (A) A total of 2 3 106 BW5147 cells nontransduced (NT) or stably
transduced with JAK1 (WT or Y652H mutant) together with JAK3 (WT, V674A, or
R657H mutants) were lysed and subjected to western blot analysis. The basal
phosphorylation level of STAT and JAK proteins was detected using anti-pY694
STAT5, anti-pY705 STAT3, anti-pY1034/1035 JAK1, and anti-pY980/981 JAK3
antibodies. Cells expressed equivalent levels of JAK1 and JAK3, as shown with anti-
JAK1 and anti-JAK3 antibodies. Membranes were reprobed with anti-STAT3, anti-
STAT5, and anti–b-actin antibodies as loading control. (B) A total of 2 3 106 CMK
cells NT or stably transduced with JAK1 (WT or A634D mutant) were lysed and
Figure 2 (continued) subjected to western blot analysis. Basal phosphorylation
level of STAT and JAK proteins was detected using anti-pY694 STAT5, anti-pY705
STAT3, anti-pY1034/1035 JAK1, and anti-pY980/981 JAK3 antibodies. Membranes
were reprobed with anti-STAT3, anti-STAT5, anti-JAK1, anti-JAK3, and anti–b-actin
antibodies as loading control. (C) HEK293 cells were transiently cotransfected with
JAK1 (WT or Y652H mutant), JAK3 (WT, V674A, or R657H mutants), the IL-9Ra
chain, and common g-chain, in addition to the STAT5-responsive luciferase reporter
construct pLHRE and the pRLTK plasmid as transfection control. Twenty-four hours
posttranfection, cells were lysed and subjected to dual luciferase activity assay.
Histograms are means 6 standard error of the mean of 5 independent experiments.
A 1-way analysis of variance test was performed to compare the condition with the 2
mutants vs each condition with 1 mutant only (**P , .01).
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transfecting JAK1 (WT, Y652H, or an equimolar mix of both) and
JAK3 (WT, V674A, or both) together with the IL-9Ra and gc cDNA.
Cells were then treated or not with increasing concentrations of CMP6
(0.01 to 0.1 mM) and STAT5 activity was assessed 24 hours
posttransfection. As shown in Figure 4, the basal level of STAT5
activity was higher in cells having 50% from each activated JAK
mutant compared with cells having 100% of mutated JAK1 or JAK3
(black histograms). This boost in JAK-STAT pathway activation
could be explained by the fact that both JAK1 and JAK3 mutants
interact within the sameheterodimeric receptor complex,whereas such
an association is not possible in a homozygous situation. CMP6 treat-
ment decreased STAT5 activity in all transfected cells but for each
inhibitor concentration, STAT5 activity remained signiﬁcantly higher
in the double heterozygous condition compared with the homozygous
ones (Figure 4). Complete titration allowing to assess IC50 concen-
trations conﬁrmed that the intrinsic ability of CMP6 to inhibit STAT5
phosphorylation is not altered in the double heterozygous condition
(JAK1 homozygous: 61 nM; JAK3 homozygous: 365 nM; double
heterozygous: 250 nM) (data not shown). These results support the
hypothesis that acquiring a secondary mutation in the JAK partner
from heterodimeric cytokine receptor complex activates the pathway
further than becoming homozygous. In addition, when basal STAT5
activity is boosted to strong levels by the 2 mutated JAKs, CMP6 still
interferes with STAT5 activation, but higher concentrations would be
required to reach a critical threshold.
Secondary mutations in JAK3 confer increased resistance to
a JAK1-specific inhibitor
It is well known that the transforming effect of an active JAKmutant
depends on its association with cytokine receptor chains allowing
homo- or heterodimerization with another JAK and subsequent cross-
phosphorylation.31,32 For instance, an active JAK3 mutant requires a
functional JAK1 partner for constitutive signaling.33 When CMP6, a
pan-JAK inhibitor, was used to select resistant TS1 subclones,
selective pressurewas exerted onboth themutated JAKand its partner,
and secondary mutations in the JAK partner provided a selective
advantage. We thus wondered whether the same process of selection
would occur if only JAK1 activity is blocked with a more selective
kinase inhibitor such as ruxolitinib, which is at least 100 times less
potent on JAK3.34
To address this question, we seeded 6 different GF-independent
TS1 clones harboring the primary JAK1Y652Hmutation in the presence
of ruxolitinib. Ruxolitinib-resistant subclones arose at a frequency com-
parable to what was observed during selection with CMP6. JAK1 and
JAK3 cDNA sequencing revealed that 44 of 53 ruxolitinib-selected
TS1 subclones had acquired secondary mutations in the JAKs.
Twenty-ﬁve of them (57%) had a secondarymutation in JAK3, similar
to the selection with CMP6, although ruxolitinib is not supposed to
block JAK3. However, contrasting with CMP6 selection, 18 of the
ruxolitinib-selected subclones had a secondary mutation in JAK1, ei-
ther within or outside the ATP-binding pocket, including 4 subclones
that became homozygous for the JAK1Y652H mutation (Table 3).
Finally, 1 of the ruxolitinib-selected subclones had acquired 2 secondary
mutations, JAK1F958S and JAK3R840C.As for theprimarymutations, the
Table 2. List of secondary mutations occurring in CMP6-selected
TS1 subclones derived from 6 different GF-independent TS1 clones
TS1 clones
Primary mutation
Secondary
mutation
FrequencyJAK1 JAK3 JAK1 JAK3
A3 Y652H — — Y904H 7/10
— Y904C 1/10
— — 2/10
A4 Y652H — — R840C 1/10
— Y904H 1/10
— Y904C 6/10
— — 2/10
A6 — L586S F958C — 3/6
F958V — 3/6
A11 — V674A Y652H — 1/27
F958C — 4/27
F958V — 1/27
F958L — 1/27
— — 20/27
T4 — V674A F958C — 10/13
F958V — 3/13
T15 — T848A Y652H — 4/10
F804L — 1/10
F958C — 1/10
— — 4/10
The autonomous TS1 clones with their corresponding primary JAK mutation
and the secondary mutations identified in their CMP6-selected subclones. For
each combination, relative frequency is indicated.
Figure 3. Sensitivity to pan-JAK inhibitor CMP6 of GF-independent and CMP6-
selected TS1 clones. (A-B) GF-independent TS1 clones with endogenous JAK1 or
JAK3 mutants and CMP6-selected TS1 clones with endogenous JAK1 and JAK3
mutants were seeded in 96-well plates at a density of 1000 cells/well with increasing
concentrations of pan-JAK inhibitor CMP6 (0 to 1 mM). After 48 hours, methyl-3H
thymidine was added to the cells for 4 hours and thymidine incorporation was
measured. Results are means 6 standard deviation of triplicate cultures represented
in % of control untreated cells.
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observation of a single predominant mutation within an experiment
(eg, JAK3Y824D inA3) is consistent with the hypothesis of preexisting
secondary mutations before selective pressure with the inhibitor.
Altogether, our results indicate that when 1 JAK from a heterodimeric
cytokine receptor complex is speciﬁcally targeted by a tyrosine kinase
inhibitor, resistance can be conferred either by a secondarymutation in
the other JAK partner or by a secondary activating mutation in the
same JAK. In both cases, and in line with CMP6-selected clones, the
secondary mutations are not restricted to the ATP-binding pocket.
Discussion
In the present study, we describe a new mechanism of resistance to
JAK kinase inhibitors. We show that 2 concomitant spontaneous
activating mutations in endogenous JAK1 and JAK3 cooperatively
activate the JAK-STAT pathway leading to increased resistance to
CMP6 or Ruxolitinib. Interestingly, such resistance could be con-
ferred by combining mutations that do not affect the sensitivity of
cells to JAK inhibitors when present individually.
In our series of subclones selected in the presence of tyrosine
kinase inhibitors (TKI), TKI resistance was not primarily conferred
by impairing drug binding to the oncogenic kinase, but rather by
increasing the activity of the heterodimeric JAK–receptor complex.
Indeed, secondary mutations associated with CMP6 resistance did
not affect the originally mutated JAK. In addition, the secondary
mutations in the JAK partner observed here were previously de-
scribed as activating mutations per se, associated with oncogenesis
in vitro and in vivo (supplemental Table 1; Hornakova et al30).
However, these activating mutations can be further divided into 2
types. First, a series of mutations can either lead to GF independence
with normal TKI sensitivity when occurring as primary mutations or
increase TKI resistance when occurring as secondary mutations. This
ﬁrst set of mutants is illustrated in Figure 4 with JAK1Y652H. On the
other hand, another series of secondary mutations target the JAK1
F958 residue or the JAK3 Y904 residue, which correspond to
homologous amino acids that were previously found to confer both
constitutive activation and lower sensitivity to JAK inhibitors.30
Thus, selective pressure with the JAK inhibitor selects essentially
for activating mutations, but with a further advantage for gain-of-
function mutations that also affect drug binding.
In patients relapsing after treatment with TKI targeting oncogenic
proteins such asBCR-ABL, c-Kit and epidermal growth factor receptor
(EGFR) secondary mutations frequently occur in the kinase domain
of the respective target. A great part of those substitutions affect the
conserved threonine gatekeeper residue regulating access of TKIs to
the ATP binding pocket, pointing to impaired drug binding as the
main cause of resistance. Classic examples include theBCR-ABLT315I
mutation in chronic myeloid leukemia (CML),35 the c-KitT670I
mutation in gastrointestinal stromal tumors36 and EGFRT790M in
lung adenocarcinomas.37 There are other substitutions described in
imatinib-resistant CML patients that are not located near the ATP-
binding site of BCR-ABL, but are postulated to destabilize the
conformation of the kinase domain required for inhibitor binding.38
Interestingly, some of the BCR-ABL imatinib-resistant muta-
tions (Y235F/E255K/T315I) have also been reported to enhance
the oncogenic potency or kinase activity of the fusion protein inde-
pendently of their effect on drug sensitivity and are therefore con-
sidered as gain-of-function mutations.39-41 Using high-sensitivity
detection methods, BCR-ABL imatinib-resistant mutations could
be detected at low levels in a considerable fraction (12.5% to 22%)
of untreated CML patients, indicating that resistant mutations can
preexist to the onset of treatment.42-44 Noticeably, the majority of
pretreatment secondary mutations are gain-of-function substitutions,
Table 3. List of secondary mutations occurring in
ruxolitinib-selected TS1 subclones derived from 6 different
GF-independent clones
TS1 clones
Primary mutation
Secondary
mutation
FrequencyJAK1 JAK3 JAK1 JAK3
A3 Y652H — — Y824D 8/9
— — 1/9
A4 Y652H — — Y904C 2/9
— Y904H 3/9
F958C — 1/9
— — 3/9
A5 Y652H — — L586S 3/11
— F666L 1/11
— R840H 1/11
— Y904C 5/11
L910P — 1/11
A7 Y652H — Y652H — 1/10
F958S — 8/10
F958S R840C 1/10
T16 Y652H — — R840H 1/9
Y652H — 1/9
S1042I — 2/9
— — 5/9
T18 Y652H — — Y904C 1/5
Y652H — 2/5
F958V — 1/5
S1042I — 1/5
The GF-independent TS1 clones with their corresponding primary JAK1
mutation and the secondary mutations identified in their ruxolitinib-selected
subclones. For each combination, relative frequency is indicated.
Figure 4. Inhibition by CMP6 of STAT5 activity in cells expressing JAK1 and/or
JAK3 mutants. HEK293 cells were transiently cotransfected with JAK1 (WT, Y652H
mutant, or both in equimolar concentration to mimic heterozygous vs homozygous
configuration), JAK3 (WT, V674A mutant, or both), IL-9Ra, and gc, in addition to the
STAT5-responsive luciferase reporter construct pLHRE and the pRLTK plasmid as
transfection control. Cells were maintained in the presence of increasing concentra-
tions of pan-JAK inhibitor CMP6 or left untreated. Twenty-four hours posttransfec-
tion, cells were lysed and subjected to dual luciferase activity assay. Raw values were
standardized with BCR-ABL–induced STAT5 activity. Histograms are means6 standard
error of the mean of 5 independent experiments performed in triplicate. A 1-way
analysis of variance test was used to determine P values between the heterozygous
and the 2 homozygous configurations for each CMP6 concentration (*P , .05, **
P , .01, ***P , .001).
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suggesting that theymight confer a slight proliferation advantage over
parental BCR-ABL in the absence of imatinib, and expand during
treatment under selective pressure.43,44 In our TS1 model, a similar
selection process of preexisting activating JAK1 and JAK3mutations
might take place. During culture, spontaneous mutations occur
randomly throughout the TS1 cell genome and some of them activate
JAK1 or JAK3. GF-independent cells with a single activating JAK
mutation that acquired by chance a secondary activating mutation in
the JAK partner activate further the JAK-STAT pathway, which pro-
vides a subtle growth advantage allowing for their persistence and
slow relative expansion in the culture. JAK inhibitor selection pressure
will foster the emergence of these double-mutated cells because their
higher basal level of JAK-STAT activation will raise the threshold
inhibitor concentration needed to induce apoptosis. The hypothesis
that the secondary mutations preexisted before selection with JAK
inhibitors is supported by the fact that, in several experiments, a
majority of TKI-resistant subclones showed the same secondary
mutation (Tables 2 and 3).
In ALL patients, activating mutations in either JAK1, JAK3, and
IL-7Ra have beendescribed in approximately20%of the patients,18,45
raising a potential indication for JAK inhibitors. Our data suggest that
such treatment could favor the selection of tumor clones with pre-
existing mutations in both JAK1 and JAK3. This possibility is
supported by the fact that several cases of leukemia patients with
concomitantmutations in the pseudo-kinase or kinase domains of JAK1
and JAK3 have already been reported (supplemental Table 3). 18,46-48
Secondary mutations are not the exclusive way for transformed
cells to survive in the presence of TKIs, and some of our TKI-
resistant subclones did not show any secondary mutation in JAK1
or JAK3 (Tables 2 and 3). The 2 types of JAK inhibitor–selected
subclones (mutated and nonmutated) cannot be distinguished based
on their sensitivity to inhibitors. All JAK inhibitor–selected sub-
clones do not exhibit an absolute resistance, but rather a relative shift
in sensitivity (Figure 3A-B). This gives us a rationale to speculate that
the unknown mechanism allowing the nonmutated subclones to
proliferate in the presence of inhibitor still relies on JAK activity.
However, no mutations in JAK2 and TYK2 were found in 20
nonmutated subclones analyzed so far. Alternatively, a shift in
oncogene addiction from the JAK-STAT toward phosphatidylinositol
3-kinase or mitogen-activated protein kinase pathways is not excluded.
In JAK2V617F-transformed cell lines treatedwith gradually increasing
doses of ruxolitinib in vitro, JAK2 overexpression was associated
with a reversible stage of so-called JAK2 inhibitor persistence.49 In
our laboratory, we observed a similar increase in the expression of
JAK1 messenger RNA in BAF3 cells expressing the endogenous
JAK1F958Vmutantwhen cellswere cultured in the presence ofCMP6.30
However, we did not observe any signiﬁcant increase in JAK1 and
JAK3 messenger RNA expression levels for our TKI-resistant
subclones without secondary mutations in JAK (data not shown).
An alternative resistance mechanism might result from loss of
negative regulators of the pathway, such as PTPN2, a phosphatase
active on phospho-tyrosine residues located in the activation loop
of JAK1 and JAK3 and necessary for full kinase activity.50 Deletions
of PTPN2 were identiﬁed in 6% of T-cell ALL cases51 and knock-
down of PTPN2 reduced sensitivity of cells to JAK inhibition.52
Because of its high versatility, the TS1model described here rep-
resents an invaluable tool for further studies aimed at unraveling new
secondary mutation in such genes that might cause increased TKI
resistance.
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Supplementary data 
 
Mutation Tumor type Proof of Activity 
JAK1 V645F Hepatocellular carcinoma 1 + 2 
JAK1 S646F Childhood ALL 3 + 3 
JAK1 Y652H T-ALL 4 + 2 
JAK3 A572V AMKL 5, NKT-CL 6, 
T-PLL 7 
+ 5, 6 
JAK3 R657Q DS-AMKL8, JMML 9,T-PLL 10 +!11 
JAK3 V674A T-ALL 12,T-PLL 7 + 11 
JAK3 Y824D T-PLL 7 ND 
 
Supplementary table 1. JAK1 and JAK3 mutants identified in our TS1 model 
and in human cancers. Proof of activity was defined as the ability to transform 
BAF3 cells, or to activate STAT factors in HEK293 cells. ALL acute lymphoblastic 
leukemia, AMKL acute megakaryoblastic leukemia, NKT-CL natural killer T-cell 
leukemia, T-PLL T-prolymphocytic leukemia, DS-AMKL Down syndrome-related 
acute megakaryoblastic leukemia, JMML juvenile myelomonocytic leukemia. 
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 JAK1 JAK3 Mutation occurrence  
(n=55) 
Y652H  6/12 
F958V  1/12 
 L586S 3/12 
 V674A 1/12 
EXP1 
 
 
 
 
 Y935C 1/12 
V645A  1/16 
S646P  1/16 
Y652H  1/16 
K847E  3/16 
 A572V 1/16 
 L586V 1/16 
 R657H 2/16 
 F666L 1/16 
 V674A 4/16 
EXP2 
 
 
 
 
 
 
 
 
 
 T848A 1/16 
Y652H  4/9 
F958V  1/9 
 R657H 1/9 
 Y824C 2/9 
EXP3 
 
 
 
 
 Y904C 1/9 
 L586S 2/6 EXP4 
  V674A 4/6 Y652H  3/5 
Y652D  1/5 
EXP5 
 
 
 V674A 1/5 
Y652H  6/7 EXP6 
  L586S 1/7  
Supplementary table 2. Frequencies of the JAK1 and JAK3 mutations 
identified in GF-independent clones coming from 6 independent selection 
experiments. 
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JAK1 JAK3 Tumor type 
Y652D A572V NKT-CL6 
E997K A572V T-ALL12 
L910P L857P T-ALL12 
L653F M511I T-PLL7 
R724H R657Q T-ALL10 
 
Supplementary table 3. Concomitant JAK1 and JAK3 mutations identified in 
human leukemia. NKT-CL natural killer T-cell leukemia, T-ALL acute lymphoblastic 
leukemia, T-PLL T-prolymphocytic leukemia. 
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Supplementary figure 1. Growth factor-independent TS1 clones show 
constitutive activation of JAK1 and JAK3  and downstream signaling 
molecules. 106 cells from starved parental IL-9-dependent TS1 cell line and from 9 
GF-independent clones (A1/2/3/8/11 and T1/2/5/9) were lyzed and subjected to 
Western Blot analysis. Basal phosphorylation level of molecules was detected using 
anti-JAK3(pY980/981), anti-JAK1(pY1022/1023), anti-STAT5(pY694), anti-
STAT3(pY705), anti-Akt(pS473) antibodies. Membranes were reprobed with anti-
JAK1, anti-JAK3, anti-STAT5 and anti-ß-Actin antibodies as loading controls. 
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ABSTRACT 
 
Genomic instability drives cancer progression by promoting genetic abnormalities 
that allow for the multi-step clonal selection of cells with growth advantages. We 
previously reported that the IL-9-dependent TS1 cell line sequentially acquired 
activating substitutions in JAK1 and JAK3 upon successive selections for growth-
factor independent and JAK inhibitor-resistant cells, suggestive of a defect in 
mutation avoidance mechanisms. In the first part of this paper, we discovered that 
the gene encoding MLH1, a key component of the DNA mismatch repair system, is 
silenced by promoter methylation in TS1 cells. By means of stable ectopic expression 
and RNA interference methods, we showed that the high frequencies of growth 
factor-independent and inhibitor-resistant cells with activating JAK mutations can be 
attributed to the absence of MLH1 expression. In the second part of this paper, we 
confirm the clinical relevance of our findings by showing that chronic myeloid 
leukemia relapses upon ABL-targeted therapy correlated with a lower expression of 
MLH1 messenger RNA. Interestingly, the mutational profile observed in our TS1 
model, characterized by a strong predominance of T:A>C:G transitions, was identical 
to the one described in the literature for primitive cells derived from chronic myeloid 
leukemia patients. Taken together, our observations demonstrate for the first time a 
causal relationship between MLH1-deficiency and incidence of oncogenic point 
mutations in tyrosine kinases driving cell transformation and acquired resistance to 
kinase-targeted cancer therapies.  
      
       
INTRODUCTION 
 
Malignant cell transformation requires the 
acquisition of various aberrant phenotypic 
hallmarks through the accumulation of 
advantageous genetic abnormalities, defined as 
driver mutations1. The notion of “mutator 
phenotype” has been formulated to reconcile the 
disparity between the low spontaneous mutation 
rate of normal cells and the thousands of 
mutations present in a single cancer genome2. 
This concept states that malignant cells exhibit a 
higher mutation rate that increases the likelihood 
of acquiring advantageous alterations needed to 
overcome each selective bottleneck in cancer 
evolution2. As a result, across multiple rounds of 
selections for driver mutants, there is a 
simultaneous progressive enrichment of 
inactivating mutations in caretaker genes that will 
further enhance random mutagenesis and fuel 
tumorigenesis.  
The mutator hypothesis also has major 
implications concerning the response to targeted 
therapies. Indeed, it predicts that cancers 
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constitute a highly heterogeneous population of 
stochastically mutated malignant cells within which 
drug-resistant variants pre-exist and are selected 
upon treatment causing rapid disease relapse3. 
The importance of such pre-existing mutants is 
best exemplified in chronic myeloid leukemia 
patients treated with Imatinib by the emergence of 
tumors variants with point mutations in the kinase 
domain of BCR-ABL, which could be detected at 
low frequency in the bone marrow before 
treatment4. 
Whether all cancers invariably acquire a mutator 
phenotype as a driving force for progression is still 
controversial5. However, it is well accepted that 
certain tumors exhibit a marked genetic instability 
under the form of chromosomal rearrangements or 
small deletions/insertions within regions of short 
tandem repeated nucleotide tracks called 
microsatellites, a phenotype referred to as 
microsatellite instability (MSI). For instance, MSI is 
observed in about 85% of hereditary non-polyposis 
colon cancers (HNPCC) as a consequence of DNA 
polymerase slippage errors that are not properly 
resolved by the mismatch repair (MMR) system6. 
The MMR system guarantees genome fidelity by 
recognizing and correcting post-replicative errors 
that escape proofreading activity of DNA 
polymerases. MMR process is initiated by the 
binding of a heterodimer composed of MutS 
homolog-2 and -6 (MSH2 and MSH6) to mispaired 
or misinserted bases in the newly synthesized 
DNA strand. Subsequent recruitment of a second 
heterodimer composed of MutL homolog-1 (MLH1) 
and post-meiotic segregation protein-2 (PMS2) at 
the site of the mismatch triggers downstream 
events that eventually lead to exonuclease-1-
mediated removal of the error and resynthesis by 
DNA polymerases ! or "7. Inefficient MMR confers 
a strong mutator phenotype characterized by a 
mutation rate 100- to 1000-fold greater in MMR-
deficient cells as compared with normal cells8-10.  
The link between MMR deficiency and 
tumorigenesis is well established in HNPCC 
patients who inherit a heterozygous germ-line 
mutation in one of the MMR components (mainly 
MSH2 and MLH1) and are prone to cancer 
development during the fifth or sixth decade of life 
further to somatic inactivation of the remaining 
wild-type allele10. Rare individuals with inheritance 
of bi-allelic mutations in the MMR genes present 
with early childhood onset of hematological and 
brain malignancies11. Besides familial cancers, 
MMR defects are present in a significant 
proportion (12-20%) of sporadic counterparts of 
the HNPCC-spectrum tumors (gastro-intestinal, 
urologic and gynecologic tracts)12-15. More 
recently, growing evidence for involvement of 
MMR defects in sporadic hematological 
malignancies has also been provided16-22. In 
contrast to HNPCC, MMR deficiency in sporadic 
cancers is commonly caused by silencing of MLH1 
owing to promoter methylation. 
We previously described a murine lymphoid cell 
line, called TS1, which was initially dependent on 
interleukin-9 (IL-9) for proliferation but sequentially 
gained growth factor (GF)-independence and 
resistance to JAK-inhibitors at high frequencies 
(1/20,000 for GF-independent clones and 1 in 2 
millions for JAK inhibitor-resistant subclones)23. 
Each of the 2 successive selection steps was 
accompanied by newly acquired activating point 
mutations in one of the kinases associated with 
the IL-9 receptor, namely JAK1 and JAK3. Our 
data showed that the relative expansion of the 
mutated cells occurred in culture prior to the 
selective pressure exerted by cytokine withdrawal 
or by the inhibitor. The high phenotypic plasticity of 
the TS1 cell line is somewhat reminiscent of the 
mutator concept where selection from a large 
spectrum of randomly pre-existing variants 
facilitates rapid adaptation to environmental 
pressures. In the present study, we took 
advantage of the TS1 model to investigate the 
molecular mechanisms underlying the acquisition 
of oncogenic and inhibitor-resistant mutations in 
JAK kinases. 
 
METHODS 
 
Cell culture 
TS1 and TS2 cells were cultured in the presence 
of murine IL-9 (100U/ml) in Iscove-Dulbeccoʼs 
medium supplemented with 10% fetal bovine 
serum, 50µM ß-mercaptoethanol, 0.55mM L-
arginine, 0.24mM L-asparagine, 1.25mM L-
glutamine. Genome-wide demethylation of TS1 
cells was achieved by supplementation of cell 
medium with 0.5-2µM 5-AZA-2ʼdeoxyCytidine 
(Sigma-Aldrich, cat#A3656) during 48 hours. 
Plasmids construction, cell electroporation 
and selection of stable transfectants 
Murine MLH1 cDNA was inserted into the 
pEF6V5HisTOPO plasmid (Invitrogen) containing 
the resistance gene to blasticidin. 107cells were 
electroporated with 50µg of DNA (280V, 1500µF, 
75#) and selected in the presence of blasticidin 
40µg/ml (Invivogen, ANT-BL-1) 24 hours after 
electroporation. 
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Retroviral infection with sh-RNA and selection 
of stable transfectants 
Retroviruses were obtained by transient 
transfection of HEK293 cells with pLKO.1 lentiviral 
vector coding for shRNA against murine MLH1 
(TRCN00000042721, Thermo Scientifics) or anti-
GFP  (SHC004, Sigma), packaging vector psPAX2 
and VSV-G protein vector pMD2-G following the 
RNAi Consortium recommendations. HEK293 
supernatants were harvested at 24 hours and 48 
hours post-transfection and used to spin-infect 
0.5x106 cells. 3 days after the second infection, 
stable transfectants were selected with puromycin 
5µg/ml (MP biomedicals, cat#194539).  
Selection of growth factor-independent clones 
and JAK inhibitor-resistant subclones  
For the selection of GF-independent clones, IL-9-
dependent TS1 or TS2 cells were washed 3 times 
in PBS and seeded in 96-well plates at a 
concentration of 5,000 cells/well in the absence of 
cytokines. After 1-2 weeks, GF-independent 
clones were picked up from plates where less than 
20% of wells were positive for proliferation, 
corresponding to a probability of clonality superior 
to 0.9 according to the Poisson distribution. For 
the selection of JAK inhibitor-resistant subclones, 
GF-independent TS1 clones were seeded in 96-
well plates at a density of 30,000 cells/well in the 
presence of 300-600nM of pan-JAK inhibitor 
CMP6 (Calbiochem, cat#420097). After 2-3 
weeks, proliferation-positive wells from plates 
meeting clonality conditions were counted.  
Microarray 
Whole transcripts were amplified from 250ng total 
RNA and converted into single-stranded DNA 
using the Ambion® WT expression kit. 5.5µg DNA 
was fragmented, labeled (Genechip® WT terminal 
labeling kit, Affymetrix) and hybridized on 
Genechip® Mouse Genome 1.0 ST array 
(Affymetrix). 
RNA extraction, cDNA synthesis and qRT-PCR 
Total RNA was isolated from 106 cells using 
TriPure Isolation Reagent (Roche). Reverse 
transcription was performed on 1µg of total RNA 
using an oligo-dT primer and M-MULV Reverse 
transcriptase (RevertAid Reverse Transcriptase, 
Thermo Scientific). qRT-PCR was performed using 
the qPCR core-kit for Sybrgreen I (Eurogentec) 
and primers set annealing to murine MLH1 (5ʼ-
AGATGCTCCGTAACCATTCCTTTGTG-3ʼ(fw) and 5ʼ-
TAGAACAGCTCTTCACTGAGCTTGGTA-3ʼ(rev)), murine 
ß-Actin (5′-TCCTGAGCGCAAGTACTCTGT-3′(fw) and 5′-
CTGATCCACATCTGCTGGAAG-3′(rev), human MLH1 
(5′-ACAGTAGCTGATGTTAGGACACTACC-3′(fw) and 5′-
CTATCAGTTCTCGACTAACAGCATTTCC-3′(rev)), human 
EF1 (5′-GCTTCACTGCTCAGGTGAT-3′ (fw) and 5′-
GCCGTGTGGCAATCCAAT-3′  (rev)). 
Bisulfite treatment of genomic DNA and 
sequencing  
Genomic DNA was extracted (Dneasy Blood and 
tissue kit (QIAGEN), digested by EcoRI, and 
purified with the phenol-chloroform/isopropanol 
method. Digested DNA was denaturated with 
NaOH 0.4M (10 minutes at room temperature) 
before treatment with 3.9M bisulfite solution and 
0.5mM hydroquinone during 16 hours (at least 5 
cycles of 3 hours at 50°C and 5 minutes at 95°C). 
The DNA solution was then desalted and 
concentrated on a silica membrane (GeneClean® 
DNA purification kit, MP BIOMEDICALS LLC). 
Alkaline desulfonation was achieved by 0.3M 
NaOH (10 minutes at room temperature) and 
neutralized by ammonium acetate. Bisulfite-
modified DNA was precipitated with ethanol and 
Taq DNA polymerase-mediated PCR amplification 
(TaKaRa) was performed with primers annealing 
to the modified sequence of the murine promoter 
of MLH1 (5ʼ-GTTTTTAGAAATGAGTTAATAGGAAGAG-3ʼ 
(fw) and 5ʼ-
TACCAATTTTCTATCATCTCTTTAATAACATTAACC-3ʼ 
(rev)). PCR products were cloned into the 
PCR2.1TOPO vector (invitrogen) and transformed 
into DH5! bacteria. Plasmid DNA was extracted 
from 7 colonies for each PCR amplification 
(Nucleospin plasmid-8, Macherey and Nagel) and 
insert was sequenced using the DYEnamic Big 
Dye Terminator Kit (Amersham). 
Western-blot 
For Western blot analysis, 2x106 cells were lysed 
in 200 !l of lysis buffer containing 50 mM Tris-HCl, 
1 % NP40, 150 mM NaCl, 1mM EDTA, 15% 
glycerol, Halt Protease Inhibitor Cocktail 1/100, 
PMSF 0.1mM, and Sodium Orthovanadate 0.1mM. 
35 !l of lysates were loaded on Bolt 4-12% Bis-
Tris pre-cast gels (Novex) and electrophoretically 
transferred to nitrocellulose membranes (i-blot Gel 
Transfer Stacks, Novex). Blots were probed with 
anti-MLH1 (Cell Signaling Technology, #4256) and 
anti-"-actin (Sigma, #A5441) antibodies. 
CML Patient samples 
Peripheral blood leucocyte RNA extracts from 8 
patients at diagnosis and 8 patients relapsing after 
one or more TKI were obtained from the Cliniques 
univeristaires Saint-Luc. Reverse transcription was 
performed on 1µg of total RNA using an oligo-dT 
primer and M-MULV Reverse transcriptase 
(RevertAid Reverse Transcriptase, Thermo 
Scientific). An independent cohort of 17 diagnostic 
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and 10 relapse samples obtained from the 
University of Bordeaux, was used as validation 
cohort. In all samples, the BCR-ABL/ABL 
transcript levels were above 10% (IS). 
 
RESULTS 
 
MLH1 expression is repressed by promoter 
methylation in TS1 cells. 
TS1 and TS2 are T-lymphocyte derived cell lines 
that strictly depend on the presence of IL-9 for 
survival24,25 (Figure 1A). IL-9 withdrawal results in 
rapid cell death in both cell lines though few TS1 
cells occasionally succeed to proliferate 
independently of growth factor at a frequency of 
1/20,000 cells. We previously showed that 100% 
of those GF-independent TS1 clones acquired 
activating point mutations in JAK1 and/or JAK323 
suggestive of a high rate of spontaneous 
mutagenesis. Interestingly, IL-9-starved TS2 cells 
failed to give rise to GF-independent clones (108 
cells tested) indicating that this phenotype was 
specific for the TS1 cell line (Figure 1B). 
Based on this observation, we hypothesized that 
TS1 cells have lost the expression of crucial 
genome maintenance protein(s). Using a 
microarray technique, we compared the 
transcriptomes of TS1 and TS2 cells and obtained 
a list of 44 genes showing at least a 20-fold 
differential expression (Figure 1C and 
supplementary table 1). Among these genes, we 
identified MLH1 as a relevant candidate because 
of its pivotal role in MMR, namely coordination of 
mismatch recognition with effective repair. 
Expression values for MLH1 transcript were 25-
fold lower in TS1 compared with TS2 cells. All 
other components of the MMR system showed 
similar expression profiles between TS1 and TS2 
cells (data not shown). Loss of MLH1 expression 
in TS1 versus TS2 cells was confirmed both at the 
mRNA level by quantitative RT-PCR and at the 
protein level by western blot analysis (Figures 1D 
and 1E).  
 
 
Figure 1. MLH1 expression is lost in TS1 cells. (A) TS1 
and TS2 cells were seeded in 96-well plates at a density of 
1,000 cells/well in the presence of increasing concentrations 
of murine IL-9. After 48 hours of culture, methyl-H3Thymidine 
was added to the cells for 4 hours and thymidine incorporation 
was measured. Thymidine incorporation values were 
standardized relative to the value in the presence of IL-9 100 
U/ml. (B) TS1 and TS2 cells were plated in the absence of IL-
9 on 96-well plates at different densities ranging from 200 to 
40,000 cells/well. 1-2 weeks later, wells positive for 
proliferation were visually screened. For TS1 cells, histogram 
represents mean +/- SEM of 7 independent selection 
experiments. Concerning TS2 cells, no GF-independent 
clones arose from a total of 108 tested cells. (C) Microarray 
data are represented as hierarchical clustering of transcripts 
20X differentially expressed in TS1 versus TS2 corresponding 
to a list of 44 genes (biological duplicates). The image was 
obtained with the Multiple experiment Viewer program (MeV). 
The line corresponding to MLH1 transcript is indicated. (D) 
MLH1 mRNA levels were assessed by quantitative RT-PCR in 
TS1 and TS2 cells. Histograms represent means +/- SD of 
biological triplicates. Studentʼs t-test was performed to 
determine p-value. (E) MLH1 protein levels were assessed by 
western blot in TS1 and TS2 cells. The membrane was 
probed with anti-!-Actin antibody as loading control.  
 
Given that the promoter of MLH1 is frequently 
hypermethylated in sporadic human tumors, we 
determined its cytosine methylation status through 
sequencing of bisulfite-treated genomic DNA. As 
illustrated in figure 2A, most CpG sites present in 
the MLH1 promoter region appeared to be 
methylated in TS1 cells while this promoter was 
totally unmethylated in TS2. In line with these data, 
TS1 cells treated with demethylating agent 5-AZA-
2ʼdeoxycytidine (5-AZAdC) partially recovered 
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MLH1 expression in a dose-dependent manner 
(Figure 2B). Considering those results, we 
postulated that MMR-deficiency caused by 
silencing of MLH1 locus accounts for the high rate 
of spontaneous mutagenesis in TS1 cells. 
 
Figure 2. MLH1 expression is repressed by promoter 
methylation in TS1 cells. (A) Methylation status of the MLH1 
promoter was determined by bisulfite sequencing of genomic 
DNA in TS1 and TS2 cells. Circles represent CpG sites 
(methylated in black, unmethylated in white). Data represent 
sequencing results of 7 clones from the PCR product for each 
cell line. Numbers indicate the nucleotide position relative to 
the origin of transcription. (B) MLH1 mRNA levels were 
assessed by quantitative RT-PCR in TS1 cells treated with 
0/0.5/1/2 µM of 5-AZA-2ʼdeoxycytidine for 48 hours. 
Histograms represent means +/- SEM of 3 independent 
experiments. One-way ANOVA test was performed to 
determine p-values. (*p<0.05, ***p<0.001) 
 
Ectopic MLH1 expression in TS1 cells prevents 
oncogenic point mutations in JAK kinases. 
In order to demonstrate that loss of MLH1 is 
responsible for the acquisition of oncogenic 
mutations, we electroporated IL-9-dependent TS1 
cells with an expression vector coding for MLH1 or 
the empty vector as control. Doing so, we obtained 
3 independent sets of MLH1-expressing cells and 
paired control cells coming from distinct 
electroporation experiments. Effective restoration 
of MLH1 was confirmed by western blot on a 
representative set (Figure 3A). Exogenous MLH1 
expression did not modify the proliferation of TS1 
cells in response to IL-9 (Figure 3B). By contrast, 
when MLH1-expressing cells were plated in the 
absence of IL-9 in order to select GF-independent 
clones, the frequency of GF-independent clones 
displays a 50-fold decrease in cells that express 
MLH1 compared to control cells (Figure 3C). 
Because in TS1 cells, GF-independence is 
systematically associated with acquisition of point 
mutations23, this difference reflects a reduced 
mutation rate in MLH1-expressing cells. 
Figure 3. Ectopic MLH1 expression in TS1 cells 
decreases the frequency of GF-independent clones. (A) 
MLH1 protein levels were assessed by western blot in TS1 
cells electroporated with MLH1 or empty vector. The 
membrane was probed with anti-!-Actin antibody as loading 
control. (B) TS1 cells electroporated with MLH1 or empty 
vector were seeded in 96-well plates at a density of 1,000 
cells/well in the presence of increasing concentrations of IL-9. 
After 48 hours of culture, methyl-H3Thymidine was added to 
the cells for 4 hours and thymidine incorporation was 
measured. Thymidine incorporation values were standardized 
relative to the value in the presence of IL-9 100 U/ml. (C) TS1 
cells were plated in the absence of IL-9 on 96-well plates at 
different densities ranging from 200 to 20,000 cells/well. 1-2 
weeks later, wells positive for proliferation were visually 
screened. Histograms represent means +/- SEM of 6 
independent selection experiments (3 independent 
electroporated bulks, each bulk was tested twice). Studentʼs t-
test was performed to determine the p-value. (***p<0.001) 
 
As previously shown, GF-independent clones were 
sensitive to JAK inhibitors, such as CMP6, in 
short-term assays. However, resistant subclones 
arose upon long-term culture in the presence of 
inhibitor as a result of secondary mutations in 
JAK1 or JAK323. Hence, we asked whether 
restoration of MLH1 in TS1 GF-independent 
clones could prevent the occurrence of secondary 
mutations and thereby the emergence of CMP6-
resistant subclones. Two different GF-independent 
clones (TS1 A6 and T4) were electroporated with 
MLH1-vector (Figure 4A). In short term assays, 
ectopic MLH1 expression had no impact on the 
sensitivity of clones to CMP6 (Figures 4B and 4C). 
However, when cells were seeded in the presence 
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of the inhibitor for 3 weeks, significantly less 
CMP6-resistant subclones emerged from cells that 
express MLH1 as compared to control cells 
(Figures 4D and 4E). Altogether, these 2 
experiments demonstrate that ectopic expression 
of MLH1 in TS1 cells significantly diminishes the 
incidences of GF-independent clones and CMP6-
resistant subclones. 
 
Figure 4. Ectopic MLH1 expression in GF-independent 
TS1 clones decreases the frequency of CMP6-resistant 
subclones. (A) MLH1 protein levels were assessed by 
western blot in TS1 A6 and T4 GF-independent clones 
electroporated with MLH1 or empty vector. The membrane 
was probed with anti-!-Actin antibody as loading control. (B) 
and (C) GF-independent TS1 A6 and T4 clones 
electroporated with MLH1 or empty vector were seeded in 96-
well plates at a density of 1,000 cells/wells in the presence of 
increasing concentrations of CMP6. After 48 hours of culture, 
methyl-H3Thymidine was added to the cells for 4 hours and 
thymidine incorporation was measured. Thymidine 
incorporation values were standardized relative to the value in 
the absence of CMP6. (D) and (E) GF-independent TS1 A6 
and T4 clones electroporated with MLH1 or empty vector were 
plated in the presence of CMP6 (300-600nM) on 96-well 
plates at a density of 30,000 cells/well. 2-3 weeks later, wells 
positive for proliferation were visually screened. Graphs 
represent paired frequency values from 7 and 8 independent 
selection experiments (each of the 4 electroporated set was at 
least tested once). Paired Wilcoxon test was performed to 
determine p-values (*p<0.05) 
 
 
 
MLH1 knock-down in TS2 cells promotes 
oncogenic point mutations in JAK3.  
We next sought to determine if the TS2 cell line 
could give rise to GF-independent clones with 
acquired mutations in JAK1 and JAK3 upon MLH1 
knock-down. To that end, TS2 cells were infected 
with retroviruses coding for shRNAs against MLH1 
or against GFP as a control. In doing so, we 
obtained 7 paired TS2 bulks coming from 7 
independent infection experiments. As presented 
on figure 5A, shRNA targeting MLH1 successfully 
silenced 78% of the mRNA expression. 
Subsequent reduction in MLH1 protein amount 
was corroborated by western blot on a 
representative set of cells (Figure 5B).  
 
Figure 5. shRNA-mediated MLH1 knock-down in TS2 cells 
increases the frequency of GF-independent clones. (A) 
MLH1 mRNA levels assessed by quantitative RT-PCR in TS2 
cells infected with retroviruses coding for shRNA against 
MLH1 or GFP. Histograms represent means +/- SEM of 7 
independent infection experiments. Studentʼs t-test was 
performed to determine p-value. (B) MLH1 protein levels 
assessed by western blot in shRNA-infected TS2. The 
membrane was probed with anti-!-Actin antibody as loading 
control. (C) TS2 cells infected with retroviruses coding for 
shRNA against MLH1 or GFP were plated in the absence of 
IL-9 on 96-well plates at a density of 40.000 cells/well. 1-2 
weeks later, wells positive for proliferation were visually 
screened. Histograms represent means +/- SEM of 7 
independent selection experiments (each set of infected cells 
was tested once). Studentʼs t-test was performed to determine 
p-values (*p<0.05, ***p<0.001). 
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Altogether, 162 106 shRNA-infected TS2 cells 
were plated in the absence of IL-9 with the hope to 
select GF-independent clones from MLH1-silenced 
cells. In line with our expectations, a series of GF-
independent clones arose at an average frequency 
of 1 in a million MLH1-knocked-down TS2 cells. By 
contrast, only rare (three) GF-independent clones 
emerged from the control TS2 cells, at an 
extremely low frequency (< 2X10-8). 45 GF-
independent TS2 clones (including the 3 clones 
from the control cells) were picked up and 
screened for mutations in JAK1 and JAK3 (Table 
1). 89% (40/45) of them had acquired a mutation 
in JAK3 whereas none did in JAK1. Altogether, we 
identified 9 different substitutions affecting 6 
conserved residues between mouse and human 
JAK3. All residues were previously shown to be 
mutated in GF-independent TS1 clones23 and for 3 
of them (A572, R657 and V674), mutations have 
been also described in human leukemia26,27. The 
remaining 5 clones displayed no mutation 
indicating that acquiring a mutation in JAK3 is not 
the only way for TS2 cells to proliferate 
independently of growth factor. This contrasts with 
the TS1 cell line where 100% of GF-independent 
clones gained a mutation in JAK1 and/or JAK3. 
Thus, these data show that selection of GF-
independent clones with activating mutations in 
JAK3 from the MLH1-expressing TS2 cell line is a 
rare event but its incidence is strongly increased 
upon MLH1 silencing. 
 
Table 1. JAK3 mutations identified in GF-independent 
TS2 clones 
 
 
 
 The list of 9 different JAK3 mutations occurring in our 
collection of 45 sequenced GF-independent TS2 clones 
(amino acid numbers correspond to human sequence). For 
each mutation, the absolute frequency is indicated. No 
mutations were found in JAK1.  
 
 
TS1 cells and primitive CML cells share a 
commonmutational profile dominated by 
T:A>C:G transitions. 
Next, we investigated if the loss of MLH1 would be 
translated into a mutational signature present in 
our collection of TS1-derived JAK1 and JAK3 
mutations. As illustrated on figure 6, nucleotide 
exchanges in TS1 cells are strongly biased 
towards T:A>C:G transitions in comparison with 
the expected pattern of mutations arising 
spontaneously in normal human cells28. Thus, in 
TS1 cells, the accumulation of T:A>C:G 
substitutions is favored, potentially as a reflect of 
MLH1-deficiency or MMR- defect in general. Our 
data are consistent with studies in bacteria 
demonstrating that the spectrum of base 
substitutions is dominated by T:A>C:G mutations 
in the absence of efficient MMR29,30. 
As already mentioned in the introduction, a fraction 
of CML patients treated with Imatinib experience 
disease relapse owing to the emergence of 
preexisting tumors variants with point mutations in 
the kinase domain of BCR-ABL. This is somewhat 
reminiscent of the selection of JAK inhibitor-
resistant subclones with acquired mutations in our 
MLH1-deficient TS1 model. Interestingly, point 
mutations in BCR-ABL arising in primitive CML 
cells from Imatinib-naive and -resistant patients 
are characterized by a predominance of T:A>C:G 
transitions and an under-representation of 
C:G>T:A transitions, as a result of a unknown 
mutator process31,32. Knowing this, we compared 
the profile of nucleotide exchanges in our TS1 
model with the one described in CML cells. As 
depicted on figure 6, TS1 cells and primitive CML 
cells display an identical mutational pattern, which 
differs significantly from the standard profile. This 
analysis indicates that a defect in MLH1 is a 
potential suspect for the mutator mechanism 
operative in CML cells that renders them prone to 
acquire new mutations in BCR-ABL. 
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Figure 6. TS1 and CML cells share a common mutational 
profile distinct from normal cells. The diagrams present the 
percentages of T:A>C:G and C:G>T:A transitions as well as 
transversions (substitutions of a purine by a pyrimidine base 
and conversely) occurring in JAK1 and JAK3 genes for the 
TS1 cells, in BCR-ABL for CML cells and in unselected 
regions of the genome for the normal cells (M.Lynch 2010). 
!2-test was performed to determine the p-values (***p<0.001; 
NS, non significant). 
 
MLH1 expression is down-regulated in 
Imatinib-resistant versus newly diagnosed  
CML patients. 
Given the here above described results, we sought 
to compare the expression of MLH1 in peripheral 
blood samples coming from CML relapsed 
Imatinib-resistant patients and newly diagnosed 
Imatinib-naïve ones. First, we assessed the mRNA 
expression of MLH1 in a test cohort including 16 
non-paired CML samples (8 at diagnosis and 8 at 
relapse) from patients referred to the Saint-Luc 
Hospital in Brussels. For 6 out of the 8 relapsed 
samples, mutations in BCR-ABL could be 
detected. In this cohort, MLH1 expression was 
significantly down-regulated in the samples at 
relapse as compared to samples at diagnosis 
(figure 7A, left panel). BCR-ABL/ABL ratios were 
similar between diagnosis and relapse indicating 
that CML blood samples from both groups have an 
equal representation of tumor cells (figure 7A, right 
panel).  
The difference in MLH1 expression was further 
confirmed on a separate validation cohort coming 
from the University of Bordeaux comprising 17 
diagnosed and 10 relapsed samples from which 6 
harbored mutations in BCR-ABL (figure 7B). Thus, 
selection of Imatinib-resistant tumor subclones in 
CML patients is accompanied by a simultaneous 
enrichment of cells with a reduced MLH1 
expression, corroborating the clinical significance 
of our previous in vitro findings.  
 
Figure 7. MLH1 mRNA expression is downregulated in 
Imatinib-resistant versus newly diagnosed CML patient 
samples. MLH1 mRNA levels assessed by quantitative RT-  
PCR in CML blood samples taken at diagnosis or at relapse 
after Imatinib treatment from 2 independent sets of patients, 
(A, left panel) samples of our test cohort from Saint-Luc 
Hospital, Brussels (n=8 for both diagnosis and relapse) and 
(B) samples of the validation cohort from the University of 
Bordeaux (n=17 for diagnosis, n=10 for relapse). (A, right 
panel) BCR-ABL/ABL ratios of our test cohort from Saint-Luc 
Hospital. Horizontal lines represent the mean values. Non-
parametric Mann-Whitney one-tailed test was performed to 
calculate the p-values (*p<0.05, **p<0.01, NS non significant) 
 
DISCUSSION 
 
In this paper, we made the clinically relevant 
observation that loss of MLH1 expression (or 
possibly MMR defects in general) continuously 
promotes the appearance of point mutations in 
kinases leading to genetically distinct cell variants 
within a population that are selected by their 
fitness to adapt upon cytokine deprivation or 
therapeutic pressure. This finding stems from 
experiments carried out on the MLH1-deficient 
TS1 model in which sequential acquisition of 
activating mutations in JAK1 and JAK3 are 
required to overcome successively IL-9 withdrawal 
and exposure to JAK inhibitor. Restoration of 
MLH1 expression at both stages, IL-9-dependent 
TS1 cells or GF-independent TS1 clones, 
significantly reduces the frequencies of further 
transformed cells with newly acquired JAK 
mutations, whereas conversely, down-regulation in 
MLH1-proficient TS2 cells enhances the incidence 
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of GF-independent clones harboring mutations in 
JAK3.  
At the moment, Ruxolitinib is the only JAK inhibitor 
that achieved FDA-approval. Although no clinical 
resistance mediated by acquired mutations have 
been reported yet upon treatment with 
Ruxolitinib33, we believe that our model system 
would be also relevant in other cancer therapies 
for which patient-derived drug-resistant mutations 
are described, as illustrated here for BCR-ABL+ 
CML. Indeed, it seems very likely that mutations in 
MMR-deficient cells are not restricted to JAK1 and 
JAK3 genes but rather occur randomly across the 
genome. Therefore, extrapolation of our findings to 
other oncogenes strongly suggests that MLH1-
silenced tumors are predisposed to develop 
secondary resistance against any clinically used 
targeted therapy.  
Imatinib, an ABL1 inhibitor, represents an 
appropriate clinical illustration of targeted therapy 
whose effectiveness is limited by the emergence 
of pre-existing tumor subclones carrying drug-
resistant mutations in the kinase domain of BCR-
ABL resulting in CML relapse34. It has been 
assumed that the appearance of CML cells 
harboring such Tyrosine Kinase Inhibitor (TKI)-
resistant mutations is fostered by the increased 
genomic instability in the subset of cells from 
which the leukemic cells are derived, the so-called 
leukemia stem cells (LSCs)35. This genomic 
instability in LSCs, manifested as chromosomal 
aberrations and point mutations (including BCR-
ABL mutations)31, is believed to stem from a 
combination of increased DNA damages and 
inefficient repair36,37. BCR-ABL itself promotes 
genetic instability through excessive ROS 
production38-40 and inhibition of MLH1-PMS2 
dimers assembly41.  
Here, we provide arguments in favor of a down-
regulation of MLH1 expression playing a role in 
genetic instability of LSCs. We show that the 
pattern of BCR-ABL arising in vivo and in vitro in 
primitive CD34+ cells from Imatinib-naive and -
resistant CML patients strikingly resembles the 
JAK1 and JAK3 mutations occurring 
spontaneously in our MLH1-deficient TS1 cells31. 
Indeed, both mutational profiles are characterized 
by a marked prevalence of T:A>C:G transitions, 
which is distinct from the natural predominance of 
C:G>T:A mutations due to spontaneous cytosine 
deamination28.  
A link between genomic instability and high risk of 
relapse upon TKI therapy was already evoked by 
the observation that the overall frequency of BCR-
ABL mutations increases with sequential TKI 
use42. In particular, patients who harbor BCR-ABL 
mutations conferring resistance to first-line 
inhibitor are more likely to develop additional 
mutations on second-line or third-line TKI therapy 
than patients without such mutations43,44. This 
correlation suggests that, in this specific subset of 
patients, a higher genetic instability boosts 
spontaneous mutagenesis and fosters the rapid 
emergence of resistant clones upon treatment. In 
our paper, we demonstrate that MLH1 expression 
is significantly down-regulated in leukemic cells 
from Imatinib-resistant CML patients compared to 
newly diagnosed ones. This indicates that therapy 
relapse might be due to selection of a subset of 
leukemic progenitors with lower MLH1 expression 
that consequently possess a higher likelihood to 
acquire additional mutations in BCR-ABL. Our data 
are further supported by a DNA methylation array 
study that identified the MLH1 gene as being 
down-regulated in a Imatinib-resistant subclone of 
the CML cell line K56245. 
Restoration of MLH1 expression in GF-
independent TS1 clones significantly lowers the 
frequency of JAK inhibitor-resistant subclones. 
This result suggests that re-activation of the MLH1 
locus could promote the effective eradication of 
MLH1-silenced malignancies. This can be 
achieved by interfering with epigenetic regulators 
such as DNA-methyltransferases (DNMT) and 
histone deacetylases (HDAC). In colon cancers, 
MLH1 methylation strongly correlates with 
overexpression of SIRT1, a HDAC frequently up-
regulated in many types of solid tumors and 
hematological malignancies46.  It has been shown 
that SIRT1 binds to the hypermethylated promoter 
of MLH1 and its inactivation causes re-expression 
of MLH147. This is of particular interest since 
pharmalogical inhibition of SIRT1 activity blocked 
acquired resistance to Imatinib in the blast crisis 
CML cell line KCL-2248. However, targeting the 
epigenetic machinery in order to re-activate the 
MLH1 locus might fall short from preventing 
disease relapse. First, as stated by the mutator 
hypothesis, the accumulation of mutations in 
genetically unstable cells increases the probability 
of pre-existing resistant subpopulations within the 
tumor prior to treatment. In this regard, MLH1 
reactivation will have no impact on development of 
resistance. Second, this approach would be 
restricted to tumors with epigenetic silencing of 
MLH1, but ineffective on others harboring 
inactivating mutations in MLH1 or other MMR 
components.  
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An alternative tumor-specific therapeutic strategy 
would be to exploit the MMR-deficiency by taking 
advantage of synthetic lethal interactions49. Two 
pathways are synthetic lethal when loss of function 
of either alone is viable but loss of both causes cell 
death50. For instance, oxidative DNA lesions are 
mainly removed by the base excision repair 
pathway (BER), but MMR proteins also contribute 
to this process as a result of functional redundancy 
between components of these two DNA-repair 
systems51-53. Therefore, inhibiting or overwhelming 
the BER machinery would be selectively toxic to 
MMR-deficient cancer cells through accumulation 
of oxidative DNA damage while relatively sparing 
normal MMR-proficient cells54. Three different 
strategies have been explored. First, it has been 
demonstrated that siRNA-silencing of DNA 
polymerases specialized in repair of nuclear 
(POL!) or mitochondrial (POL") oxidative lesions 
specifically killed cells with deficiency of MSH2 or 
MLH1 respectively55.  Albeit potent inhibitors of 
these polymerases are not currently available, 
Vitamin K3, better known as menadione, was 
shown to specifically inhibit POL" in various cancer 
cell lines56. Interestingly, MLH1-deficient cells were 
indeed more sensitive to menadione than their 
MLH1-proficient counterparts55. In a second study, 
silencing of PTEN-induced putative kinase 1 
(PINK1) has been identified to elicit synthetic 
lethality in cells with MSH2, MLH1 or MSH6 
dysfunction57. PINK1 protects cells from oxidative 
stress-induced apoptosis and its downregulation 
resulted in excessive ROS production probably 
saturating the BER system. To our knowledge, no 
PINK1 inhibitors have been developed yet. Finally, 
a comprehensive screening of clinically used 
chemotherapeutics discovered that cytosine-based 
nucleoside analogs, such as cytarabine, were 
selectively lethal to MMR-deficient tumor cells by 
enhancing levels of intracellular oxidative stress 58.  
In conclusion, our results indicate that MLH1-
deficient tumors are associated with a high-risk of 
relapse upon oncogene-inhibitor as monotherapy. 
Restoring MLH1 function in cancer cells is unlikely 
to prevent the selection of pre-existing resistant 
subclones within the tumor cells population. 
However, the use of described synthetic lethal 
interactions between MLH1-deficiency and 
menadione or cytarabine seems more potent in 
yielding complete and sustained disease 
remission. Therefore, associating oncogene-
targeted therapies with synthetic lethal approaches 
could represent an attractive strategy in order to 
specifically and efficiently ablate the MMR-
defective cancer cells while avoiding the selection 
of tumor variants harboring drug-resistant 
mutations.  
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Probe Set 
ID Gene Symbol 
TS1 / 
TS2 TS1 A TS1B TS2A TS2B 
10569017 Ifitm3 0.01 13.89 26.32 4080.82 3489.12 
10346168 Stat4 0.01 21.24 25.17 2402.56 2724.41 
10600504 Fundc2 0.01 14.36 12.86 1003.35 1137.31 
10593024 Cd3e 0.01 87.25 84.94 6847.35 5929.78 
10529711 Clnk 0.01 48.27 40.09 2698.58 3402.52 
10358224 Ptprc 0.02 32.03 31.87 2209.53 1989.76 
10466127 AW112010 0.02 32.27 30.05 2084.86 1862.02 
10574246 Gpr114 0.03 48.93 46.55 1904.56 1804.43 
10448202 --- 0.03 145.03 151.9 5079.72 4915.08 
10463070 Entpd1 0.03 52.46 70.28 1972.67 1825.14 
10440340 --- 0.03 12.41 10.68 282.91 397.69 
10461979 Aldh1a1 0.03 47.37 41.49 1035.42 1525.82 
10573451 Syce2 0.04 210.01 126.86 3778.96 4356.5 
10548345 Klrk1 /// Klrk1 0.04 19.84 22.41 432.12 584.92 
10519983 Fgl2 0.04 47.28 31.04 945.47 921.85 
10457644 Cdh2 0.04 39.36 43.16 952.45 975.04 
10597288 Mlh1 0.04 21.3 30.65 556.2 632.29 
10545101 Hpgds 0.05 35.08 37.9 905.55 669.66 
10440131 Gpr15 0.05 33.23 30.02 682.36 531.78 
10602277 Luzp4 ///... 20.45 673.77 558.15 31.48 28.76 
10602293 Luzp4 /// ... 20.49 660.16 547.01 30.67 28.24 
10441787 Airn /// Airn 20.79 1012.31 1537.35 53.85 68.76 
10494672 Tbx15 21.51 621.99 490.46 21.62 30.1 
10406782 Fam169a 22.29 467.75 738.58 29.47 24.66 
10373950 Nipsnap1 22.31 820.89 1160.86 47.31 41.52 
10474419 Lgr4 22.72 353.01 349.4 13.85 17.06 
10417176 Zic2 24.91 1188.5 1084.22 43.68 47.56 
10539873 Gata2 25 2387.56 2922.92 92 120.4 
10542965 Sgce 26.2 940.54 720.35 29.83 33.57 
10436804 Mrap 26.83 1400.52 1243.41 47.4 51.15 
10518358 2610305D13Rik  28.47 261 355.86 12.27 9.4 
10403796 Amph 30.07 891.52 981.2 31.41 30.87 
10416522 Tsc22d1 30.92 861.23 1361.62 35.76 36.14 
10430066 Foxh1 33.47 1963.21 1640.58 61.77 45.9 
10606445 Rps6ka6 34.46 677.43 823.37 19.67 23.88 
10601844 Bhlhb9 34.59 667.61 784.95 22.78 19.21 
10517808 Padi3 35.67 2771.23 2957.54 75.66 84.96 
10536294 Peg10 46.33 2057.26 1956.32 42.79 43.84 
10602690 Foxr2 47.92 1292.06 1761.86 37.15 26.58 
10502240 Npnt 53.1 3453.54 3659.13 69.43 64.53 
10416057 Clu 54.59 5990.94 3832.89 94.14 85.81 
10580382 Neto2 69.12 909.54 1278.76 18.04 13.62 
10522090 Wdr19 77.15 3104.41 3051.51 47.54 32.25 
10606178 Xist 96.46 2978.13 2893.62 32.91 27.96 
Supplementary table 1. List of genes at least 20X down- or upregulated in TS1 versus 
TS2 cells.
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DISCUSSION 
 
The list of hematological malignancies with a significant percentage of cases 
conveying genetic alterations activating the JAK-STAT pathway is constantly 
growing. Among them, 42-76% of T-ALL patients present with activating mutations 
in JAK1, JAK3, TYK2 or IL7Rα, LNK deletions and rare JAK2 fusions, pinpointing a 
therapeutically targetable "Achilles' heel". As the underlying molecular mechanisms 
are heterogeneous, exploiting the signaling bottleneck afforded by the limited 
number of JAK kinases with small molecule TKIs represents an appealing strategy. 
However,  
intra-tumor heterogeneity, dictated by the degree of genetic instability, facilitates 
rapid adaptation to therapeutic pressures by selection of preexisting cells variant 
harboring drug-resistant mutations. Consequently, the translation of the oncogene 
addiction model into clinical use of JAK inhibitors in T-ALL involves a substantial 
risk for the development of acquired drug resistance phenomena, particularly in the 
context of a mutator phenotype. 
In the present thesis, I took advantage of an original in vitro model recapitulating 
JAK-STAT pathway-driven T-cell transformation in order to evaluate the efficacy of 
short-term and long-term treatments with JAK inhibitors. At the end of this work, my 
main observations can be stated as follows: (i) Long-term exposure to JAK inhibitor 
of cells transformed by activating JAK1 mutations leads to the emergence of 
resistant cells with acquired activating mutations in JAK3 and vice versa; (ii) JAK1 
and JAK3 mutants cooperatively activate STAT transcription factors thereby rising 
the threshold of inhibitor concentration needed to induce cell death; (iii) The 
acquisition of activating point mutations in JAK kinases is favored by the loss of 
MLH1; (iv) Substitutions occurring in the context of MLH1-deficiency are strongly 
biased towards T:A>C:G transitions, so are the point mutations in BCR-ABL arising 
in primitive CML cells; (v) Cells from Imatinib-resistant CML patients have a lower 
expression of MLH1 compared to Imatinib-naive patients.  
Each of these findings has already been discussed in the manuscripts that 
compose the results section of this thesis. However, several intriguing questions 
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raised by our observations deserve deeper considerations. The discussion will 
address 2 main themes: first the known and yet to be discovered mechanisms 
underlying the activation of the JAK-STAT pathway in our experimental model, 
second the origin and significance of the mutational signature observed in TS1 
cells in relationship with MMR deficiency. 
 
1. Mechanisms underlying the activation of the JAK-STAT pathway 
  
Why don't we find the same type of CMP6-resistant mutants as previously 
identified using JAK2 mutagenesis screens?   
During my thesis, I identified endogenous mutations that confer resistance to JAK 
inhibitors by selecting spontaneous preexisting subclones that were able to grow in 
the presence of CMP6. Unexpectedly, in our TS1 model, resistance to CMP6 was 
caused by the acquisition of an activating mutation in the JAK partner rather than 
secondary mutations in the ATP–binding pocket of the JAK mutant that would 
preclude drug binding. This contrasts with previously reported JAK inhibitor-
resistant mutations identified with alternative methods consisting in the screening 
of randomly mutagenized activated forms of JAK2. 
A first screen was performed on BaF3 cells transduced with a library of 
mutagenized JAK2 V617F cDNA and treated with Ruxolitinib. This study identified 
6 secondary mutations located in the kinase domain of JAK2 in Ruxolitinib-
resistant cells (M929I/Y931C/G935R/R938L/I960V/E985K)139. Using a similar 
approach, another group isolated 2 identical (Y931C/G935R) and one novel 
(E864K) mutations in BAF3 cells transduced with a mutagenized JAK2 R683G 
cDNA library and selected in the presence of another JAK2-inhibitor, BVB-808140. 
In a third study, mutagenesis screen conducted on BaF3 cells expressing the 
constitutively active TEL-JAK2 fusion protein, revealed several additional mutations 
(E864K/V881A/N909K/Y918H/R975G/P1057S/R1127K) that could confer 
resistance to CMP6141. Altogether, 13 different inhibitor-resistant substitutions in 
the kinase domain of JAK2 were described so far. Several affected residues are 
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located near the ATP-binding pocket, among which 2 (Y931 and G935) were 
postulated to directly interact  with CMP6 based on crystallographic analyses342. 
With the exception of the Y931 residue, which is homologous to the F958 in JAK1 
and Y904 in JAK3, there is no evidence that those secondary mutations of JAK2 
are gain-of-function mutations.  
Surprisingly, except for the Y931 JAK2 residue, none of those 13 resistant 
mutations were homologous to any of the 15 secondary JAK1 and JAK3 mutations 
in our collection of inhibitor-selected TS1 subclones. Differences in model settings 
might explain the discrepancy in the type of mutants identified. JAK2 TKI-resistant 
mutants were selected from cell lines ectopically expressing the JAK2 cDNA, after 
in vitro random mutagenesis. By contrast, our model involves spontaneous 
heterozygous mutations of the endogenous JAK1 or JAK3 genes. Since JAK1 and 
JAK3 function as partners in heterodimeric cytokine-receptor complexes, such as 
IL-9R or IL-7R, only half of these receptor complexes present in clones with a 
primary mutation can be associated with an active JAK molecule and are in a 
partially activated state. As a result of the acquisition of a secondary activating 
mutation in the JAK partner, half of these receptor complexes can be associated 
with an active JAK1 or JAK3, but 25% of the receptor complexes can involve both 
activated kinases, thereby significantly increasing basal activation of the JAK-STAT 
pathway. By contrast, the aforementioned mutagenesis screens used BAF3 cell-
based assays in which active mutant forms of JAK2 were overexpressed, 
mimicking a homozygous configuration. As JAK2 binds to receptor chains that form 
homodimers (EPO-R, TPO-R) or heterodimers with another JAK2-binding chain 
(IL-3R in BAF3 cells), most of the cytokine-receptor complexes are associated with 
2 active JAK2 molecules and are in a fully active state. Therefore, secondary gain-
of-function mutations in JAK2 are not expected to have a major effect on the 
activation level of the pathway, which might be already maximal. Instead, acquiring 
a secondary mutation that would impair drug binding can restore activation of the 
JAK-STAT pathway in the presence of inhibitor. As a result, the 13 identified JAK2 
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resistant mutations hinder the effect of the inhibitor without necessarily improving 
the activity of the kinase. 
 
Does the localization of the secondary resistant mutations support an in 
trans or in cis mode of JH2-mediated inhibition of JH1 within heterodimeric 
receptor-JAK complexes?  
It is commonly accepted that the function of pseudokinase domain (JH2) of JAKs is 
to repress the activity of the kinase domain (JH1). However, the molecular 
mechanism of JH2-mediated suppressive action on the catalytic activity of JH1 is 
continuously under active debate. Because cytokine receptor complexes crucially 
comprise at least two subunits each associated with one JAK monomer, both an 
intermolecular in trans or an intramolecular in cis mode of inhibition are 
conceivable and experimental evidences in support of either models have been 
provided (see the introduction section). However, previous studies used purified 
recombinant JH1-JH2 peptides or JAK proteins fused to fluorochromes, which 
mimic conditions distant from the physiological context. The type of JAK1 and 
JAK3 mutants arising spontaneously in our CMP6-selected TS1 subclones and 
cooperating in downstream signaling, can inform us about the mode of JH1-JH2 
inhibition operative within an unactivated γc-containing heterodimeric receptor. 
Based on the observation that cancer-associated JAK mutations map at the JH1-
JH2 interface, we can assume that they all share a common mechanism of 
activation involving the relief of inhibitory interactions between both domains. Given 
that, in a receptor complex, 2 JAK molecules work as partners, there are 2 
inhibitory JH1-JH2 interfaces, either intra- or intermolecular. Consequently, a 
combination of 2 mutations able to yield a cooperative effect on the overall activity 
of the complex would be substitutions that abrogate each of the 2 inhibitory 
interfaces. On the contrary, 2 activating mutations that hit the same JH1-JH2 
interface do not cooperatively activate the complex and will not be part of the 
spectrum of configurations observed in our JAK inhibitor-selected subclones. 
Figure 11 sketches the possible secondary mutations, starting for example from a 
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JAK1 JH2 primary mutation of the residue Y652 which participates directly to the 
interface with JH125,343, that would yield or not cooperation according to either an in 
cis or in trans mode of inhibition.  
 
Figure 11. Schematic representation of the different possible concomittant JAK1 and 
JAK3 mutations and their impact on the overall activity of the heterodimeric receptor 
complex regarding the 2 proposed models of JH2-mediated inhibition on JH1 
catalytic activity. The figure gives an overview of the possible localization of secondary 
JAK1 and JAK3 mutations starting from a mutation in JAK1 JH2 and indicates if the 
combination of the 2 substitutions in an in trans or in cis model can yield a cooperative effect 
on the overall activity of the receptor complex.  Configurations observed in our collection of 
CMP6-resistant subclones match the ones that yield cooperation in a in cis model but not a 
in trans model. The residue JAK1Y625 and JAK3T848 participate directly to the JH1-JH2 
inhibitory interface, JAK3V674 is located near the interface. All 3 mutations (JAK1Y652H, 
JAK3V674A and JAK3 T848A) are activating and have been associated with human cancers.  
 
In accordance with the in trans model, secondary mutations that could provide 
cooperation with a primary JAK1 JH2 mutation would occur either in JH2 of JAK3 
or in JH1 of JAK1, but the latter was not observed in our CMP6-selected 
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subclones. By contrast, the in cis model predicts that the 2 types of cooperating 
mutations with a JAK1 JH2 mutation can occur in JH1 or JH2 of JAK3, and these 
are indeed the configurations isolated from our resistant subclones. Furthermore, a 
JAK1 JH1 mutation would not be cooperative according to this model and is not 
encountered experimentally leading to the conclusion that our data are consistent 
with a in cis mode of inhibition of JAK1 and JAK3 within a heterodimeric receptor 
complex.  
 
What are the secondary genetic events occurring in JAK inhibitor-resistant 
TS1 subclones with no secondary mutations in any JAK kinase?  
Altogether, 34% of our JAK inhibitor-resistant TS1 subclones have no secondary 
mutations in JAK kinases indicating that there exist other ways for transformed 
cells to grow in the presence of TKI. However, a similar relative shift in sensitivity to 
JAK inhibitors is observed in both types of selected subclones (mutated and 
nonmutated), suggesting that the unidentified resistance mechanism causes a 
boost in the cascade activation to the same extent as cooperation between 2 JAK 
mutants. As depicted in the first part of the introduction, the molecular alterations 
underlying JAK-STAT pathway activation in hematological malignancies 
encompass, besides point mutations in JAK kinases, activating alterations of 
cytokine receptors or STAT factors, overexpression of cytokine receptors or JAK as 
well as loss of negative regulators such as tyrosine phosphatases. Each of them 
represents a potential secondary event that could cooperate with a JAK mutant for 
downstream signaling, except activating STAT mutations, which are relatively 
insensitive to JAK inhibition. 
Within the framework of the master thesis that she realized in our laboratory, Fanny 
Lambert, identified the Protein Tyrosine Phosphatase Receptor-type Gamma 
(PTPRG) as being downregulated in some inhibitor-resistant subclones, albeit 
without a strict correlation with the absence of secondary JAK mutations. PTPRG is 
a known tumor suppressor gene whose expression is silenced in 63% of LLA344 
and whose activation has been recently shown to induce JAK2 
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dephosphorylation345.  Further studies are needed in order to establish if PTPRG 
negatively regulates JAK1 or JAK3 activity in which case its absence could boost 
downstream signals resulting in increased resistance to JAK inhibitors. The fact 
that loss of PTPRG can arise together with a secondary JAK mutation within the 
same subclone suggests that, in some instances, multiple genetic events 
contribute to the resistant phenotype.  
 
Why are TS2 cells transformed by JAK3 mutations but not JAK1? 
Strikingly, while activating mutations in JAK1 or JAK3 were identified at similar 
frequencies in growth factor-independent TS1 clones, only JAK3 mutations were 
isolated from TS2 cells. This intriguing observation could be the outcome of 
differentially expressed genes that create distinct cellular contexts within which the 
presence of a JAK1 or JAK3 active mutant would exert divergent effects on cell 
proliferation. There are 3 possible options: first, TS2 cells that acquired a JAK3 
mutation might have a substantial growth advantage resulting in a relative 
expansion within the cell population due to natural selection pressure; second, TS2 
cells with a mutation in JAK1 might be weeded out owing to a detrimental effect on 
cell survival; finally, TS2 cells with a mutation in JAK1 might not emerge because 
the transforming activity of JAK1 mutant is kept silent. Based on micro-array data 
comparing the transcriptomes of TS1 and TS2 cells, several hypothetical 
mechanisms consistent with each of the 3 scenarios can be proposed. 
In the first case where JAK3 mutants are positively selected, variations in the 
expression of JAK1-binding receptor chains that associate with γc bound to JAK3 
can represent a plausible explanation. Indeed, while the IL-9Rα and IL-4Rα are 
present at similar levels in TS1 and TS2, the expression of IL-7Rα, IL-2Rβ and IL-
2Rα are restricted to TS2 cells. JAK3 mutants might possibly produce higher pro-
proliferative signals when it is part of an IL-7R or IL-2R complex rather than IL-9R 
or IL-4R. 
The second alternative hypothesis postulates that JAK1 mutants arising in a TS2 
cellular context are subjected to negative selection because it generates 
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unfavorable signaling. JAK1 participates in the intracellular transduction of type I 
interferons (IFN), which are known to exert an anti-proliferative activity on various 
cell types. It has been previously shown that some JAK1 mutants potentiate the 
cellular response to type I IFNs rendering cells hypersensitive 75,78. TS2 cells might 
be intolerant to the presence of JAK1 mutants that would exacerbate constitutive 
type I IFNs signaling up to a threshold incompatible with cell survival.  
The third option states that the transforming potency of JAK1 mutants is repressed 
in TS2 cells and therefore does not confer growth supremacy over neighboring 
cells. One possible mechanism implicates PTPRC, a protein tyrosine phosphatase 
that negatively regulates JAK-STAT signaling downstream of cytokine 
receptors346,347 and which is present in TS2 cells but absent in TS1 cells. It is 
conceivable that PTPRC presents variable substrate affinity among the JAK family 
members and that, in a γc-containing heterodimeric receptor complex, its catalytic 
activity is mainly focused on JAK1 rather than JAK3. Therefore, as TS2 cells 
express high levels of PTPRC and TS1 cells do not, JAK1 mutants can only 
manifest in a TS1 cellular context. 
2. MMR-deficiency and mutational signature 
 
Can the mutational bias towards T:A>C:G transitions observed in our TS1 
model be attributed to the deficiency in MMR? 
The molecular fingerprint of MMR-deficient tumors is shaped by DNA replication 
errors that persist in defiance of the sequential operation of 2 evolutionary 
conserved processes: the selectivity of replicative DNA polymerases for 
incorporating complementary bases into Watson-Crick pairs and their proofreading 
activity348. The accuracy of polymerases relies on the thermodynamic stability 
afforded by the formation of 2 or 3 hydrogen bonds between the incoming 
nucleotide and the first non-paired base of the template strand as well as spatial 
restrictions within their active site349. High-fidelity polymerases are intolerant to 
helix distortions caused by the incorporation of non-complementary base pairs and 
have inbuilt proofreading activity that precludes further extension unless the 
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terminal mispaired nucleotide is excised and replaced. Even this, however, is not 
sufficient to prevent mismatch formation, the most frequent being the wobble T:G 
mispair that is stabilized by 2 inter-base hydrogen bonds and brings about only a 
slight distortion of the DNA helix from which polymerases are able to extend with 
the least difficulty349,350. If not repaired by the MMR system, the T:G mispairs gives 
rise to transitions (i.e. purine-to-purine or pyrimidine-to-pyrimidine substitutions) in 
50% of progeny. 
Interestingly, among the different possible mismatches, MutS dimers bind with the 
highest affinity to T:G heteroduplexes351-353. Thus, the most commonly formed 
mispair corresponds to the one best recognized by MutS proteins indicating that 
the MMR system has evolved to efficiently counteract post-replicative mismatches 
arising at the highest rate, in a reciprocity between generating and correcting 
errors354-356. Consequently, in the absence of functional MMR, a general increase 
in the relative frequency of transitions versus transversions is observed in 
bacteria357,358, yeast359,360 and human cells267,361 as a result of highly prevalent 
uncorrected T:G mispairs. In normal human cells, the transitions versus 
transversions ratio is 1.7362, in MMR-deficient tumors this ratio ranges from 2.35267 
to 2.85361 and in our TS1 model it reaches 4.  
In almost all organisms, the pattern of spontaneous mutations is dominated by 
C:G>T:A transitions resulting from the natural deamination of C to U (and of 
methylated C to T at CpG sites). Strikingly, in our TS1 model and in 2 different 
MMR-deficient bacteria strains (one lacking MutS358, the other lacking MutL357), the 
expected trend is inverted in favor of T:A>C:G. It is worth noting that the bias 
observed in TS1 is distinct from the one induced in the context of mutated 
proofreading-deficient polymerases ε or δ, characterized by a particular increase in 
C:G>A:T transversions288,363. This suggests that an enhanced frequency of 
T:A>C:G transitions specifically reflects a defect in MMR.  
As already mentioned, unrepaired T:G mispairs generate transitions in either 
directions according to the symmetry of the error. The incorporation of a dTTP 
opposite to a template G (G:dTTP) gives rise to C:G>T:A while the other way round 
(T:dGTP) brings about T:A>C:G transitions. Based on the observed bias in our TS1 
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model, T:dGTP mispairs seem to be more frequent or less corrected relative to 
G:dTTP in MMR-deficient cell genome as a result of a still elusive mechanism.  
Since many DNA repair pathways crosstalk with each other, it is conceivable that, 
in the absence of MMR, an alternative system works as compensatory backup364. 
The functional interplay of MMR with BER elects this latter as prime candidate for 
this job. Indeed, BER has been shown to participate in repair of engineered T:G 
mismatches but might not completely counterbalance the lack of MMR as it does 
not discriminate between parental and daughter strands365. In 75% of cases, T:G 
mispairs were reverted to C:G indicating that the G-containing strand was 
preferentially used as template, thereby inducing a mutational bias towards 
T:A>C:G transitions. A second hypothesis would postulate that compensatory 
repair involves the action of low-fidelity DNA polymerases366. Several of those 
error-prone polymerases such as polη367, polλ368 and polι369,370 frequently 
misincorporate a dGTP opposite to template T thereby increasing the level of 
T:dGTP mismatches371 (Figure 12).  
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Figure 12. Proposed model for the increased frequency of T>C transitions in the 
absence of efficient MMR. T:G mispairs (triangles) are the most frequent post-replicative 
errors. In the presence of MMR, T:G are efficiently corrected and the mutation pattern is 
dominated by C>T transitions resulting from the spontaneous deamination of cytosines. In 
the absence of MMR, T:G are handled by a compensatory backup system that either 
preferentially converts T:G into C:G or involves the action of low-fidelity polymerases that 
misincorporate G opposite to template T. In this case, the ratio of transitions versus 
transversions is exacerbated due to the considerable increase in T>C substitutions. 
 
Is the mutational signature identified in our TS1 model relevant for MMR-
deficient human cancers? 
The collective somatic mutations observed in a cancer are the outcome of multiple 
mutagenic processes, including DNA damages and inefficient or error-prone repair, 
that have been operative over a lifetime, each of which leaving a characteristic 
imprint on the genome372. The proportion of the total mutation load enforced by 
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each mutagenic process correlates with its intensity and duration of exposure 
throughout the biological history of the cancer372. According to the here above 
proposed model, the absence of efficient MMR can account for the particular 
pattern of mutations dominated by T>C transitions in TS1 cells. Consequently, it 
was expected that computational analysis aiming at deciphering molecular imprints 
of mutational processes in cancers would yield a similar molecular signature in 
tumors lacking MMR. Nevertheless, such bias towards T>C transitions has not 
been reported in MLH1-silenced colon and endometrial cancers248,373. Rather, the 
mutational signature associated with low expression of MLH1 was characterized by 
a predominance of C>T transitions and C>A transversions248,373. 
Differences in time scales and degree of heterogeneity within the studied cell 
population might underlie the discrepancy between human tumors and in vitro TS1 
model. First, contrasting with mutations arising over a relatively short interval in 
TS1 cells, the genetic alterations composing the mutational landscape of human 
cancers are accumulated over a lifetime and a substantial part of them likely 
occurred prior to the inactivation of MMR. Second, patient tumors comprise a mix 
of cell subpopulations, which might be exposed differentially to various mutagens, 
possess variable residual MMR activity or convey dysfunctions of multiple DNA 
repair proteins. For instance, a certain number of colon and endometrial cancers 
are known to bear loss-of-proofreading mutations in POLE additionally to MLH1 
silencing. Therefore, the final mutational portrait of such tumors represents a 
complex composite of different signatures374 within which the T>C transitions are 
overwhelmed by other types of substitutions, while the mutational pattern in less 
heterogeneous populations such as TS1 cell cultures might more faithfully and 
specifically reflects MMR deficiency.  
Finally, it should be noted that although several of the actual 21 validated 
mutational signatures248,372 have been attributed to a specific mutagenic process, 
the mechanisms underlying other recognized signatures (among which some 
featuring a predominance of T>C mutations) remain to be undertsood248,373. 
Furthermore, it is likely that additional signatures of cryptic origin will be extracted 
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from the growing number of sequenced cancer genomes. In the future, we predict 
that a signature characterized by an overrepresentation of T>C transitions will be 
identified as being the outcome of inefficient MMR. 
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CONCLUSIONS 
 
Over the past decade, advances in the understanding of cancer etiology fuelled 
efforts to develop pharmaceuticals targeting signaling proteins that acquired tumor-
promoting functions, especially mutated tyrosine kinases, and some of these small 
molecule inhibitors are now part of current treatment protocols. However, according 
to experiences in the clinic, it has become clear that the use of TKIs in oncokinase-
driven malignancies will not be curative as stand-alone therapies owing to the 
emergence of diverse acquired resistance phenomena that cause disease to 
relapse.  
In this thesis, we described a new mechanism of resistance to JAK inhibitors and it 
is likely that other strategies implemented by cancer cells to overcome TKI will 
emerge with the growing number of treated patients and the enlargement of clinical 
indications. Avoiding those resistance phenomena therefore represents a major 
challenge. 
In this context, the future of targeted therapies might reside in the alliance of drugs 
targeting effectors of parallel signaling cascades, such as inhibitors of JAK, PI3K 
and MAPK that act synergistically and involve a lower risk of circumvention by 
single-target mutations or the activation of bypass pathways. However, such 
combinatory therapeutic approaches could be too simplistic to face a more 
complex situation. Kinase mutations are generally associated with recurrent 
additional genetic lesions affecting transcription factors or epigenetic modifiers that 
can modulate cancer progression and drug sensitivity. Attaining the optimal clinical 
efficacy of TKI would probably require the entire molecular characterization of the 
cancer in order to predict the rationale drug combination with the highest likelihood 
of success157. The advent of low-cost NGS techniques is expected to enable such 
"personalized medecine" by carrying out the inventory of oncogenic variants 
present in a given tumor375. However, tumors are constituted of genetically distinct 
cell variants and interpreting the mutational identity card of a cancer as a 
homogenous population could generate a biased picture and compromise 
prediction of therapeutic response. 
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Nevertheless, the analysis of the global mutational portrait, regardless of whether 
the alterations are drivers or passengers, can unveil particular signatures attesting 
the abrogation of specific DNA repair pathway(s). In this thesis, we demonstrate 
that loss of MLH1 expression not only raises the level of point mutations but also 
imprints their pattern of substitutions with a remarkable increase in T>C transitions. 
Knowledge of the invalidated repair system in a given tumor, such as MMR 
deficiency, could assist clinical decisions regarding potential sensitivity to 
therapeutics and thus provide a more successful path for cancer disease control 
from 2 sides372. First, information about MMR status would enable the stratification 
of patients with a higher probability of primary refractoriness to classical DNA-
damaging agents or acquired resistance to targeted therapy that would require 
special follow-up care. Second, it could pinpoint tumors eligible for synthetic lethal 
approaches where the absence of MMR is specifically exploited.  
This latter therapeutic strategy is made possible by the fact that DNA repair 
operates as a network of pathways sharing functional overlap rather than isolated 
entities so that cancer cells lacking one system often become reliant on an 
alternative backup376. For instance, MMR system is involved in the non-canonical 
processing of oxidized bases and inhibiting or overwhelming BER that classically 
resolves these lesions is selectively toxic for MMR-deficient tumor cells while 
sparing normal MMR-proficient cells. An on-going phase II clinical trial is evaluating 
the potential of methotrexate, an inducer of oxidative DNA damages, to translate 
into clinically efficient treatment options for MSH2-deficient metastatic colorectal 
cancers (NCT00952016)377. 
The second aspect of the paradox related to MMR deficiency being both a strength 
and a weakness for a cancer cell, concerns the boost in immunogenicity resulting 
from the generation of tumor-specific antigens due to increased somatic mutations. 
In this regard, benefit can be gained by using inhibitors of programmed death-1  
(PD-1), a repressor of TH1 cytotoxic immune responses. A phase II study has 
been conducted on patients suffering from progressive metastatic carcinoma (colon 
cancer and melanoma) with or without MMR deficiency and concluded that MMR-
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deficient tumors were indeed more responsive to PD-1 blockade than MMR-
proficient counterparts (NCT01876511)378.  
In conclusion, switching-off the oncogenic pathway by targeted therapies involves 
the risk of accelerating and worsening the natural history of the disease by 
selecting tumor cell variants with additional genetic lesions. Moreover, repeated 
rounds of selection, for example by sequential use of small molecule inhibitors, are 
likely to promote progressive enrichment in DNA repair deficiencies that will entail 
increased mutagenesis and tumor heterogeneity. However, this higher plasticity 
evolves at the cost of supplementary vulnerabilities that can be turned to account 
by synthetic lethality or anti-tumor immune surveillance. Therefore, the 
comprehensive consideration of cancers by integrating their targetable 
advantageous properties as well as exploitable shortcomings should serve as 
guidelines for the design of future clinical trials.  
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Background
Activating mutations in JAK1 and JAK2 have been described in patients with various hemato-
logic malignancies including acute lymphoblastic leukemia and myeloproliferative neoplasms,
leading to clinical trials with JAK inhibitors. While there has been a tremendous effort towards
the development of specific JAK inhibitors, mutations conferring resistance to such drugs have
not yet been observed. 
Design and Methods
Taking advantage of a model of spontaneous cellular transformation, we sequenced JAK1 in
selected tumorigenic BaF3 clones and identified 25 de novo JAK1 activating mutations, including
5 mutations already described in human leukemias. We further used this library of JAK1 muta-
tion-positive cell lines to assess their sensitivity to ATP-competitive inhibitors. 
Results
While most JAK1 mutants were sensitive to ATP-competitive JAK inhibitors, mutations target-
ing Phe958 and Pro960 in the hinge region of the kinase domain rendered JAK1 constitutively
active but also resistant to all tested JAK inhibitors. Furthermore, mutation of the homologous
Tyr931 in JAK2 wild-type or JAK2 V617F mutant found in patients with myeloproliferative
neoplasms also conferred resistance to JAK inhibitors, such as INCB018424, which is currently
in clinical use.  
Conclusions
Our data indicate that some activating mutations not only promote autonomous cell prolifera-
tion but also confer resistance to ATP-competitive inhibitors. In vivo, such a mutation can
potentially occur as primary JAK-activating mutations but also as secondary mutations combin-
ing oncogenicity with drug resistance.
Key words: JAK, tyrosine kinase, mutations, inhibitors, STAT.
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Introduction
Persistent activation of signal transducer and activator
of transcription (STAT) factors is characteristic of many
types of leukemia and solid tumors. In normal cells,
cytokine-induced activation of STAT proteins provides
the stimulus for proliferation, survival, self-renewal, dif-
ferentiation and functional activation. In leukemic cells,
like in other cancers, STAT proteins are frequently consti-
tutively activated in the absence of cytokine stimulation,
providing malignant cells with persistent signals and self-
sufficiency for survival and proliferation.1
The most common mechanism for constitutive activa-
tion and phosphorylation of STAT factors is the dysregu-
lation of tyrosine kinases. In 2005, the identification of an
activating mutation in JAK2 (the V617F mutation) as a
STAT5-activating and disease-causing genetic alteration
in a significant proportion of patients with myeloprolifer-
ative neoplasms (MPNs) has emphasized the oncogenic
role of the JAK tyrosine kinases in hematologic malignan-
cies.2-5 JAK2 is a member of the Janus tyrosine kinase fam-
ily comprising three other mammalian non-receptor tyro-
sine kinases (JAK1, JAK3 and TYK2) that associate with
cytokine receptors lacking intrinsic kinase activity to
mediate cytokine-induced signal transduction and activa-
tion of STAT transcription factors.6 All JAKs share a simi-
lar protein structure and contain a tyrosine kinase domain
at the C-terminus flanked by a catalytically inactive
pseudokinase domain with kinase-regulatory activity, by
an atypical SH2 domain and by a FERM domain that
mediates association to the membrane-proximal region of
the cytokine receptors.7,8 Soon after the discovery of JAK2
V617F, we and others described that activating JAK1
mutations are relatively common in adult patients with T-
cell acute lymphoblastic leukemia (ALL) and participate in
ALL development allowing for constitutive activation of
STAT5.9-11 Several STAT5-activating JAK1 mutations were
also reported in AML and breast cancer patients.10
Because of its central role in the pathophysiology of
MPNs, the JAK2 V617F is an attractive therapeutic target.
Several JAK2 inhibitors are now under development
or/and undergoing clinical trials for MPNs. Some of these
JAK2 inhibitors were also shown to be remarkably active
on JAK1 and have, therefore, a strong therapeutic poten-
tial for JAK1 mutation-positive patients. One of the most
promising JAK1/JAK2 inhibitors is INCB018424,12 cur-
rently in phase III clinical trials for MPNs. The major
drawback of tyrosine kinase inhibitor therapy is the
development of secondary resistance caused by the acqui-
sition of new mutations. The best example of this sce-
nario comes from BCR-ABL positive neoplasms. Here
patients treated with imatinib become resistant because
of the acquisition of mutations in the ABL kinase
domain.13
In our laboratory, we have previously described an in
vitro model of spontaneous transformation of the IL-3-
dependent hematopoietic BaF3 cell line towards growth
factor-independent tumorigenic clones with constitutive
STAT5 activation.14 This model was developed from the
study of BaF3 cells transfected with an IL-9R! mutant
lacking the STAT-recruiting site (BaF3 phe116). This BaF3
phe116 almost completely fails to proliferate and activate
STATs in response to IL-9.15 However, upon prolonged
culture with IL-9, a small number of cells manage to sur-
vive and even proliferate, allowing an IL-9-dependent cell
line (BaF3 phe116/9) to be selected.14 In contrast to
parental BaF3 phe116 cells, those IL-9-selected cells could
progress to autonomous cells (BaF3 Aut) after a second
selection step in the absence of cytokine. These
autonomous cells show a cytokine-independent activa-
tion of JAK1 and STAT5 and are highly tumorigenic when
injected in mice, which is not the case for parental BaF3
phe116 and BaF3 phe116/9.14,16 We previously showed
that upregulation of the endogenous JAK1 gene was asso-
ciated with the first step of transformation, namely
increased sensitivity of BaF3 phe116 cells to IL-9, and pro-
motion of the second step of transformation, namely pro-
gression towards cytokine-independent BaF3 auto -
nomous cells.16
In this study, we show that 80% of the autonomous
BaF3 clones, selected in our in vitro model, acquired acti-
vating point mutations in the kinase or pseudokinase
domain of JAK1. These JAK1 mutations provide cells
with tumorigenic potential by inducing constitutive acti-
vation of the JAK-STAT pathway, which supports their
autonomous proliferation. We took advantage of this col-
lection of JAK1 mutation-positive autonomous cell lines
to study the sensitivity of different JAK1 mutations to
JAK inhibitors. For the first time, we report that muta-
tions of the Phe958 and Pro960 not only constitutively
activate JAK1, but also render the mutated JAK1 protein
resistant to ATP-competitive inhibitors. The homologous
mutation in JAK2, namely Y931C, also renders JAK2
wild-type or V617F mutant resistant to all tested ATP-
competitive inhibitors.
Design and Methods
Cell culture and cytokines
BaF3 mouse hematopoietic pro-B cells were cultured in
Dulbecco’s modified Eagle’s medium with fetal bovine serum
(10%) and IL-3 (150 U/mL), which was produced by transfected
CHO cells. Recombinant human IL-9 was produced in the bac-
ulovirus system and purified by affinity chromatography in our
laboratory. The generation of BaF3 phe116 as well as BaF3
phe116/9 cells and the selection of autonomous cells has been
previously described.14 The frequency of autonomous cells was
assessed as previously described.14 IL-9-selected BaF3 phe116/9
and non-selected BaF3 phe116 cells were grown in the presence
of IL-3, while autonomous clones were selected and subsequent-
ly amplified in the absence of IL-3. 
RNA extraction, cDNA synthesis, PCR and sequencing
Total RNA was isolated from 106 IL-3 dependent BaF3 phe116,
BaF3 phe116/9 or autonomous BaF3 (BaF3 Aut) clones using
TriPure reagent (Roche) according to the manufacturer’s instruc-
tions. Reverse transcription was performed on 1 µg of total RNA
with an oligo (dT) primer (Roche) and M-MLV RT (Invitrogen).
PCR amplification was performed from cDNA corresponding to
20 ng of total RNA at 94°C for 1 min, 58°C for 1 min, and 72°C
for 2 min with a total of 39 cycles. Depending on the region of
JAK1 to be sequenced, different sets of primers were used to
amplify and sequence JAK1 PCR product (available upon
request). PCR product was purified using Chromaspin technolo-
gy (Clontech): 50-100 ng of PCR product was used for sequenc-
ing with the DYEnamic ET Dye Terminator Kit (Amersham
Biosciences) according to the manufacturer’s instructions. Two
independent PCR reactions were performed to rule out the pos-
sibility of Taq-induced mutations during amplification.
T. Hornakova et al.
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Interestingly, all the nucleotides mutated in the murine JAK1
sequence were conserved in the human JAK1 sequence (data not
shown). Therefore, the numbering of mutated amino acids was
based on the human JAK1 sequence, allowing currently used
nomenclature for JAK1 protein mutations in literature to be
adopted and to localize our JAK1 mutations in the previously
described three-dimensional structure model of human JAK1
protein.9
Reverse transcription-quantitative PCR (RT-PCR)
Reverse transcription was performed as described above.
Quantitative PCR reactions were performed using primer sets
corresponding to murine JAK1 or murine Actin with qPCR™
Mastermix for SYBR Green I (Eurogentec). The sequences of
primers (final concentration 300 nM) were: mJAK1 5’-GGAGT-
GCAGTATCTCTCCTCTCT-3’ (forward) and 5’-CCATGC-
CCAGGCACTCATTTTCA-3’ (reverse); mActin 5'-GCTG-
GAAGGTGGACAGTGAG-3' (forward), 5'-CTCTGGCTCC-
TAGCACCATGAAG-3' (reverse). To amplify corresponding
cDNA, PCR conditions were used as previously described.17,18
Results were analyzed using MyiQ software. Starting quantity
of the transcripts was calculated using standard curves from a
cDNA clone. 
Plasmid construction, stable DNA transfections and
analysis of transfected cells
All JAK1 and JAK2 mutants were generated using
QuickChange XL II site-directed mutagenesis kit (Stratagene)
and subcloned into the pMX-GFP (for JAK1) or pMEGIX-GFP
(for JAK2) biscistronic retroviral vector upstream of the IRES as
previously described.17-19 The mutated JAK1 and JAK2 constructs
were verified by sequencing the full-length JAK1 and JAK2 using
DYEnamic ET Dye Terminator Kit (Amersham Biosciences). For
stable transduction, typically 0.5!106 BaF3 cells were infected by
retroviruses produced by BOSC packaging cells using a previ-
ously described standardized protocol.20 Cells were subsequent-
ly sorted by FACS according to equal levels of GFP.
Western blots
For Western blot analysis, 106 BaF3 cells were starved for 4 h
and lysed in 250 µL of Laemmli buffer (BioRad). We separated
proteins using 12% pre-cast Tris-Glycine gels (Invitrogen) and
transferred them to nitrocellulose membranes (Hybond-C,
Amersham). Phosphorylation of signaling proteins was investi-
gated using the following phospho-specific antibodies from Cell
Signaling Technology: anti-pY1034/1035 JAK1 (#3331S), anti-
pY1007/1008 JAK2 (#3771S), anti-pY705 STAT3 (#9131S), anti-
pY694 STAT5 (#9351S) and anti-p44/42 MAPK (#9101L). Blots
were re-probed with anti-JAK1 (#3332), anti-JAK2 (#24B11) (Cell
Signaling Technology, Beverly, MA, USA), anti-STAT5  (Santa
Cruz) or anti-"-Actin (Sigma) antibodies, as control. All the anti-
bodies were used at dilutions recommended by the manufactur-
er. 
JAK inhibitors and proliferation assay
To test the effect of JAK inhibitors, 10,000 stably-transduced
or JAK1 mutation-acquired autonomous BaF3 cells were seeded
in 96-well plates in the presence of JAK inhibitors CMP6 or
INCB018424 at different concentrations (10 - 0.001 nM) and
DMSO as control. After 48 h, tritiated thymidine was added to
the cells for 4 h. Cells were then collected on microfiltered
plates, and thymidine incorporation was measured with a Top
Count microplate scintillation counter (Canberra-Packard,
Meriden, CT, USA).
JAK1 structures
The three-dimensional structural model of the kinase and
pseudokinase domain of JAK1 has been previously described9
and was obtained by employing Deep View software and the
Swiss Model server after manual regulation of the best align-
ment. Structural data from recently solved crystal structure of
JAK1 kinase domain in complex with CPM, an ATP-competitive
inhibitor (PDB 3EYH),21 were used to analyze more precisely the
impact of the kinase domain-located JAK1 mutations. Molecular
graphic images were produced using the UCSF Chimera package
from the Resource for Biocomputing, Visualization, and
Informatics at the University of California, San Francisco, USA.22
Statistical analysis
Significant differences were determined using InStat software.
The mean of 2 groups was compared with Student’s t-test.
Normality tests were used to test the assumption of a normal
distribution. Mean values ± SEM are shown. 
Results
De novo mutations in kinase and pseudokinase domain
of JAK1 spontaneously occur during selection of BaF3
autonomous clones
The transformation of BaF3 phe116 into autonomous
tumorigenic clones is a two-step model of tumorigenesis.
The first step requires spontaneous upregulation of JAK1,
while the mechanism involved in the second step of
transformation is not known.16 As constitutive phospho-
rylation of JAK1 was detectable in autonomous clones,14
we systematically sequenced JAK1 from autonomous
clones and found that the vast majority of them (139 of
164) were heterozygous for a single de novo mutation.
Altogether, 25 different missense mutations were identi-
fied as listed in the Online Supplementary Table S1 and
Online Supplementary Figure S1. Among the 25 different
mutations identified, 12 affect residues located in the
pseudokinase domain and 13 in the kinase domain (Figure
1A and B). Most of the remaining JAK1 mutation-nega-
tive clones have acquired the IL-3 autocrine loop (data not
shown). An unknown genetic or epigenic event remains to
be identified in 3 last autonomous clones that are JAK1
mutation-negative and IL-3 autocrine loop-negative.
To better highlight the localization of mutated residues,
we took advantage of the three-dimensional model struc-
ture of kinase (JH1) and pseudokinase (JH2) domain of
JAK1 previously described.9 As shown in Figure 1B, half
of the affected residues (6 of 12 de novo mutations) of the
pseudokinase domain (F635V, S646F, Y652H and
V658I/L/F), including 3 mutations (S646F, Y652H and
V658F) that were previously identified in T-ALL
patients,10,11,23 are located within the pocket formed
between the JH2 #C helix and an adjacent loop compris-
ing Val658 and Tyr652 residues. These two regions of the
JH2 domain were predicted to interact with the activation
loop of the kinase domain in the active conformation.24
The enrichment of this region in activating mutations
suggests that this area represents a hotspot for mutations
that might share a common mechanism to activate JAK1.
Three of the JH1-located mutations (K1026E, Y1035C and
S1043I) are also targeting the activation loop of the JH1
domain that is part of the interface between the kinase
(JH1) and the pseudokinase (JH2) domain, further sup-
TK inhibitor-resistant JAK-activating mutations
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porting this hypothesis. 
For the mutations located in the JH1 kinase domain, we
took advantage of the recently solved crystal structure of
the JAK1 JH1 domain to detail their localization.21 As
shown in Figure 1C, D and E, from 13 JH1-located muta-
tions, 3 (K1026E, Y1035C and S1043I) are located in the
activation loop (A-loop), 4 mutations affect the same
residue (F958V, F958C, F958S, F958L) in the hinge region
of the kinase domain at the entry of the ATP-binding
pocket, 3 others (D895H, E897K and T901R) are located
at the top of the kinase domain in the loop formed
between two antiparallel !-strands (!2 and !3) and one
mutation affects the loop formed between the !-strand-3
(!3) and the "C helix of the JH1 domain (L910Q).
Altogether, beside the mutations targeting the JH1/JH2
interface, the other activating mutations found in this
study point to two other hotspots for the regulation of
JAK enzymatic activity: the hinge region and in the loop
formed between !2- and !3-strand in the kinase domain.
Moreover, structural modeling of these hotspots also sug-
gests that each of them might have a distinct molecular
mechanism for kinase activation.25
JAK1 mutations spontaneously occurring 
in autonomous BaF3 cells are JAK-STAT 
pathway activating mutations
We previously showed that progression of BaF3
phe116/9 cells toward cytokine-independence was asso-
ciated with constitutive activation of JAK1 and STAT5.14
We, therefore, examined whether all JAK1-mutated
autonomous clones (BaF3 Aut) showed a similar signaling
profile. We chose one representative JAK1 mutation-pos-
itive autonomous BaF3 clone for each of the 25 JAK1
mutations and performed Western blot analysis to assess
the activation status of JAK1, STAT5 and ERK1/2. As
shown in Online Supplementary Figure S2A, none of these
proteins were phosphorylated in BaF3 phe116 or IL-9-
selected BaF3 phe116/9 in the absence of cytokine. In
contrast, all autonomous BaF3 clones showed constitutive
activation of STAT5 and, for most of them, constitutive
phosphorylation of JAK1 and ERK1/2 was also detected,
confirming that all JAK1-mutated autonomous clones har-
bored constitutive activation of the JAK-STAT and the
MAP kinase pathways. As expected, the total level of
JAK1 was 2-3 times higher in BaF3 phe116/9 and in
autonomous clones as a consequence of the first selection
step, which consists of spontaneous JAK1 upregulation.16
To confirm that the acquisition of mutations in JAK1 is
responsible for autonomous BaF3 cell proliferation, we
produced mutated JAK1 constructs for the first 13 of the
25 JAK1 mutations that we had found. We transduced
parental BaF3 cells with either mutated or wild-type (WT)
JAK1. In contrast to cells stably transduced with WT
JAK1, which quickly died after IL-3 starvation, all JAK1
mutated constructs were able to promote the
autonomous growth of BaF3 cells (data not shown).
Moreover, similarly to autonomous BaF3 harboring spon-
taneously acquired mutations, all JAK1 mutants induced
the constitutive activation of STAT5 and MAP kinase
pathways when ectopically expressed in BaF3 cells
(Online Supplementary Figure S2B) for 8 representative
mutants. As a control for this experiment, we used an
autonomous BaF3 cell line obtained by transfection with
an oncogenic mutant of M-RAS (Glu71Lys), which shows
constitutive activation of the MAP kinase but not the
T. Hornakova et al.
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Figure 1. De novo mutations in kinase and pseudokinase domains of
JAK1 spontaneously occur during selection of BaF3 autonomous
clones. (A) Localization of 25 identified missense point mutations
affecting 19 residues in the schematic structure of JAK1 with its
functional domains and (B) in the three-dimensional modeled struc-
ture of kinase and pseudokinase domain published by Flex9. Ten
affected residues (red balls) in pseudokinase (in green) and 9 (yellow
balls) in kinase domain (in blue) are shown. (C) Localization of 9
affected residues (black balls) in the crystal structure of JAK1 kinase
domain solved with ATP-competitive JAK inhibitor CMP6 (PDB
3EYH).21 The JAK inhibitor is presented in white using a ball-and-stick
representation. (D) Magnification of structure of the activation loop
showing the side chains of the residues at positions 1026 and 1035
for the wild-type JAK1 (top panel), the K1026E mutant (middle
panel), and the Y1035C mutant (lower panel). (E) Magnification of
the !2/!3 linking loop highlighting the side chains of the residues at
positions 895, 897 and 901 for the wild-type JAK1 (left panel), the
Asp895His mutant (left middle panel), the Glu897Lys (right middle
panel) and the Thr901Arg mutant (right panel).
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JAK/STAT pathway (Online Supplementary Figure S2B).
Altogether, these results confirmed that the JAK1 muta-
tions occurring spontaneously in vitro were JAK1/STAT5-
activating mutations.
The F958V mutation confers resistance 
to ATP-competitive JAK inhibitors
JAK inhibitors represent a promising therapy for JAK
mutation-positive neoplasms. We used our JAK1 muta-
tion-positive autonomous cell lines to evaluate sensitivity
of different JAK1 mutants to treatment with CMP6
inhibitor (JAK inhibitor I) by assessing tyrosine phospho-
rylation of JAK1 and STAT5, one of the main JAK1 phos-
pho-substrates. As shown in Figure 2A, treatment of BaF3
Aut(V658I) with CMP6 completely blocked phosphoryla-
tion of JAK1 and STAT5, while the same treatment did
not affect either JAK1 or STAT5 phosphorylation in the
BaF3 Aut(F958V) cells. Similar results were obtained with
BaF3 stably transduced with the corresponding JAK1
mutants (Figure 2B), confirming that the F958V mutation
confers resistance to CMP6. To visualize the Phe958 to
Val mutation, we used the crystal structure of the JAK1
kinase domain with CMP6 inhibitor (Figure 2C). The
Phe958 is in direct interaction with CMP6 through its
main-chain atoms as previously reported in this model
(Figure 2C, left panel). The replacement of the Phe958 by
Val abolishes this interaction (Figure 2C, right panel).
We further measured proliferation of BaF3 Aut(V658F)
and Aut(F958V) in the presence of different concentra-
tions of CMP6 or INCB018424. The BaF3 Aut(F958V)
cells were more resistant to the effect of these inhibitors
when compared to the Aut(V658F) cells, with a 10-15
times increase in the IC50 (Figure 2D and E). In contrast,
no difference was observed in the sensitivity of these cell
lines to cytosine arabinoside (ARA-C), a standard chemo -
therapeutic drug which targets different pathways (data
not shown). Conversely, JAK inhibitors did not affect MAP
kinase-dependent proliferation of control autonomous
cells transfected with an activated mutant of M-RAS. In
line with these results, treatment of Aut(V658) cells with
INCB018424 blocked constitutive phosphorylation of
JAK1 and STAT5, while their phosphorylation was pre-
served in Aut(F958V) cells even after treatment with 10
µM of inhibitor (Figure 2F). Altogether, these results show
that the F958V mutation confers resistance to ATP-com-
petitive JAK inhibitors.
TK inhibitor-resistant JAK-activating mutations
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Figure 2. The F958V mutation confers resistance to ATP-competitive JAK inhibitors. (A) 106 BaF3 Aut(V658I), Aut(F958V) and BaF3 cells sta-
bly transduced with M-RAS or (B) JAK1 V658I and F958V mutants were treated for 30 min with 500 nM CMP6 inhibitor or with 0.1 % DMSO
as a control (- condition), lysed and subjected to Western blot analysis. Phosphorylation of JAK1 and STAT5 was detected using specific anti-
p1034/35 JAK1 and anti-pY694 STAT5. Membranes were re-probed with anti-JAK1, anti-STAT5 and anti-!-Actin antibodies as a control.
Similar results were obtained in 3 independent experiments. (C) Magnification of the hinge region and ATP-binding pocket in the crystal
structure of JAK1 kinase domain solved with ATP-competitive JAK inhibitor CMP6 (PDB 3EYH) in ribbon representation21 showing the side
chains of the Phe and Val residue at positions 958 for the wild-type JAK1 (left panel) and the F958V mutant (right panel), respectively. (D
and E) 10,000 BaF3 Aut(V658F), Aut(F958V) cells or BaF3 cells stably transduced with activated M-RAS as a control, were seeded in 96-
well plates and treated with increasing concentration of (D) CMP6 or (E) INCB018424 JAK inhibitor. After 48 h, tritiated thymidine was added
to the cells for 4 h and thymidine incorporation was measured. Results are mean ± SD of triplicate cultures. Similar results were obtained
in at least 3 independent experiments with 2 different autonomous clones for each JAK1 mutation. (F) 106 BaF3 Aut(V658I), Aut(F958V)
were treated for 30 min with 100 nM, 1 µM or 10 µM INCB018424 inhibitor or with DMSO as a control (- condition), lysed and subjected
to Western blot analysis. Phosphorylation of JAK1 and STAT5 was detected using specific anti-pY1034/35 JAK1 and anti-pY694 STAT5.
Membranes were re-probed with anti-JAK1, anti-STAT5 and anti-!-Actin antibodies as a control. Similar results were obtained in 3 independ-
ent experiments.
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Mutations targeting JAK1 Phe958 and Pro960 confer
JAK inhibitor resistance 
To assess the sensitivity of other JAK1 mutation-posi-
tive cell lines to JAK inhibition, we performed a prolifer-
ation assay with increasing doses of INCB018424. The
concentration of INCB018424 necessary to inhibit 50% of
cell proliferation is represented in the Online Suppl -
ementary Figure S3A. Out of the 25 mutants, 6 showed a
significant reduction in their sensitivity to INCB018424
(Online Supplementary Figure S3A). The other 19 mutants
had the same sensitivity as the V658F (data not shown). All
the mutants affecting Phe958 conferred BaF3 resistance to
the inhibitor, as already shown for the F958V, with a 5 to
15-fold increase in the IC50 compared to V658F mutation-
positive cells. The mutations of Pro960 to Thr or Ser,
affecting a residue close to the Phe958, also reduced sen-
sitivity to INCB018424 with an approximately 2 to 4-fold
increase in IC50. Similar results were observed when we
tested CMP6 and other ATP-competitive inhibitors (data
not shown). In line with these observations, all F958- and
P960-targeting JAK1 mutations showed reduced inhibi-
tion of STAT5 phosphorylation in response to CMP6,
while all the other mutations had similar IC50 to that of
the parental BaF3 cells growing in the presence of IL-3
(data not shown).
One of the main mechanisms of secondary resistance in
patients treated with tyrosine kinase inhibitors is acquisi-
tion of new inhibitor-resistant mutations. The JAK1
V658F mutation is constitutively active26 and has been
described in ALL and AML patients.10,11 This makes it a
good candidate for JAK inhibitor therapy. We decided to
investigate whether the acquisition of a secondary JAK
inhibitor resistant mutation in the kinase domain would
make JAK1 V658F insensitive to JAK inhibition. We,
therefore, transduced parental BaF3 cells with the V658F
(JAK inhibitor sensitive), F958C (JAK inhibitor resistant)
and the V658F/F958C double JAK1 mutants and selected
these cells for autonomous proliferation. We then meas-
ured the proliferation of these cells with increasing con-
centrations of INCB018424 and calculated the IC50
(Online Supplementary Figure S3B). As expected, BaF3 cells
expressing the F958C mutant were less sensitive than
BaF3 V658F, while the level of JAK1 mutant expression
was identical (Online Supplementary Figure S3C). Im -
portant ly, cells expressing the double mutants
V658F/F958C showed identical sensitivity to the inhibitor
as cells expressing F958C mutant alone (Online Suppl -
ementary Figure S3B). These results show that acquisition
of a JAK inhibitor resistant mutation such as the F958C in
cells dependent on activated JAK1 for growth is a poten-
tial mechanism of secondary resistance to JAK inhibitor
therapy. 
Long-term culture of F958V-positive BaF3 cells with
JAK inhibitor leads to increased expression of F958V
JAK1 that correlates with increased resistance to JAK
inhibitor
We demonstrated that the F958V JAK1 mutation makes
BaF3 cells resistant to JAK inhibitors. Therefore, prolifer-
ation of the F958V-positive cells in the presence of the
JAK inhibitor CMP6 is not completely abolished and
allows further expansion and proliferation of these cells in
the presence of the JAK inhibitor CMP6 for days or even
weeks (Online Supplementary Figure S4A). We tested the
sensitivity of the F958V-positive cells to CMP6 before and
after long-term culture in the presence of this inhibitor.
Cells cultured with CMP6 for two weeks were more
resistant to CMP6 than F958V-positive cells which had
never been exposed to this inhibitor before (Online
Supplementary Figure S4B). The JAK1 cDNA from several
clones from this long-term culture have been entirely
sequenced to rule out secondary acquired mutations. No
secondary mutations have been detected in these cell
lines. However, this increase in intrinsic resistance corre-
lated with increased expression of JAK1 protein and RNA
levels (Online Supplementary Figure S4C and D). Similar
results were observed using F958C-positive cells (Online
Supplementary Figure S4D). Altogether these results show
that treatment of cells expressing JAK inhibitor-resistant
mutants with JAK inhibitor allows an increase in the
intrinsic resistance of these cells by increasing the level of
mutated JAK1.
JAK2 Y931C, the homologous mutation of JAK1 F958C,
confers resistance to JAK inhibitors
Because of its central role in the pathophysiology of
MPNs, the JAK2 V617F is an attractive therapeutic target.8
Currently several JAK2 inhibitors are under development
or/and undergoing clinical trials for MPNs.27 Identification
of JAK inhibitor-resistant mutations in JAK2 is, therefore,
of great importance. We, therefore, introduced the
Y931C, a homologous mutation of JAK1 F958C, into WT
or V617F JAK2 protein and selected these cells for
autonomous proliferation. All three JAK2 mutants, but
not JAK2 WT or control BaF3 cells, were able to prolifer-
ate in the absence of IL-3 (Figure 3A). The ability to pro-
liferate autonomously was associated with constitutive
JAK2 and STAT5 activation in these cells (Figure 3B).
Proliferation of the autonomous cells was measured in
the presence of increasing concentrations of INCB018424
or CMP6 to calculate the IC50 (Figure 3C and D). The
JAK2 Y931C mutation dramatically reduced sensitivity of
BaF3 cells to INCB018424 compared to JAK2 V617F-pos-
itive BaF3 cells (Figure 3C). Moreover, cells expressing the
V617F/Y931C double JAK2 mutant showed identical sen-
sitivity to the inhibitors as cells expressing Y931C mutant
alone, with a 20 to 50-fold increase in the IC50
(INCB018424 and CMP6, respectively) compared to
V658F mutation-positive cells. Similar results were
observed when we tested other ATP-competitive
inhibitors (data not shown). The resistance of the JAK2
Y931C positive cells to inhibitor was associated with per-
sistent JAK2-phosphorylation in the presence of JAK
inhibitor (Figure 3E). These results show that acquisition
of a JAK inhibitor-resistant mutation such as the Y931C in
cells dependent on activated JAK2 V617F for growth is a
potential mechanism of secondary resistance to JAK
inhibitor therapy in MPN patients.
Discussion
The acquisition of growth signal self-sufficiency is one
of the hallmarks of cancer.28 In this paper, we show that a
broad spectrum of spontaneous mutations in one of the
endogenous JAK1 alleles is the main mechanism that con-
fers to BaF3 cells cytokine-independent growth capability
in vitro and full tumorigenicity in vivo (Online Supplement -
ary Figure S5), secondary to the upregulation of the JAK1
transcript. We use this in vitro model of spontaneous tu -
T. Hornakova et al.
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mori genesis to generate a library of cell lines with 25 dif-
ferent de novo JAK1-activating mutations, 6 of which are
targeting two residues, Phe958 and Pro960, located in the
hinge region at the periphery of the ATP-binding pocket.
The important property of these mutations targeting
Phe958 and Pro960 is that they not only make the kinase
constitutively active, but also give increased resistance to
ATP-competitive inhibitors, including INCB018424,
which is currently used in clinical trials for JAK2 V617F-
positive MPNs.12
The major drawback of tyrosine kinase inhibitor thera-
py is the development of secondary resistance caused by
the acquisition of new mutations, as best exemplified by
imatinib-resistant mutations in BCR-ABL positive CML.13
Multiple BCR-ABL kinase domain mutations conferring
imatinib-resistance have been described including the
T315I mutation, which targets the gate-keeper Thr315 in
ABL kinase. This gatekeeper Thr residue is not conserved
in the JAK kinase family, but the Phe958 residue of JAK1
is the homologous residue of Phe317 in ABL kinase,
which is close to the gatekeeper residue and was also
found to be mutated in imatinib-resistant BCR-ABL posi-
tive patients13,29,30 (Online Supplementary Figure S6A and
S6B). Along the same lines, in non-small cell lung cancer
(NSCLC), acquired resistance to Gefitinib/Erlotinib
kinase inhibitors has also been associated with a second-
ary mutation of the gatekeeper Thr790 residue of the epi-
dermal growth factor receptor (EGFR). The T790M muta-
tion has been shown to activate the wild-type EGFR, act-
ing both as a drug-resistance and as an activating muta-
tion, similar to JAK mutations reported here.31
The gatekeeper Thr residue in ABL and EGFR is located
at the periphery of the nucleotide-binding site and directly
interacts with imatinib, so that mutation into more bulky
amino acids such as Met and Ile sterically hinders the bind-
ing of imatinib and other ATP-competitive inhibitors.
However, at least for the EGFR, increased affinity for ATP
appears to be the primary mechanism by which the
T790M mutation confers drug resistance, and might also
explain its activating property.32 Based on the crystal struc-
ture of the JAK1 kinase domain (PDB 3EYH),21 replacement
of Phe at position 958 by the less voluminous Val, Cys, Ser
or Leu residues is predicted to change the orientation of
the side chain to the opposite direction (Figure 2B).  This
rules out the possibility that resistance to inhibitors results
from a steric hindrance as proposed for the Thr315 muta-
tions of ABL.13,33 However, the crystal structures of JAK1
and JAK2 also show that Phe958 or Tyr931, respectively,
are in direct contact with the CMP6 inhibitor.21 The
replacement of Phe958 by Val/Cys/Ser/Leu abolishes this
TK inhibitor-resistant JAK-activating mutations
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Figure 3. JAK2 Y931C, the mutation homol-
ogous to JAK1 F958C, confers resistance to
JAK inhibitors. (A) BaF3 cells control or sta-
bly transduced with wild-type or with V617F,
Y931C or V617F/Y931C mutant were
washed 3 times in PBS to remove the resid-
ual IL-3 and seeded in 6-well plates at a con-
centration of 100,000 cells/mL in culture
medium. Living cells were counted at 24 h
intervals. Results are mean±SD of triplicate
cultures. Similar results were obtained in 2
independent experiments. (B) BaF3 cells
stably transduced with V617F, Y931C or
V617F/Y931C mutant were lysed and sub-
jected to Western blot analysis.
Phosphorylation of JAK2 and STAT5 was detected using specific anti-pY1007/8 and anti-pY694 STAT5. Membranes were re-probed with anti-
JAK2, anti-STAT5 and anti-!-Actin antibodies as a control. Similar results were obtained in 3 independent experiments. (C) 10,000 BaF3 cells
stably transduced with V617F, Y931C or V617F/Y931C JAK2 mutants were seeded in 96-well plates and treated with increasing concentra-
tion of INCB018424 JAK inhibitor. After 48 h, tritiated thymidine was added to the cells for 4 h and thymidine incorporation was measured.
Results are mean ± SD of triplicate cultures. Similar results were obtained in at least 3 independent experiments. (D) IC50 for INCB08424
and CMP6 inhibitor calculated based on dose-dependent proliferation curves of BaF3 cells stably transduced by V617F, Y931C and
V617F/Y931C double JAK2 mutant. Results are mean ± SEM of at least 3 independent experiments (**P<0.01; ***P<0.001). (E) 106 BaF3
cells stably transduced with JAK2 V617F, Y931C and V617F/Y931C double JAK2 mutant were treated for 30 min with 300 nM CMP6
inhibitor or with DMSO as a control (- condition), lysed and subjected to Western blot analysis. Phosphorylation of JAK2 was detected using
specific anti-pY1007/8 JAK2. Membranes were re-probed with anti-JAK2 and anti-!-Actin antibodies as a control. Similar results were
obtained in 3 independent experiments.
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interaction and should decrease the affinity for this com-
pound (Figure 2C). Further structural data are necessary to
determine whether a critical interaction also takes place
between Phe958 and INCB018424 or other inhibitors used
in this study, but the observation that these JAK mutations
confer resistance to different ATP-competitive inhibitors
and that they are activating mutations is more in line with
a mechanism of increased affinity for ATP, as shown for
the T970M EGFR mutation.32 The homologous residues to
JAK1 Phe958 are either Phe or Tyr in other kinases such as
ABL, SRC, PDGFR, KIT and JAK2, suggesting that an aro-
matic side chain at this position is required for proper reg-
ulation of the kinase activity. The effect of mutations
affecting Phe958 in JAK1 and Tyr931 in JAK2, combined
with the F317L/I mutations in drug-resistant BCR-ABL
patients supports the notion that this residue plays a criti-
cal functional role for the ATP access into the ATP-binding
pocket.
The clinical relevance of our in vitro model is highlighted
by the fact that 5 of the 25 activating mutations (S646F,
Y652H, V658F, R724H, L783F) have been previously
reported in human patients. The 6 drug-resistant mutations
have not yet been described in patients, but our observa-
tion that Tyr931 mutation confers resistance of JAK2
V617F to several JAK inhibitors, including INCB018424,
suggest that these mutations might contribute to the devel-
opment of drug-resistant clones during treatment of JAK2
V617F-positive MPNs with such inhibitors. 
It has been shown in imatinib-resistant CML that drug
resistance conferred by mutations does not necessarily
correlate with proliferative advantage and increased
kinase activity.34 Other, non-activating mutations or drug-
resistance mechanisms, might be acquired by tumor cells.
However, as proposed for the T790M mutation in the
EGFR,31 the significant gain-of-function property con-
ferred by the mutations that we describe here may favor
their initial presence before drug selection, and rapid
selection during tyrosine kinase inhibitor-based therapy.
These JAK mutants should, therefore, be considered to be
an invaluable tool to evaluate the activity of novel, poten-
tially more potent, ATP-competitive JAK inhibitors for
MPNs and other neoplastic processes associated with JAK
kinase mutations.
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